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“Extracellular vesicles: Specialized bone messengers” 
 
 
by 
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1.1. OVERVIEW 
Mammalian cells actively secrete factors that contribute to shape their microenvi-
ronment. These factors either travel freely or they are enclosed within the lipid bilayer of 
extracellular vesicles (EVs), and regulate the function of neighboring and distant cells. EVs 
are secreted by a wide spectrum of cell types and are found in various biological fluids. 
They convey their message by mediating the horizontal transfer of bioactive molecules, 
such as proteins, lipids and RNAs, between cells. Recent studies showed the vital roles of 
EVs in a wide range of physiological and pathophysiological processes. Throughout this 
chapter, we highlight the recent developments in the newly emerging EV field, including 
their biogenesis, molecular content and function. Moreover, we discuss the role of EVs in 
bone biology and their promising applications in diagnosis, drug development and regener-
ative therapy with particular focus on hematopoietic stem cell (HSC) therapy. 
 
1.2. EXTRACELLULAR VESICLES 
Multicellular organisms developed complex communication networks to regulate 
biological activities, and consequently maintain physiological homeostasis. Interruptions in 
intercellular communication lead to pathological complications and disease progression. 
Cells exchange information with each other via immobilized molecules as well as secreted 
factors. Traditionally, secreted factors include small soluble molecules, such as neuro-
transmitters, chemokines, cytokines and hormones, which can either act over short distanc-
es and affect the neighboring cells in a paracrine manner or travel long distances in an en-
docrine manner. The last couple of decades have witnessed the unprecedented dedication of 
scientists to the study of EVs as novel mediators of intercellular communication.  
EVs had long been regarded as cellular debris until Wolf and colleagues described 
their biological significance in coagulation in 19671. Later same year, Anderson and Bo-
nucci reported the discovery of matrix vesicles as specialized EVs involved in biominerali-
zation of the bone matrix2,3. Since then, EVs have been described to have a broad range of 
functions in development, immunology, angiogenesis and stem cell biology, as well as dis-
ease progression. EVs are considered to be bioactive organelles that carry genetic infor-
mation in forms of lipids, proteins and nucleic acids between cells, and have effects on di-
verse molecular functions, such as signaling and regulation of gene expression of the target 
cells4-8. EVs embrace a heterogeneous group of vesicles, including microvesicles, micro-
particles, ectosomes, exosomes, shedding vesicles, apoptotic bodies and many others re-
leased under different biological circumstances. Even though the different names reflect 
their diversity in terms of biogenesis, structure, content and function, there are still con-
flicts over the definition and characterization of different vesicular structures. For simplici-
ty, EVs are often categorized in three classes based on the well-defined processes for EV 
biogenesis: small vesicles (10-100 nm) released by exocytosis (exosomes, exosome-like 
vesicles), bigger vesicles (100-1,000 nm) formed by budding from the plasma membrane 
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(microvesicles, shed vesicles, matrix vesicles) and big vesicles (0.8-5 µm) released from 
dying cells (apoptotic bodies) (Fig. 1)8-10. 
 
 
Figure 1. Schematic representation of EV release from donor cells and the interaction with the target cells. 
EVs are released either by exocytosis of the multivesicular bodies or direct budding from the plasma membrane. 
Apoptotic bodies are released from the breakdown of the apoptotic cells. EVs interact with their targets via i) 
signal transduction mediated by docking at the plasma membrane of the target cell and/ or via releasing the bioac-
tive cargo upon ii) fusion or iii-iv) endocytosis followed by fusing with the delimiting membrane of the endoso-
mal compartment. Interaction with target cells leads to a broad range of biological functions. Interaction with the 
target cell is only shown for microvesicles but exosomes and apoptotic bodies utilize similar mechanisms. 
 
Cells release EVs either constitutively during their growth or upon activation by 
biological stimuli. Apoptotic and diseased cells also release EVs providing valuable infor-
mation about the health state of the cell10,11.  EVs have been detected in all studied cell 
types so far and most biological fluids, including blood, urine and breast milk12-14. Osteo-
blasts, the bone forming cells, also secrete EVs that have well characterized roles in miner-
alization15. There is increasing knowledge about the biological functions of EVs in other 
bone-related processes. Particularly, the regenerative role of mesenchymal stem cell- 
(MSC)-derived EVs makes them promising therapeutic agents for bone regenerative medi-
cine16-18. In this chapter, we review the various roles of EVs in diverse aspects of intercellu-
lar communication and highlight their function in bone biology. 
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1.2.1. Isolation and characterization 
With the rapid development of EV research, the optimization and standardization 
of isolation techniques have become of utmost importance to improve the understanding of 
EV biology. Currently, the most commonly applied EV isolation method relies on differen-
tial ultracentrifugation protocol developed by Thery and colleagues in 200619. According to 
this protocol, biological fluids or the conditioned media from cultured cells are subjected to 
a series of centrifugation and ultracentrifugation steps to pellet the EVs. Cells break open at 
high speeds, and as a consequence cellular organelles and big protein complexes are co-
isolated with EVs. Therefore, it is very important to start with a low centrifugation speed to 
remove floating and/ or dead cells, and perform serial centrifugation steps in increasing 
speeds to remove the contaminants in a step-wise fashion. Furthermore, it is crucial that the 
purified EV pellet is free of bovine serum contaminants, such as serum proteins and vesi-
cles. For cell cultures it is common to use EV-depleted serum and/or serum-free medium 
treatment before EV collection. This becomes, indeed, more challenging with biological 
fluids. The duration and speed of each centrifugation step varies between different proto-
cols based on the EV source. Large microvesicles and apoptotic bodies are commonly pel-
leted using 10,000g centrifugation, while smaller microvesicles and exosomes require high-
speed centrifugation at about 100,000g6,19. The crude EV pellet can be subjected to further 
purification by sucrose density gradient or high performance liquid chromatography to re-
move possible contaminants. There have been attempts to separate EVs with different sizes 
based on their sediment density by sucrose density gradient. Recent studies have reported 
the sediment densities as the following: 1.11-1.21 g/ ml for exosomes20-22, 1.25-1.30 g/ ml 
for microvesicles23, and 1.18-1.28 g/ ml for apoptotic bodies24. However, some small mi-
crovesicles can have even lighter densities than exosomes making the separation of the 
different EV populations very difficult using the conventional techniques6. 
Purified EVs are commonly characterized by microscopic, biochemical and fluidic 
analyses. EVs can be visualized by electron microscopy, which gives clues about their size 
and morphology (Fig. 2A). In the past, researchers used electron microscopy to verify the 
presence of exosomes based on their cup shape morphology; however, it was recently dis-
covered that this was due to dehydration during sample processing25,26. Atomic force mi-
croscopy, on the other hand, allows samples to be in their native state, and hence it proves 
to be a better alternative to study the morphology of different EVs (Fig. 2B)27.  Other 
common methods to study EVs include western blot and flow cytometry analyses using 
known vesicle markers. On-going studies are focusing on identifying markers specific to 
unique EV classes. A major challenge of EV characterization is the accurate quantification. 
ELISA and immunoadsorption are possible methods to determine the abundance of EVs 
using known markers; however, they do not give comprehensive information about the 
total EV concentration28. Conventional flow cytometry is a useful technique to quantify big 
EVs, while accurate quantification of EVs smaller than 250 nm is difficult. Van der Vlist 
and colleagues developed a high-resolution flow cytometry-based technique that can be 
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used to detect smaller EVs based on their fluorescence intensity29. Recently, several com-
panies developed techniques that allow multi-parameter analysis of EVs of certain size 
ranges providing greater accuracy than fluidic-based techniques. Nanoparticle tracking 
analysis measures concentration and absolute size distribution of particles as small as 50 
nm based on their Brownian motion in fluids27,30. qNano is another method that uses na-
nopores to measure size distribution of EVs bigger than 100 nm31. 
 
 
Figure 2. EV morphology and topography. EVs isolated from mineralizing human fetal pre-osteoblasts (SV-
HFO cells) were fixed with glutaraldehyde and analyzed by A) transmission electron microscopy, scale bar: 500 
nm, and B) atomic force microscopy (non-contact mode), scale bar: 223 nm.  Both images show that EVs are 
heterogeneous in size and have spherical morphology. 
 
1.2.2. Molecular composition  
EVs are small cell fractions consisting of a lipid bilayer enclosed lumen that con-
tains vesicular cargo, which is a selective combination of lipids, proteins and nucleic acids 
essential for EV structure and function. Even though the parent cell and EV biogenesis are 
the contributing factors to cargo differences, most of the structural cargo is shared among 
EVs released by different cells. Comprehensive understanding of the molecular composi-
tion of different EV populations is crucial to understand their molecular function. Prote-
omics, lipidomics, microarrays and deep sequencing analyses have been applied to charac-
terize the molecular content of EVs from diverse cellular sources. ExoCarta and EVpedia 
are the two new databases that list the entire lipid, protein and RNA content of EVs de-
scribed in the literature32-37. 
 
1.2.2.1. Lipids 
EVs are formed by a specific selection of lipids organized in a bilayer membrane 
that provides structure and protects the bioactive cargo from degradation before they reach 
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their targets. Most EVs are enriched with structural lipids, such as cholesterol, sphingomye-
lin and phosphatidylserine, compared to the cellular plasma membrane38-40. The mode of 
biogenesis greatly affects the lipid composition of a given EV class. Exosomes are enriched 
with endosomal phospholipid bis-monoacylglycero-phosphate, whereas microvesicles con-
tain plasma membrane levels of phosphatidylcholine and are devoid of phospholipid bis-
monoacylglycero-phosphate41,42. Lipids are not only the structural elements of EVs but they 
also contribute to their bioactivity. Vesicular lipids play pivotal roles in EV biogenesis, 
release and interaction with other cells and biological function. Lipid rafts formed by cho-
lesterol and sphingomyelin are shown to be important for clathrin pit formation that medi-
ates exosome biogenesis43. These lipid rafts can also act as signaling complexes along with 
the lipid-associated proteins. Furthermore, exosomes contain prostaglandins and leukotri-
enes important to mediate cell signaling44,45. Transfer of vesicular lipids to recipient cells 
may lead to changes in cell homeostasis caused by the accumulation of lipids and their as-
sociated enzymes. For instance, T cells release EVs that upon uptake by monocytes result 
in cholesterol accumulation leading to phenotypic alterations22. 
 
1.2.2.2. Proteins 
As with lipids, EVs are enriched with proteins that contribute to the biogenesis, 
structure, motility and the biological function of EVs. The most commonly identified pro-
tein cargo includes cytoskeletal proteins, tetraspanins, membrane and nuclear receptors, 
heat shock proteins, proteases, adhesion molecules, signaling molecules, metabolic en-
zymes, annexins, transporters and ion channels. Table 1 lists the top 25 identified EV pro-
teins as described by ExoCarta32,34. Despite the large number of shared proteins among 
different EV classes, the mode of biogenesis determines the enrichment of endosomal-
associated proteins and plasma membrane proteins in exosomes and microvesicles, respec-
tively5,46. Tetraspanins that cluster at the site of exocytosis and plasma membrane budding 
act as sorting machineries to target proteins into EVs47,48. Chaperones, such as heat shock 
proteins coupled to tetraspanins, also aid in sorting lumen proteins. Cytoskeleton proteins 
are crucial for EV release, structure, and motility49. EVs are particularly enriched in cellular 
markers based on the cell of origin. For instance, tumor-EVs are enriched with metallopro-
teinases and other proteolytic enzymes involved in the digestion of extracellular matrix 
necessary for invasion and tumor progression50,51. 
 
1.2.2.3. Nucleic acids 
The discovery of EV-associated nucleic acids with regulatory capacity greatly 
contributed to understand the role of EVs in gene-based cell communication. In late ‘90s, 
EVs co-isolated with viruses were already suggested to contain RNA52. A decade later, 
researchers found messenger RNA (mRNA) for chemokines and growth factors in tumor 
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EVs derived from different cancer cell lines53. In 2007, Valadi and colleagues showed that 
mast cell exosomes are enriched with microRNAs (miRNAs)20. Since then there have been 
a great amount of research demonstrating the presence of functional RNA molecules in 
EVs derived from cell cultures and biological fluids54-59. Bioanalyzer profiles showed that 
EVs are devoid of the cellular ribosomal RNA peaks, instead they are enriched with small 
RNAs20. Deep sequencing analyses identified mainly the presence of mRNAs and miRNAs 
but also other small non-coding RNA molecules, such as transfer RNA, Y RNA, vault 
RNA, small interfering RNA (siRNA), repeat sequences, structural RNA and RNA tran-
scripts overlapping with protein coding regions, within EVs60,61. Turchinovich and col-
leagues demonstrated that miRNAs associated with the outer membrane of EVs also have 
important implications in EV function62. Even though most EV preparations are devoid of 
DNA, several groups reported the presence of functional DNA in apoptotic bodies secreted 
by cancer cells as a way of transferring their activated oncogenes11,63.   
 
Table 1. The most commonly identified EV proteins described in ExoCartaa. 
Protein Family Gene Symbol 
Heat Shock Proteins HSPA8 
HSP90AA1 
HSP90AB1 
Tetraspanins CD9 
CD63 
CD81 
Metabolic Enzymes ALDOA 
ENO1 
GAPDH 
LDHA 
PGK1 
PKM2 
Annexins ANXA2 
ANXA5 
Cytoskeletal and Associated Proteins ACTB 
ACTG1 
CFL1 
MSN 
Elongation Factors EEF1A1 
EEF2 
14-3-3 Family Proteins YWHAE 
YWHAZ 
Other ALB 
PDCD6IP 
SDCBP 
a ExoCarta: http://www.exocarta.org/ 
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1.2.3. Biogenesis and cargo loading 
In spite of the recent progress in elucidation of EV biology, the exact process of 
EV biogenesis and cargo sorting is still not known; however the amount of data is fortu-
nately increasing. EVs are generated via diverse biological mechanisms triggered by mi-
croenvironmental stimuli, cellular activation, stress, transformation and programmed cell 
death. We know at least three distinct mechanisms of EV biogenesis: exocytosis, direct 
budding from the plasma membrane, and breakdown of dying cells, each leading to the 
release of distinct EV classes.  
Exosomes and exosome-like vesicles are small vesicles (10-100 nm) that originate 
from exocytosis of multivesicular bodies (MVBs)64,65.  Vesicle budding into exosomal 
MVB lumen is still under investigation, nevertheless there are studies suggesting that exo-
some formation follows a mechanism parallel to endosomal degradation pathway. Cellular 
cargo destined for degradation in lysosomes are selectively sorted into vesicles that bud 
into MVB lumen under the control of endosomal sorting complex required for receptor 
transport (ESCRT) and their associated proteins, such as ALIX and VPS466,67. ESCRT sub-
units ESCRT-0, -I, and –II recognize and control the destination of ubiquitinated cargo 
proteins at the endosomal delimiting membrane. Silencing of ESCRT complex components 
and/or their associated proteins reduce exosome secretion suggesting that ESCRT-mediated 
sorting plays a role in exosome formation but possibly via a different mechanism than the 
degradation pathway68. Exosomes are also released in a lipid-dependent manner inde-
pendently from the ESCRT pathway, depending on cell type and stimuli. Trajkovic and 
colleagues showed that ceramides that are concentrated around lipid-rafts of oligoden-
droglial cells sort exosomal cargo into vesicles and mediate budding into the MVB lu-
men69. The importance of lipids is further supported by the findings showing that that exo-
somal MVBs are rich in cholesterol and phosphatidylserine on the outer lipid leaflet, while 
degradative MVBs are cholesterol poor, but rich in lysobisphosphatidic acid28. There is 
evidence showing that cells can produce exosomes independently of both ESCRT complex 
and ceramides.  For instance, tetraspanins are also suggested to play a role in exosome sort-
ing48. The process of MVB fusion with plasma membrane and release of exosomes is still 
unclear. It is noted that exosome release process is a cytoskeleton dependent and p53-
controlled process70. Furthermore, ESCRT-III subunit and GTPases, such as RAB5, 
RAB27 and RAB35, have been implicated to play roles in exosome release6,71. 
The molecular mechanisms of microvesicle and apoptotic body biogenesis are far 
less understood than exosome biogenesis. Direct budding from the plasma membrane re-
leases a heterogeneous EV population with a size range between 100-1,000 nm43. These 
EVs are commonly referred to as microvesicles as well as shed vesicles, and to a lesser 
extent microparticles. Microvesicles contain a specific group of plasma membrane proteins 
suggesting that budding occurs at specific parts of the membrane. As with exosomes, cho-
lesterol-rich lipid rafts enriched with ceramides, cholesterol and other lipids are described 
to be involved in biogenesis of microvesicles72,73. It has been reported that increase in cyto-
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solic calcium leads to exposure of phosphatidylserine residues, which in turn causes bud-
ding from the plasma membrane74. Several reports suggest the involvement of the ESCRT 
complex indicating that microvesicle budding might be similar to exosome budding into 
MVBs75.  Actin-based motors are also proposed to be involved in the detachment of the 
microvesicle bud from the plasma membrane76. Apoptotic bodies, large vesicles with a di-
ameter range between 0.8-5 µm, are released from cellular breakdown of dying cells10. 
These EVs are usually engulfed by phagocytic cells and quickly removed before the con-
tents can be spilled out to the surrounding cells and cause damage. Studies showing their 
role in intercellular communication suggest that they can escape phagocyte ingestion and 
target neighboring cells; however, the molecular mechanism of apoptotic body targeting is 
still unknown63.  
 
 
Figure 3. EV uptake by HEK 293 cells. A) Flow cytometry histogram shows increasing fluorescence intensity 
shift of HEK 293 cells treated with different concentrations of PKH67-labeled SV-HFO EVs. EV concentrations: 
red-1X; blue-2X; orange-5X; light green-10X; dark green-20X; pink-40X. (1X: 0.25% v/v) B) Confocal micros-
copy image of HEK 293 cells that were treated with the highest dose (40X) of PKH67-labeled SV-HFO EVs 
shows EV uptake. Analyses were performed after overnight treatment with labeled EVs. Scale bar: 8 µm. 
 
1.2.4. Interactions with target cells 
EVs originate from their parent cells, and travel in extracellular space until they 
interact with their target cells. The literature contains an increasing number of studies veri-
fying the specificity of EV target interaction and subsequent biological effect.77,78. Even 
though the molecular mechanism of EV targeting is not yet well described, it is thought to 
mainly occur via adhesion (peripheral) and heat shock proteins that interact with the recep-
tors located on the target cell surface79-82. Phosphatidylserine lipids also participate in target 
recognition via interaction with their receptors on the target cell83. Upon interaction with 
the target cells EVs can dock at the plasma membrane and exert their biological function 
via signal transduction or fuse with the cell membrane and transfer their bioactive cargo8. 
EV membrane fluidity and pH of the environment greatly affects the efficiency of EV fu-
sion. High cholesterol, sphingomyelin, and saturated fatty acid content contribute to EV 
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rigidity, and prevent fusion at neutral pH. The acidity of the tumor microenvironment in-
creases the efficiency of tumor EV fusion by the target stromal cells84. EVs can also be 
internalized by endocytosis, broken down in lysosomes, and subsequently release their car-
go into the lumen of their targets. EV targeting can be monitored via different methods that 
rely on imaging techniques and fluorescence dyes. Docking can be detected by targeting 
cell surface proteins with antibodies, while fusion is commonly detected using self-
quenching lipophilic dyes (e.g. R18)59. Thanks to their tendency to form aggregates in 
vitro, EVs internalized by endocytosis can be easily observed by membrane intercalating 
dyes, such as PKH dyes (Fig. 3). EV aggregation is usually explained by the formation of 
bridges between the anionic phospholipids due to the calcium content of culture media; 
however, we cannot rule out that aggregation may be important for EV propagation similar 
to viruses85. 
 
1.2.5. Biological functions 
Only a few decades ago it was commonly accepted that intercellular communica-
tion was solely mediated via receptors and small soluble molecules. Vesicular structures 
secreted to the extracellular space were mainly considered to be cell artifacts as a way of 
disposing cellular waste. During the ‘80s, several studies attributed more functions to EVs 
in antigen-presentation, antitumor activity and immune response86-89. Today, EVs have 
been shown to be involved in many biological functions, such as development, immunity, 
inflammation, coagulation, cardiovascular function and stem cell biology, as well as cancer 
and chemotherapy resistance.  
EVs are important regulators of coagulation via the exchange of active cargo that 
promotes vessel formation, angiogenesis, clotting and platelet aggregation8,89,90. EVs regu-
late coagulation by transferring cargo with either anticoagulant activity (e.g. activated pro-
tein C) or procoagulant activity (e.g. arachidonic acid) between activated and resting plate-
lets91-93. Neuronal EVs are known to play a regulatory role in myelin formation, neuron 
outgrowth and neuronal survival94-96. Neuronal EVs are also essential in recycling receptors 
and removing potential pathological proteins from the central nervous system95. EV pro-
duction is up-regulated during inflammatory response5. Elevated ATP levels caused by 
cellular injury triggers macrophage EV secretion, which in turn have the capacity to acti-
vate other macrophages97. EVs also have essential implications in immune response as they 
are released both by infected cells and immune cells. Hepatitis C infected cells release EVs 
that contain viral RNA that is transferred to target plasmacytoid dendritic cells, and conse-
quently activate immune response98. Ramakrishnaiah and colleagues showed that hepatitis 
C virus RNA could also evade the immune system by transmitting the infection between 
human hepatocytes99. Recently studies showed that EVs have crucial implications in the 
regulation of stem cell fate. Ratajczak and colleagues showed that embryonic stem cells 
stimulate the pluripotency of hematopoietic progenitors via transferring Wnt3 protein100. 
General introduction 
	   19 
EVs released from apoptotic T cells induce differentiation of leukemic cells towards 
megakaryocytes via the associated hedgehog morphogen101. EVs isolated from the periph-
eral circulation of pregnant women contain different cargo in different gestation phases, 
suggesting a role for EVs in morphogenesis during vertebrate development102. Several re-
ports showed that EVs carry developmental proteins, such as β-catenin, Wnt proteins and 
sonic hedgehog, further supporting their involvement during development103. 
EVs also have many implications in cellular pathologies, such as diabetes, coag-
ulopathies, inflammation, infection, autoimmune disease and cancer, being of particular 
interest in the field104-108. Both tumor cells and the surrounding non-malignant cells in the 
tumor microenvironment produce EVs that contribute to pre-metastatic niche formation, 
immunosuppression, angiogenesis, invasion, metastasis and tumor progression109-113. Tu-
mor EVs generally carry oncogenes and pro-metastatic cargo consisting of metalloprotein-
ases, tetraspanins, plasminogens, integrins, heath shock proteins, growth factors, etc. that 
promote extracellular matrix degradation, invasion and consequent tumor progression54. 
Several reports showed the role of EVs in priming metastatic niches for enhanced metastat-
ic propensity of the target cells via the exchange of pro-angiogenic factors and chemo-
attractants114. Hood and colleagues reported that melanoma EVs prime the sentinel lymph 
nodes for melanoma metastasis115, while Peinado and colleagues reported that melanoma 
EVs stimulate the bone marrow cells to support metastasis and tumor growth via receptor 
tyrosine kinases116. Interestingly, EVs shed by tumor cells inhibit immune surveillance and 
promote chemotherapy resistance by expulsion of therapeutic drugs from tumor cells via 
exchange of ABC transporters and drug metabolizing enzymes117-119. 
 
1.3. INTERCELLULAR COMMUNICATION IN BONE  
Bone, the key structural component of the vertebral endoskeleton that mechanical-
ly supports the body, protects the integral organs and enables motility, is a living organ 
made up of diverse tissues. The primary tissue is the osseous tissue consisting of bone cells, 
including osteoblast, osteoclasts and osteocytes. The bone cells communicate with each 
other throughout adult life to regulate the balance between bone resorption and bone for-
mation, which is important to maintain normal bone mass and strength as well as mineral 
homeostasis120,121. Bone also houses the bone marrow tissue forming a complex microenvi-
ronment that supports other vital biological functions, including hematopoiesis, adipogene-
sis and chondrogenesis122. Keeping the constant balance of bone homeostasis as well as the 
efficient regulation of other essential physiological events that occur within the bone mi-
croenvironment requires the formation of balanced signaling networks between the resident 
cells. Elucidation of the regulatory mechanisms involved in EV-mediated cell communica-
tion within the bone microenvironment is critical for a deeper understanding of the skeletal 
system in health and disease. 
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1.3.1. EV-mediated communication between bone cells 
Over the past few years, researchers have shown increasing interest in delineating 
the role of EVs in bone biology. The work of Anderson and Bonucci not only pioneered the 
development of EV field but also contributed to study the regulation of bone matrix devel-
opment, mainly via matrix vesicles secreted by osteoblasts. Matrix vesicles with diameters 
between 30 and 300 nm originate from the plasma membrane of mineralizing osteoblasts, 
and are involved in bone matrix mineralization via hydroxyapatite deposition123. Matrix 
vesicles are also released by cartilage during endochondral calcification. Proteome profiles 
of matrix vesicles obtained from bone and cartilage of different species revealed a large 
number of shared proteins, such as phosphatases, annexins and ion channels, which con-
tribute to the understanding of mineral formation124,125. Studies with hypophosphatasia pa-
tients showed that the defects in proper mineral crystal propagation from matrix vesicles 
lead to improper or complete failure of bone calcification126. In vitro manipulation of oste-
oblast mineralization further supported the parallels between matrix vesicle production and 
mineralization. Inhibition of mineralization by activin A triggers reduced expression of 
matrix vesicle markers implying deficient or altered matrix vesicles production127, while 
vitamin D treatment successfully increases matrix vesicle secretion from osteoblasts lead-
ing to higher mineralization rates128. Osteocytes also secrete EVs with possible roles in 
regulation of mineral deposition via communication with osteoblasts and osteoclasts129,130. 
On-going studies have reported preliminary results showing the enrichment of osteocyte 
EVs with receptor activator of nuclear factor kappa-B ligand, of which the vesicular levels 
are elevated upon parathyroid hormone treatment, suggestive of a role in promoting osteo-
clast formation (BoneKEy reports). Recent studies with osteoclasts reported the importance 
of the miRNAs in osteoclastogenesis131,132. Current studies are focusing on elucidating 
whether miRNAs are transported via EVs secreted by osteoclasts. 
 
1.3.2. EV-mediated communication in the bone microenvironment 
EV-mediated signaling in bone is particularly a crucial determining factor for the 
regulation of essential biological processes other than bone tissue regeneration. The favor-
able bone microenvironment hosts a great diversity of cells, such as HSCs, fat cells, MSCs, 
endothelial cells, cartilage and nerves. There are numerous studies highlighting the im-
portance of EV-mediated signaling in the regulation of hematopoietic development58,100,133. 
Moreover, CD34+ hematopoietic stem and progenitor cells (HSPCs) stimulate angiogenesis 
via miRNA exchange.134. MSCs also actively secrete EVs containing selected patterns of 
mRNA and miRNAs55,56. Several studies reported the role of MSC-EVs in tissue damage 
repair, inflammatory responses, and immune system135. MSC-EVs regulate inflammation 
by inhibiting auto-reactive lymphocyte proliferation and promote secretion of the anti-
inflammatory cytokines IL-10 and TGF-β136. Ekstrom and colleagues demonstrated that 
monocyte EVs stimulate osteogenic differentiation of regenerative MSCs during bone inju-
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ry at the site of titanium implants137. Recently, EVs have been implicated in osteoblast-
adipocyte crosstalk via horizontal transfer adipogenic RNAs138. Furthermore, the discovery 
of cartilage-derived EVs made a significant contribution to the understanding of cartilage 
disease and repair139. 
 
1.3.3. EVs in bone metastases 
In cancer, the favorable bone microenvironment attracts distant bone-
metastasizing tumors, in particular breast and prostate tumors. EVs secreted by cancer cells 
are responsible for stimulating angiogenesis and thereby facilitating the migration of the 
tumor cells into the bone microenvironment. Remarkably, Renzulli and colleagues showed 
that prostate tumor cells release EVs that educate the bone cells to act as a pre-metastatic 
niche57.  In vitro manipulation of pro-metastatic EV cargo resulted in several successful 
studies where they managed to repress the tumor-induced angiogenesis leading to a reduc-
tion in bone metastatic lesions in mice140,141.  
EVs derived from human bone marrow MSCs also have crucial consequences in 
cancer cell growth and behavior. However, studies show contradictory roles of MSC-EVs 
in tumor microenvironment. Several groups reported that MSC-EVs favor tumor growth 
and angiogenesis, while others showed the inhibition of these processes142-144. MSC-EVs 
inhibit cancer cell growth of different cancer cell lines in immunodeficient mice145.  EVs 
derived from murine MSCs are shown to significantly down-regulate VEGF expression in 
breast cancer cells leading to an inhibition of angiogenesis both in vitro and in vivo146. On 
the other hand, MSC-EVs promote tumor growth in vivo by increasing VEGF expression in 
tumor cells as a result of activating the extracellular signal-regulated kinase 1/2 pathway143.  
 
1.4. APPLICATIONS IN DIAGNOSTICS AND THERAPY 
In the last two decades, significant advances have been made in the characteriza-
tion of EV content and function leading to their implications in health and disease. Better 
understanding the role of EVs in bone remodeling and bone microenvironment may pro-
vide insights into the complexity of diverse physiological and pathophysiological events. 
Furthermore, their clinical implementations may open the doors for translational medicine, 
both in diagnostics and therapy.  
 
1.4.1. Biomarkers and diagnosis 
Pathological EVs contain molecular disease signatures, and hence function as ex-
cellent molecular biomarkers to be used for diagnosis and prognosis. Particularly, EVs in 
body fluids can be easily collected making them optimal non-invasive biomarkers to detect 
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renal disease, obesity and diabetes, and cancer147-151. EVs are considered to be promising 
biomarkers for early diagnosis because they are already released at early stages of the dis-
ease and they are very stable and easily detectable. EV-derived miRNAs represent one of 
the most attractive cancer biomarkers as they provide a miRNA pattern that is different in 
benign and malignant forms, correlating with different stage of tumors152. Altered levels of 
circulating miRNAs are also proposed to be biomarkers for bone cancers, such as osteosar-
coma153. However, the involvement of EVs is still not clear. Early diagnosis of metabolic 
bone diseases is essential for subsequent effective treatment. Currently, the conventional 
diagnostics techniques rely on the detection of bone turnover biomarkers in patient urine 
and blood154,155. Interestingly, osteoprotegerin containing EVs are detected in elevated lev-
els in the urine of patients with chronic kidney disease suggestive of a role in preventing 
vascular calcification156. Investigating the roles of bone EVs in metabolic bone diseases 
and inappropriate biological mineral formation is promising to provide novel avenues for 
early diagnosis.  
 
1.4.2. Regenerative medicine, vaccines and drug delivery 
Stem cell-derived EVs have been of increasing interest for their potential use in 
cell-free therapies in regenerative medicine exploiting their physiological functions mim-
icking their parental cells. They have been shown to improve cellular function in damaged 
organs by preventing apoptosis and promoting proliferation and angiogenesis via the hori-
zontal transfer of pro-regenerative factors157-159.  Several studies reported the potential of 
MSC-EVs as therapeutic agents for tendon repair160 and rheumatic diseases based on their 
anti-fibrotic, anti-apoptotic, anti-inflammatory and pro-regenerative properties161. Further-
more, MSC-EVs have been shown to be involved in repairing invertebral disc degeneration 
via transfer of their membrane components to nucleus pulposus cells162. These findings 
stress their potential in bone regenerative therapy.  
Thanks to their immunosuppressive properties, EVs have been proposed as vac-
cines for immunotherapy163,164. Particularly, EVs secreted by tumors have been shown to 
contain tumor antigens that could have an antitumor activity on other tumors165. Remarka-
bly, clinical trials with cancer patients showed that melanoma EVs added to autologous 
dendritic cells in vitro stimulate T cells that induce antitumor effects when injected into the 
patient166,167. EVs have been increasingly seen as physiological drug delivery agents168. As 
opposed to synthetic alternatives, such as liposomes and nanoparticles, EVs occur natural-
ly, exhibit a long half-life and an intrinsic homing ability, and are more efficiently tolerated 
by the recipient cells. Several reports demonstrated the possibility to load EVs with thera-
peutic molecules via in vivo and in vitro manipulations169. Wood and colleagues showed 
that they could use electroporation techniques to load EVs with siRNA that is delivered to 
target cells resulting in gene regulation170. Human MSC-EVs are shown to be promising for 
drug delivery. Chai Lai and colleagues manipulated MSCs to produce infinite numbers of 
General introduction 
	   23 
EVs from a single clone171. Several groups are focusing on developing biomimetic drug 
delivery vehicles inspired by EVs to effectively deliver the therapeutics to the target 
site172,173. 
 
1.5. REGENERATION OF THE BLOOD-FORMING SYSTEM  
HSCs are multipotent stem cells that give rise to all blood lineages, including my-
eloid and lymphoid lineages, while maintaining the ability to self-renew (Fig. 4). Their 
potential to replenish blood has made them attractive for stem cell therapies to treat a broad 
diversity of hematological disorders. HSC transplantation, where the bone marrow of pa-
tients is replenished with the stem cells of healthy donors, is one of the most widely applied 
stem cell therapies. To date, bone marrow is the most commonly used HSC source but re-
searchers continue to explore alternative strategies to improve therapy. 
 
 
Figure 4. Diagram of hematopoiesis in humans. HSC, hematopoietic stem cell; CLP, common lymphoid pro-
genitor; CMP, common myeloid progenitor; BCP, B cell progenitor; TNK, T/ natural killer cell progenitor; GMP, 
granulocyte macrophage progenitor; MEP, megakaryocyte erythroid progenitor.  
 
1.5.1. Stem cell transplantations  
Pioneer work in early 1950s showed that bone marrow cells from healthy donors 
when injected intravenously could repopulate the bone marrow of patients with defected 
hematopoiesis, and regenerate all the blood cells174. The first successful European bone 
marrow transplantation trial was performed to treat patients suffering from leukemia175. 
Since then HSC transplantations have been used to treat patients with hematological malig-
Figure 4 Chapter 1_Morhayim et al. 
Primitive  
progenitor cells 
Committed  
precursor cells 
Lineage  
committed cells 
CMP 
HSC 
GMP 
MEP 
CLP 
BCP 
TNK 
B cells 
T cells 
NK cells 
Monocytes 
Neutrophils/ 
 eosinophils 
Platelets 
Erythrocytes 
Self-renewal 
§ Chapter 1 
	  24 
nancies, such as blood cancers and other blood disorders, and non-malignant disorders, 
such as immune system disorders. Today more than 50,000 transplants are carried out an-
nually worldwide to cure patients where transplantation remains as the last hope for cure.  
HSC transplantations can be performed with an autologous (patient) transplant or 
with an allogeneic (donor) transplant176. Allogeneic transplants are typically harvested from 
the bone marrow or peripheral blood of healthy donors.  The stem cells are then infused to 
the patient whose own HSCs have been impaired or ablated by chemotherapy or radiation. 
As though it may seem straightforward with numerous success stories, HSC transplantation 
is a very complicated and risky technique. Successful transplantation relies on optimal do-
nor-recipient compatibility to minimize the likelihood of developing a life-threatening 
complication called graft-versus-host disease and to maximize the likelihood of sufficient 
regeneration in a short period of time. Unfortunately, only a small percent of those patients 
in need for a stem cell transplant have a matching donor. More recently, umbilical cord 
blood (UCB) has proven to be a great alternative HSC source for patients waiting for an 
allogeneic transplant without a perfectly matching donor.  
 
1.5.2. Umbilical cord blood as a stem cell source 
Since its first application in 1989 to treat a child with Fanconi anemia, the use of 
UCB as a source of HSCs has increased significantly177-179. UCB is a rich source of more 
primitive HSCs with attractive advantages over bone marrow and peripheral blood. The 
advantages include ease to harvest with no pain caused to the donor, decreased stringency 
of human leukocyte antigen matching requirements, and low risk of being attacked from 
the recipient’s immune system leading to relatively lower risk of graft-versus-host disease 
complications. However, low numbers of progenitor cells deriving from the small UCB 
volume cause delayed engraftment and immune reconstitution increasing the rate of failure 
of post-transplantation recovery. This poses difficulties in the clinic, especially for trans-
plantations in adult patients180.  
Currently there is a major interest in developing ex vivo expansion technologies to 
obtain sufficient HSCs for clinical use. Using a cocktail of hematopoietic cytokines, such 
as stem cell factor, Fms-related tyrosine kinase 3 ligand, thrombopoietin, interleukin 6 and 
granulocyte-macrophage colony-stimulating factor, scientists successfully managed to 
stimulate the rapid expansion of CD34+ HSPCs181,182. The discovery of small soluble mole-
cules, such as StemRegenin 1, promoted more effective ex vivo expansion while maintain-
ing the progenitor cell frequency183. The cells expanded by using cytokines, with or without 
StemRegenin1, could engraft and repopulate immunodeficient mice to replenish the blood 
in vivo. However, challenges still remain as the rapid expansion is often accompanied by 
the long-term exhaustion of the stem cell pool with true self-renewal and full repopulating 
capacity as a result of apoptosis or differentiation in vitro184. Improved culture strategies to 
promote HSPC expansion while retaining their self-renewal capacity and keeping differen-
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tiation at bay are still indispensible. Ultimately, to find the optimal ex vivo expansion con-
ditions, researchers have turned their focus on unraveling the soluble and insoluble factors 
of the bone marrow niche where HSC and HSPC self-renewal is supported. 
 
1.5.3. Bone marrow niche 
HSCs reside in special niches, which provide the spatial and mechanical cues nec-
essary to regulate the balance between self-renewal, proliferation and differentiation185. 
Bone marrow, the major location for hematopoiesis in humans, provides a favorable micro-
environment composed of niche cells, extracellular matrix, and soluble factors, such as 
cytokines, chemokines and signaling molecules186.  
There are contrasting studies regarding the identity of true niche cells. Initial re-
ports suggested that endosteal bone surface houses HSCs in close contact with osteoblasts 
that actively regulate HSCs187,188. In contrast, sinusoidal endothelial cells were suggested to 
regulate primitive HSCs in the perivascular zone189. Increasing reports showed the presence 
of other niche cells, such as CXCL12-abundant reticular cells, adipocytes, MSCs, and nes-
tin-positive cells, which play equally important roles in the HSC niche190-193. All these 
niche cells must work in harmony to maintain the hematopoietic potential of the stem cells 
located in the bone marrow. 
Bone marrow niche cells control HSC function via an intricate network of soluble 
signals and structural molecules. Signaling molecules, such as WNT proteins, Notch lig-
ands, sonic hedhehog, bone morphogenetic proteins and thrombopoietin, hold fundamental 
roles to maintain HSC homeostasis194-196. CXCL12 secreted by osteoblasts is important for 
HSC homing to the bone marrow by binding to CXCR4 located on HSC cell surface197. 
Similarly, CaSR and GNAS expressed by HSCs are essential for homing to the niche198. 
Adhesive interactions via ANG1/ TIE2, N-cadherins, integrins, VLA-4, and ANXA2 are 
critical players of engraftment and mobilization, most likely via binding HSCs to the bone 
and releasing HSCs into circulation187,199,200. Moreover, interactions with the extracellular 
matrix provide retention cues and mechanical signals, and concentrate growth factors and 
cytokines201. Temporal, metabolic and ambient cues, such as circadian rhythms, prosta-
glandins, calcium and low oxygen, regulate HSC maintenance directly and indirectly by 
regulating the niche cells and by targeting production of key cytokines202-204. 
 
1.5.4. Osteolineage cells 
Increasing evidence reports successful ex vivo expansion of UCB-derived primi-
tive progenitor cells by targeting the osteolineage cells, such as MSCs, osteoprogenitor 
cells and osteoblasts205,206. Osteoblasts were initially thought to be the major components of 
the endosteal bone marrow niche; but now it is clear that they are not the only niche cells 
with that capacity. The current debate over the role of osteoblasts extends into whether 
§ Chapter 1 
	  26 
their contribution is absolutely required for HSC regulation in the bone marrow. Neverthe-
less, several studies demonstrated that the use of osteoblast-derived soluble factors, such as 
Notch ligands, WNT proteins, angiopoietin-like proteins and bone morphogenetic proteins, 
promotes HSPC expansion in stroma-free cultures in combination with hematopoietic cy-
tokines199,207-209. Similarly, modulation of osteoblast membrane-associated molecules, such 
as N-cadherin, VLA-4 and VLA-5, results in prolonged survival in vitro making it possible 
to obtain clinically satisfactory expansion to support better engraftment184. Modulation of 
substrate elasticity is also widely applied to mimic the physical and mechanical characteris-
tics of the endosteal bone surface to obtain clinically relevant HSPC numbers.  
Currently, we still lack a detailed understanding of the cellular interactions and 
signals that coordinate normal hematopoietic development. Recent findings have proposed 
that EVs may be involved in the regulation of stem cell fate in their niches. As we dis-
cussed earlier, EVs contain regulatory cargo capable of modulating HSPC reprogramming. 
Identification of osteoblast-derived EV components critical for the regulation of the cross-
talk between osteolineage cells and HSPCs may be exploited clinically to develop im-
proved expansion strategies.  
 
1.6. ABOUT THIS THESIS 
EVs are now recognized as biologically significant structures with important roles 
in cell-to-cell communication. Advancement in the field produced tremendous information 
that gives insights into the biological role of EVs in many aspects of physiological and 
pathophysiological events. Due to their signature content and biocompatibility, EVs repre-
sent a potential source of diagnostic tools and therapeutic agents. As well, their use might 
overcome limitations and risks associated with cell-therapy approaches. Further characteri-
zation of the EV-mediated modes of communication within the bone microenvironment 
will not only provide insights into the complexity of bone development and maintenance 
but also to other biological processes that require the favorable bone microenvironment.  
In this thesis, we aim to elucidate the regulatory cargo of human osteoblast-
derived EVs and investigate their molecular function in communication within the bone 
microenvironment, in particular with HSPCs and bone-metastasizing cancer cells. Ulti-
mately, we investigate the therapeutic potency of osteoblast-EVs in regenerative medicine 
by evaluating their potential in ex vivo expansion of human UCB-derived HSPCs for clini-
cal use. 
In Chapter 2, we present an extensive proteomic characterization of human oste-
oblast-derived EVs secreted at various time-points during osteoblast differentiation under 
both mineralizing and non-mineralizing conditions. We also investigate the effect of osteo-
blast-EVs on human prostate cancer (PC3) cells by microscopic, proteomic and gene ex-
pression analyses in vitro.  
In the remainder of this thesis we focus on EVs deriving from non-mineralizing 
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osteoblasts. In Chapter 3, we present the comparative transcriptome analysis of osteoblasts 
and their corresponding EVs using next-generation sequencing. Using a bioinformatics 
workflow, we describe the mRNA species that are selectively incorporated into EVs or 
depleted from EVs during their biogenesis.  
In Chapter 4, we characterize the global expression pattern of miRNAs in osteo-
blast-EVs using next-generation sequencing. Using comparative analyses with the parental 
osteoblast miRNA profile and in silico target prediction analyses we define candidate hem-
atopoietic development pathways affected by EVs. Consequently, we study the functional 
effect of EVs on UCB-derived HSPCs by gene expression and biochemical analyses.  
In Chapter 5, we report the therapeutic application of osteoblast-EVs in stem cell 
therapy by testing their potency to expand UCB-derived HSPCs ex vivo in combination 
with hematopoietic growth factors. We further verify the functionality of the expanded 
cells in vivo by performing xenogeneic transplantation in immunodeficient mice.   
In Chapter 6, we study the effect of osteoblast-EV treatment on the transcriptome 
of UCB-derived HSPCs using next-generation sequencing. We use integrated bioinformat-
ics approach to explain the biological mechanism of EV function by showing the direct and 
indirect molecular relationships between EV cargo (described in chapters 2, 3 and 4) and 
EV-regulated HSPC genes (this chapter).  
Finally in Chapter 7, we present the conclusions of the work presented in this 
thesis. Moreover, this chapter describes the key findings, discusses the potential challenges 
and gives recommendations for prospective studies. 
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Beyond forming bone, osteoblasts play pivotal roles in various biological processes, includ-
ing hematopoiesis and bone metastasis. Extracellular vesicles (EVs) have recently been 
implicated in intercellular communication via transfer of proteins and nucleic acids be-
tween cells. Here, we focused on the proteomic characterization of non-mineralizing 
(NMOBs) and mineralizing (MOBs) human osteoblast (SV-HFOs) EVs and investigated 
their effect on human prostate cancer (PC3) cells by microscopic, proteomic and gene ex-
pression analyses. Proteomic analysis showed that 97% of the proteins are shared among 
NMOB- and MOB-EVs, and 30% are novel osteoblast-specific EV proteins. Label-free 
quantification demonstrated mineralization stage-dependent five-fold enrichment of 59 and 
451 EV proteins in NMOBs and MOBs, respectively. Interestingly, bioinformatic analyses 
of the osteoblast EV proteomes and EV-regulated prostate cancer gene expression profiles 
showed that they converge on pathways involved in cell survival and growth. This was 
verified by in vitro proliferation assays where osteoblast EV uptake leads to two-fold in-
crease in PC3 cell growth compared to cell-free culture medium-derived vesicle controls. 
Our findings elucidate the mineralization stage-specific protein content of osteoblast-
secreted EVs, show a novel way by which osteoblasts communicate with prostate cancer, 
and open up innovative avenues for therapeutic intervention.  
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2.1. INTRODUCTION 
Osteoblasts are the bone cells of mesenchymal origin that contribute to the 
strength of the skeletal system by bone matrix production and mineralization1,2. The dis-
covery of various cytokines and chemokines secreted by osteoblasts underlined the im-
portance of paracrine signaling in the establishment of favorable microenvironments that 
support the regulation of bone homeostasis, as well as growth, survival and maintenance of 
the neighboring bone marrow cells3,4. In cancer, osteoblastic microenvironment acts as a 
pre-metastatic niche by attracting bone-metastasizing tumors5,6. Identifying the regulatory 
mechanism of osteoblast paracrine signaling network may help us design therapeutics to 
reduce the risk of bone disorders and metastases.   
Extracellular vesicles (EVs) have recently emerged as a novel class of cellular 
messengers involved in communication via exchange of bioactive cargo, such as lipids, 
proteins and nucleic acids, among cells7,8. EVs are released under physiological and patho-
logical conditions, and are involved in various developmental and biological processes, as 
well as disease progression9,10. Thanks to their bioactive content and biocompatibility, EVs 
have been of increasing interest for their applications as biomarkers, vaccines and drug 
delivery agents11-13. Although there are no defined terms yet to classify different types of 
EVs, three processes of EV biogenesis have been well documented. Exocytosis of mul-
tivesicular bodies releases small vesicles (10-100 nm) called exosomes and exosomes-like 
vesicles14. Budding from the plasma membrane releases a heterogeneous group of vesicles 
(100-1000 nm) usually referred to as microvesicles15. Cells undergoing apoptosis also re-
lease EVs as apoptotic bodies (0.8-5 µm) formed by the breakdown of dying cells16. Osteo-
blasts secrete EVs called matrix vesicles (30-300 nm) mainly involved in mineralization of 
the newly forming bone matrix via hydroxyapatite deposition17. In recent years, reports 
describing the protein profiles of matrix vesicles secreted by osteoblast cell lines from dif-
ferent species indicated that they contain a broad variety of proteins important for bone 
mineralization18-20. On the other hand, there are a few studies demonstrating that matrix 
vesicles contain signaling proteins and growth factors, such as BMPs and VEGF, sugges-
tive of a role in intercellular communication21. However, comprehensive information about 
osteoblast-secreted EVs with roles other than mineralization is still lacking.  
In this study, we present an extensive characterization of human osteoblast-
secreted EVs in terms of size, morphology and protein content, and report their role in 
communication with bone-metastasizing human prostate cancer cells. We focus on identi-
fying the unique and abundant proteins packaged within EVs secreted at various time-
points during osteoblast differentiation under both mineralizing and non-mineralizing con-
ditions. We also delineate the biological function of osteoblast EVs by showing that they 
enter human prostate cancer (PC3) cells and stimulate their growth in vitro. Our findings 
define a role for osteoblast EVs in intercellular communication, and provide a foundation 
for the development and utilization of EVs as treatment agents.  
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Figure 1. Characterization of EVs secreted by NMOBs and MOBs on day 5, day 12, and day 19 of cultures. 
A) Alizarin Red S staining of the calcium deposited in the bone matrix, and B) ALPL activity (mean ± SD) of 
osteoblasts during differentiation. ALPL activity is shown as enzyme unit (U) per milligram (mg) of total protein. 
C) TEM images (magnification ×28,000) of each EV group. Scale bar: 500 nm. D) Western blot analysis of EV 
proteins (3 µg/ lane) in NMOB-EVs (-) and MOB-EVs (+) using antibodies against CD63 and ANXA2. E) ALPL 
activity (mean ± SD) measured in NMOB-EVs and MOB-EVs (N = 3). 
 
2.2. RESULTS 
2.2.1. Characterization of human osteoblast-EVs during differentiation and under 
different mineralization conditions  
In this study, we used human pre-osteoblasts (SV-HFOs), which differentiate into 
mature osteoblasts that produce extracellular matrix and deposit calcium when stimulated 
with dexamethasone22. Throughout this study, dexamethasone-treated and non-
dexamethasone-treated osteoblasts were referred to as mineralizing (MOBs) and non-
mineralizing (NMOBs) osteoblasts, respectively. To reduce serum-derived EV contamina-
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tion we cultured the osteoblasts in medium supplemented with EV-depleted serum fol-
lowed by serum-free medium for 24 hours before EV isolation. Osteoblasts behave normal-
ly under these modified conditions, and undergo proper differentiation and mineralization 
as shown by Alizarin Red S staining of the calcium deposited in the matrix and alkaline 
phosphatase (ALPL) activity (Fig. 1A & 1B).  
We isolated EVs secreted by both MOBs and NMOBs on day 5, 12, and 19 of cul-
tures by a series of ultracentrifugation steps, and referred to these six different EV prepara-
tions as “EV groups”. Transmission electron microscopy (TEM) images show that osteo-
blast EVs have irregular and spherical structures in wide ranges of diameters depending on 
the stage of differentiation and mineralization (Fig. 1C). EVs secreted by NMOBs are more 
heterogeneous in size (50-1000 nm) than EVs secreted by MOBs (50-250 nm). We further 
verified the presence of EVs by testing for known EV proteins, such as CD63 and annexin 
A2 (ANXA2) by western blot (Fig. 1D)23. We confirmed the presence of matrix vesicles 
within the EV groups derived from MOBs by measuring ALPL activity that is absent in EV 
groups of NMOBs (Fig. 1E). These results show that human osteoblasts secrete EVs under 
both non-mineralizing and mineralizing conditions at different stages of osteoblast differ-
entiation regardless of matrix vesicle activity suggestive of a role not primarily linked to 
mineralization.  
 
2.2.2. Proteomic profiling of NMOB-EVs and MOB-EVs  
EV proteomes of NMOBs and MOBs on day 5, 12 and 19 of culture were ana-
lyzed by mass spectrometry, as previously described24,25. Briefly, proteins of isolated EVs 
were separated by SDS-PAGE electrophoresis, in-gel digested and analyzed by LC-MS/ 
MS. Altogether we detected 1,120 proteins, among which 946 proteins (84%) are detected 
in every EV group despite the morphological differences shown in Figure 1C (Appendix A, 
Table A1). These proteins consist of commonly known vesicle proteins, and are mainly 
annotated to a wide array of vesicle related molecular functions and biological processes 
(Fig. 2A). Furthermore, the overlapping proteins include osteoblast-related proteins linked 
to skeletal development, mesenchymal differentiation, calcium ion binding and phospha-
tase activity, which can be attributed to the activity of matrix vesicles (Appendix A, Table 
A2). Figure 2B shows a schematic representation of the over-represented protein families 
found in all EV groups. 
Next, we combined the protein data from all three time-points for each of the min-
eralization conditions. The Venn diagram in Figure 3A shows that 1,090 proteins (97% of 
the total proteins) are overlapping. 4 and 26 proteins are uniquely detected in NMOB-EVs 
and MOB-EVs, respectively. Comparison with ExoCarta database23 shows that the majority 
of the mineralization condition-specific proteins (3 out of 4 NMOB-EV and 22 out of 26 
MOB-EV proteins) as well as 352 overlapping proteins are uniquely detected in our osteo-
blast EVs at the time of the analysis (Fig. 3A).  
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Figure 2. Protein profiling of NMOB-EVs and MOB-EVs on day 5, 12 and 19 of cultures. A) GO annotations 
for cellular components, molecular functions and biological processes of EV proteins shared across the 6 EV 
groups (N = 2). Only the highest significantly (Benjamini P < 0.001) over-represented terms are shown. B) Sche-
matic representation of the protein families detected in all EVs determined based on literature and IPA. 
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Figure 3. Identification of novel osteoblast-specific EV proteins. A) Venn diagram shows the numbers of pro-
teins in EVs derived from NMOBs and MOBs and comparison with proteins reported in ExoCarta. B) GO annota-
tions of novel osteoblast EV proteins (panel A) not recorded in ExoCarta. Only the highest significantly (Benja-
mini P  < 0.001) over-represented terms are shown. The brackets indicate the number of proteins for each term. 
 
 
Table 1. The list of osteoblast-specific proteins uniquely detected in either NMOB-EVs or MOB-EVs. 
 
Osteoblast            UniProt Accession      Gene Symbol                            Description  
 
 
NMOB-EVs 
 
Q9BUB4 
 
ADAT1 
 
tRNA-specific adenosine deaminase 1 
P19784 CSNK2A2 Casein kinase II subunit alpha 
Q02539 HIST1H1A Histone H1.1 
    
 
MOB-EVs 
 
Q8TDN6 
 
BRIX1 
 
Ribosome biogenesis protein BRX1 homolog 
P45973 CBX5 Chromobox protein homolog 5 
Q7Z7A1 CNTRL Centriolin 
Q9UBL6 CPNE7 Copine-7 
Q9NVP1 DDX18 ATP-dependent RNA helicase DDX18 
P23743 DGKA Diacylglycerol kinase alpha 
Q9HCE0 EPG5 Ectopic P granules protein 5 homolog 
P46976 GYG1 Glycogenin-1 
Q13151 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 
O43731 KDELR3 ER lumen protein retaining receptor 3 
Q6VAB6 KSR2 Kinase suppressor of Ras 2 
O15243 LEPROT Leptin receptor gene-related protein 
Q9H0P0 NT5C3 Cytosolic 5-nucleotidase 3 
Q8TAD7 OCC1 Overexpressed in colon carcinoma 1 protein 
Q5T091 RER1 Protein RER1 
Q9GZN7 ROGDI Protein rogdi homolog 
P67812 SEC11A Signal peptidase complex catalytic subunit SEC11A 
P61011 SRP54 Signal recognition particle 54 kDa protein 
Q13242 SRSF9 Serine/arginine-rich splicing factor 9 
O14787 TNPO2 Transportin-2 
P11172 UMPS Uridine 5-monophosphate synthase 
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GO annotation analysis indicates that these osteoblast-specific proteins are mostly 
annotated to ribonucleoprotein complex, RNA-binding, ribosome, initiator factor and nu-
cleotide binding (Fig. 3B). Table 1 shows the list of the osteoblast-specific proteins that are 
uniquely detected in either NMOB-EVs or MOB-EVs. Together, these findings show that 
osteoblast EVs are enriched with known vesicular proteins while they also contain unique 
proteins depending on the mineralization condition.   
 
2.2.3. Label-free quantitative distribution of osteoblast EV proteins  
Absolute protein abundances can be estimated by label-free methods based on 
quantification using the peak intensities of the LC-MS/MS data. We used the iBAQ values 
from the MaxQuant analysis output to identify the most abundant proteins in each EV 
group, and compared the protein abundances between the different EV groups26. The most 
abundant EV proteins are the commonly known vesicular proteins, such as ANXA2, 
GAPDH, CD9, ENO1, PDCD61P, etc. for all EV groups (Fig. 4A)23. Interestingly, all EV 
groups contain high levels of histones. Multi-scatter plots in Figure 4B show the strong 
correlation between the protein content of the different EV groups. EV proteins isolated at 
different time-points during culture show a higher correlation when compared within a cul-
ture condition (i.e. within NMOBs and MOBs) than between the culture conditions. The 
differences between EVs derived from NMOBs and MOBs become more apparent as the 
cells start to mineralize on day 12 (Day 5: r=0.959, Day 12: r=0.912, Day 19: r=0.905). 
Next, we compared the average intensities of NMOB-EV and MOB-EV proteins 
isolated on the same day of culture to identify specifically enriched EV proteins. Proteins 
with more than five-fold increase in iBAQ intensities were regarded as more abundant in 
either one of the EV groups on that specific day of culture (Fig. 4C- 4E). In accordance 
with the scatter plots, the number of abundant MOB-EV proteins shows a strong increase 
from 46 to 279 and 321 on day 12 (onset of mineralization) and 19 (full mineralization), 
respectively (Fig. 4D & 4E). Surprisingly, these proteins are mostly annotated to RNA-
binding and processing, and not to matrix vesicle-dependent mineralization. NMOB-EVs 
are mainly enriched with cell adhesion-associated extracellular matrix proteins and chro-
mosomal proteins. Table 2 shows a representative list of proteins that were detected with 
more than five-fold abundance in either NMOB-EVs or MOB-EVs. The Venn diagrams in 
Figures 4F & 4G show the distribution of the proteins (i.e. those shown in Figures 4C- 4E) 
specifically enriched in either NMOB-EVs (Fig. 4F) or MOB-EVs (Fig. 4G) over the dif-
ferent culture time-points. HMGA2, PLAU, TNC and HIST1H1C are highly abundant at 
every time-point in NMOB-EVs. MOB-EVs are enriched with 22 proteins throughout cul-
ture, among which ALPL and CD109 show the most striking abundance. These results 
show that despite the similarity in protein content, osteoblast EVs are enriched with distinct 
proteins depending on the mineralization condition and the stage of differentiation. 
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Table 2. Representative list of proteins significantly enriched ( > five-fold) in either NMOB-EVs or MOB-EVs. 
 
Osteoblast            UniProt Accession      Gene Symbol                            Description  
 
 
NMOB-EVs 
 
   
Extracellular matrix proteins 
 P08253 MMP2 72 kDa type IV collagenase 
 P00749 PLAU Urokinase-type plasminogen activator 
 Q15582 TGFBI Transforming growth factor-beta-induced protein ig-h3 
 P35442 THBS2 Thrombospondin-2 
 P24821 TNC Tenascin 
 P13611 VCAN Versican core protein 
 
Chromosomal proteins 
 P07305 H1F0 Histone H1.0 
 P16403 HIST1H1C Histone H1.2 
 P62805 HIST1H4A Histone H4 
 P17096 HMGA1 High mobility group protein HMG-I 
 P52926 HMGA2 High mobility group protein HMGI-C 
    
 
MOB-EVs    
 
Ribonucleoprotein complexes 
 Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 
 Q12906 ILF3 Interleukin enhancer-binding factor 3 
 P49207 RPL34 60S ribosomal protein L34 
 P62847 RPS24 40S ribosomal protein S24 
 Q92616 GCN1L1 Translational activator GCN1 
 
RNA-binding proteins 
 Q9NR30 DDX21 Nucleolar RNA helicase 2 
 Q9Y2L1 DIS3 Exosome complex exonuclease RRP44 
 P20042 EIF2S2 Eukaryotic translation initiation factor 2 subunit 2 
 Q01081 U2AF1 Splicing factor U2AF 35 kDa subunit 
 Q9HAV4 XPO5 Exportin-5 
 
Nucleotide binding proteins 
 Q9UN86 G3BP2 Ras GTPase-activating protein-binding protein 2 
 P54652 HSPA2 Heat shock-related 70 kDa protein 2 
 O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 
 Q14566 MCM6 DNA replication licensing factor MCM6 
 P22694 PRKACB cAMP-dependent protein kinase catalytic subunit beta 
 
GTPase activity 
 P84085 ARF5 ADP-ribosylation factor 5 
 Q9NZN4 EHD2 EH domain-containing protein 2 
 P20591 MX1 Interferon-induced GTP-binding protein Mx1 
 P61020 RAB5B Ras-related protein Rab-5B 
 P08134 RHOC Rho-related GTP-binding protein RhoC 
 
Other 
 Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 
 P05186 ALPL Alkaline phosphatase, tissue-nonspecific isozyme 
 Q8ND76 CCNY Cyclin-Y;Cyclin-Y-like protein 2 
 Q6YHK3 CD109 CD109 antigen 
 Q13451 FKBP5 Peptidyl-prolyl cis-trans isomerase FKBP5 
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Figure 4. Comparative proteomic analysis of EVs secreted from NMOBs and MOBs during 19 days of cul-
ture. A) Heat map shows protein abundances (iBAQ values) across the six EV groups. The most abundant pro-
teins including the top identified EV markers (ExoCarta) are shown next to the heat map. Red, high abundance; 
green, low abundance; grey, no signal. B) Multi-scatter plots show the strong correlation between NMOB-EV and 
MOB-EV protein abundances. Venn diagrams C-G) show the number of proteins that are at least five-fold more 
abundant in either NMOB-EVs or MOB-EVs on (C) day 5, (D) day 12 and (E) day 19, and the distribution of the 
abundant proteins in (F) NMOB-EVs and (G) MOB-EVs at different stages of differentiation. 
 
2.2.4. Effect of osteoblast EVs on PC3 cell growth  
Next, we tested the functionality of EVs in intercellular communication. For this 
we chose the osteoblast-prostate tumor cell interaction. Proteomics analyses indicated that 
the EV proteome content of NMOBs and MOBs starts to show greater specificity on day 12 
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of cultures. Therefore, here we focused on day 12 EVs, and analyzed whether osteoblast 
EVs regulate PC3 cell growth and survival in vitro. First, we evaluated the uptake of osteo-
blast EVs by PC3 cells using fluorescence labeling. High-resolution 4Pi microscopy analy-
sis confirms that PC3 cells internalize the PKH67-labeled osteoblast EVs within 24 hours 
(Fig. 5A & 5B). Flow cytometry analyses indicate that EV uptake is dose-dependent (Fig. 
5C).  
 
 
Figure 5. Internalization of day 12 osteoblast EVs and their functional effect on PC3 cells. A-B) 4Pi images 
show the uptake of PKH67-labeled NMOB-EVs by PC3 cells. Panel (A) shows 3D reconstruction of all confocal 
stacks; panel (B) shows the half plane showing the EVs inside the cells. Images are representative for MOB-EVs 
uptake. Red, cell membrane & nucleus; green, PKH67-labeled EVs. See the online manuscript for supplemental 
movie. C) Flow cytometry analysis shows dose-dependent uptake (mean ± SD) of PKH67-labeled EVs by PC3 
cells (N = 2). Fold change is determined relative to untreated cells. D) Venn diagram shows the PC3 genes that 
were regulated in response to day 12 osteoblast EVs (2.86% v/v) by at least 1.5-fold. The numbers in brackets 
denote the genes that were up- and down-regulated by the respective EV group. E) Fold change of PC3 cell count 
(mean ± SD) after 5 days of incubation with different EV doses (N = 3). * P  < 0.05, ** P < 0.01, compared with 
control by two-way ANOVA. Control: cell-free culture medium processed the same way as the conditioned medi-
um. 
 
Next, we performed microarray analysis to investigate the effect of osteoblast EV 
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NMOB-EVs and MOB-EVs, and collected RNA after 4, 24 and 48 hours. Interestingly, 
treatment with the two different EV groups resulted in regulation of different sets of pros-
tate cancer genes (Appendix A, Table A3). We identified 98 and 76 genes that are regulat-
ed more than 1.5-fold by NMOB-EVs and MOB-EVs, respectively, compared to the con-
trol-treated cells (Fig. 5D). The two overlapping genes are FTHL8 and LOC728499, and 
they are down- and up-regulated by both EV groups, respectively. The majority of the 
genes in both treatment groups are down-regulated (74 out of 96 genes by NMOB-EVs and 
48 out of 74 genes by MOB-EVs). Ingenuity Pathway Analysis (IPA) indicated that even 
though the regulated genes are different they are annotated to similar molecular and cellular 
functions mainly related to cell growth and survival (P < 0.05). We assessed the effect of 
osteoblast EVs on PC3 cell growth by culturing the tumor cells with different EV concen-
trations for 5 days. Both NMOB-EVs and MOB-EVs induce two-fold increase of absolute 
cell numbers compared to control-treated cells (Fig. 5E). 
We used bioinformatics to integrate the proteomics and microarray data, and thus 
correlate the proteome of day 12 osteoblast EVs to the EV-regulated PC3 genes. We used 
IPA to build a network showing the direct molecular relationships between the EV proteins 
and the regulated PC3 genes for each treatment group (Fig. 6). 25 out of the 98 NMOB-
EV-regulated PC3 genes are mapped with 157 out of 980 day 12 NMOB-EV proteins (Fig. 
6A). Most proteins are annotated to vesicle and ribosomal proteins, and mainly interact 
with YWHAG and PAK2. For the MOB-EV treatment 38 out of 76 genes interact with 337 
proteins out of 1,079 day 12 MOB-EV proteins (Fig. 6B). Most of the mapped proteins are 
ribosomal proteins, and interact predominantly with RAD21 and CDK5. Together these 
results show that NMOB-EVs and MOB-EVs are both internalized by PC3 cells and regu-
late the expression of different prostate genes, however, both converging to stimulation of 
cell growth.  
 
2.3. DISCUSSION  
The findings described in this study showed that both NMOBs and MOBs secrete 
EVs selectively packaged with known vesicle proteins as well as an interesting range of 
proteins unique to the mineralization and differentiation status of the osteoblasts. Osteo-
blast EVs enter human prostate cancer cells, regulate the expression of cell growth-related 
prostate cancer genes, and stimulate their growth in vitro demonstrating their active role in 
intercellular communication.  
Osteoblasts actively undergo sequential events of differentiation along the course 
of their maturation. Previous work in our group showed the importance of studying protein 
and genetic composition of osteoblasts at different stages of their differentiation22,25. Here, 
we used a well-characterized human pre-osteoblast cell model to isolate EVs at three stages 
of differentiation to gain a comprehensive understanding of the osteoblast EV proteome: 
pre-mineralization (day 5), onset of mineralization (day 12) and full mineralization (day 
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19). We also isolated EVs from NMOBs at the same culture time-points as a comparison to 
elucidate the EV proteins not primarily linked to mineralization and thus understand their 
role in cell communication. Interestingly, 84% of the total proteins are shared between all 
the EV groups, and 97% are detected at least in one of the time-points in both NMOB-EVs 
and MOB-EVs. This was surprising as the TEM images show clear morphological differ-
ences between the EVs secreted by osteoblasts under different mineralization conditions. A 
large number of the overlapping proteins are novel proteins, primarily associated with ribo-
nucleoproteins, which were not recorded in the EV database ExoCarta at the time of the 
analysis. Even though we cannot exclude that part of these proteins may be arising from 
non-specific background, recent studies reporting the presence of vesicle-associated RNA-
binding proteins suggest that our osteoblast EVs contain novel proteins linked to known 
vesicle-related processes27,28. 
 
Figure 6. IPA network showing the direct relationship maps between the EV-regulated PC3 genes and day 
12 EV proteins for A) NMOB-EV and B) MOB-EV treatments. Green, down-regulated PC3 genes; red, up-
regulated PC3 genes; grey, EV proteins; black, EV proteins annotated to vesicles and ribosomes. The most pre-
dominantly mapped PC3 genes are highlighted  (blue line). 
 
We hypothesized that despite the similarities in cargo the different EV groups are 
specifically enriched with distinct proteins giving clues to their biological function. Label 
free quantification is a very useful proteomics tool to compare the relative abundances of 
proteins across different samples, which leads to a selection of proteins that can be ana-
lyzed for molecular function. All of the EV groups described in this study contain abundant 
levels of the classical vesicle proteins, such as annexins (ANXA2, ANXA6), tetraspanins 
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(CD9, CD81), and metabolic proteins (GAPDH, LDHA), verifying the robustness of these 
proteins as vesicle markers. It is interesting to note that histones are also among the highly 
enriched proteins detected in all EV groups. In fact, we previously showed that histone 
proteins are among the most abundant proteins in human bone suggesting the likelihood of 
possessing extranuclear roles29. In accordance, there have been increasing number of stud-
ies reporting the functionality of circulating nuclear proteins as well as their presence in 
apoptotic bodies, exosomes and microvesicles7,30-32. While the abundances of the predomi-
nant proteins are similar across all EV groups, we detected unique group of proteins that 
are at least five-fold more abundant in EVs secreted by either NMOBs or MOBs at a given 
culture time-point. Among the bone-related proteins ALPL is significantly enriched in 
MOB-EVs with an increasing abundance in time, which parallels the vesicular and cellular 
ALPL activity. Mineralization is indeed one of the most important processes of bone for-
mation with a major role for matrix vesicles. Thus, it is not surprising to observe the high 
level of vesicular ALPL activity in MOB-EVs compared to the donor cells.  However, GO 
analyses showing over-representation of vesicle-related processes over bone-related pro-
cesses suggest a role for EVs not primarily linked to mineralization. The most striking dif-
ferences between the EV groups are the enrichment of adhesion proteins and RNA-binding 
proteins in NMOB-EVs and MOB-EVs, respectively. 
To investigate the role of EVs in intercellular communication we tested EV uptake 
by prostate cancer cells and their effect on prostate cancer cell growth. Prostate cancer, 
which is one of the most frequently diagnosed cancers among men, is primarily associated 
with bone metastasis33. Osteoblast microenvironment consisting of a network of receptors 
and secreted factors acts as an attractive force and regulator of tumor cell growth34. We 
showed that PC3 prostate cancer cells dose-dependently internalize PKH67-labeled EVs 
derived from both NMOBs and MOBs. The fluorescence intensity of PC3 cells treated with 
MOB-EVs is higher than those treated with NMOB-EVs at any given EV dose. Due to the 
challenges of absolute quantification of EVs it is difficult to make an accurate quantitative 
comparison between the EV groups35. Moreover, the mode of internalization may contrib-
ute to the difference in fluorescence signal. EVs that are internalized via endocytosis are 
more likely to retain a stronger PKH67 signal compared to the EVs that transfer their cargo 
via fusion in host cell’s plasma membrane. Here, we observed that osteoblast EVs retain 
their fluorescence upon overnight cultures. Therefore it seems that endocytosis is involved 
in their uptake, however, we cannot rule out the involvement of other uptake modes.  
Studying the molecular mechanism of cancer survival and growth is an important 
area of investigation. In particular bone metastasis, which is considered an incurable stage 
of the disease, is of great interest with clinical significance. Our EV treatment studies 
demonstrated that both NMOB-EVs and MOB-EVs stimulate the growth of PC3 cells in 
vitro. This shows that osteoblast EVs are not only internalized by the prostate cancer cells 
but that they are also functional and can stimulate prostate cancer cell growth. This was 
further supported by PC3 cell gene expression analysis, which revealed the EV-regulated 
prostate cancer genes are mainly involved in cell survival and growth. It is important to 
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note that the two EV groups affect the regulation of different sets of prostate cancer genes, 
which are annotated to similar molecular functions. This is most likely due to the differ-
ences in their bioactive cargo that may act via different pathways leading to the same bio-
logical outcome.  
Proteomic analyses showed that there are differences in protein abundances be-
tween day 12 NMOB-EVs and MOB-EVs. When we mapped the EV proteins with the reg-
ulated prostate genes in an interaction network we found that the MOB-EV-regulated genes 
are mostly mapped with ribosomal and RNA-binding proteins. Previous studies showed the 
role of ribosomal proteins in physiological events, such as proliferation and cell growth, 
besides the well-known role in protein biosynthesis36.  Lai and colleagues showed that ribo-
somal proteins are also involved in cancer progression and metastasis37. Particularly, ribo-
somal proteins have been shown to have elevated expression levels in prostate tumors, and 
hence play an important role in prostate cancer development38,39. NMOB-EV-regulated 
genes are mostly mapped with known vesicle proteins, mainly consisting of signaling pro-
teins and chaperones, as well as ribosomal proteins that may act via different pathways than 
the MOB-EV proteins. 14-3-3 family proteins are involved in various signaling cascades 
and have been shown to be regulators of prostate cancer tumor formation with the excep-
tion of 14-3-3σ protein, a tumor suppressor, which is most interestingly not present in oste-
oblast EVs40,41. Chaperones, such as heat shock proteins, have been shown to be negative 
regulators of apoptosis during prostate tumorigenesis suggesting an anti-apoptotic role for 
our chaperone-containing osteoblast EVs42. With the growing interest in the field, more 
comprehensive information on EV composition and knowledge on their molecular function 
in diverse biological and pathological processes is becoming of utmost importance. Alter-
natively, increasing reports on EV biogenesis, content and targeting may provide the basis 
for their exploitation as carriers of therapeutic cargo for targeted cancer therapy, cell thera-
py and tissue engineering43-45. In this study, we demonstrated that osteoblast EVs play a 
role in the crosstalk between osteoblasts and prostate cancer cells highlighting the im-
portance of EV cargo in cancer regulation. We anticipate that deeper investigation of EV 
function in the bone microenvironment will help us develop preventive or curative thera-
pies for a broad variety of pathological conditions.  
In conclusion, our data give insights into the morphology and proteomic composi-
tion of osteoblast EVs at different stages of differentiation under mineralizing and non-
mineralizing conditions. Proteomic analyses presented here suggest a role for osteoblast 
EVs in intercellular communication besides a well-characterized role in mineralization. We 
further demonstrate the existence of an EV-driven interaction between osteoblasts and 
prostate cancer cells stressing the clinical/pathophysiological significance of our data. Al-
beit, challenges still remain, as we need optimized tools to quantify and separate different 
sub-populations of EVs and to interpret the roles of individual proteins in the context of 
communication. The present study unequivocally demonstrates that osteoblasts produce 
EVs that can enter other cells and stimulate their proliferation. This provides an additional 
way by which osteoblasts may regulate their microenvironment, not only metastatic pros-
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tate cancer cells, but also the surrounding bone marrow cells, such as hematopoietic stem 
cells and osteoclasts.  
 
2.4. MATERIALS AND METHODS 
Cell cultures. Simian virus 40-immortalized human osteoblast cell line (SV-HFO cells) 
established from normal human fetal calvaria was cultured as described previously with 
modifications22. Cells were seeded at a density of 5 × 103 cells/ cm2 and cultured in α-
MEM (GIBCO, Paisley, UK) supplemented with 20 mM HEPES, pH 7.5 (Sigma, St. Lou-
is, MO, USA), streptomycin/ penicillin, 1.8 mM CaCl2 (Sigma), 10 mM β-
glycerophosphate (Sigma) and 2% depleted (100,000g for 90 minutes at 4°C)-FCS (GIB-
CO) at 37°C in a humidified atmosphere of 5% CO2 for up to 19 days. The culture medium 
was replaced every 2-3 days. SV-HFOs were washed with 1X PBS and refreshed with se-
rum-free medium 24 hours prior to EV isolation. PC3 cells were cultured in α-MEM 
(GIBCO) supplemented with streptomycin/ penicillin, 1.8 mM CaCl2 (Sigma) and 10% 
FCS at 37°C in a humidified atmosphere of 5% CO2. For functional experiments PC3 cell 
culture medium was supplemented with 2% FCS. 
EV isolation. Osteoblast-EVs were isolated from 20 ml conditioned medium by low speed 
centrifugation (1,500 rpm, 5 minutes; 4,500 rpm, 10 minutes) followed by ultracentrifuga-
tion (20,000g, 30 minutes; 100,000g, 1 hour at 4°C) of the supernatant using the SW28 
rotor (Beckman Coulter, Fullerton, CA, USA). The 100,000g EV pellet was re-suspended 
in 20 µl fixative for TEM, 100 µl PBS for biochemical assays and immunoblotting, and 
100 µl PC3 culture medium for functional experiments. EVs were labeled with PKH67 
(Sigma) according to the manufacturer’s instructions. The amount of experimental EV dose 
was determined as 5% (v/v). Cell- and serum-free SV-HFO culture medium was processes 
the same way as the conditioned medium, and was used as a control for functional experi-
ments. 
 
Biochemical assays. Alizarin staining, protein concentration, ALPL activity assay, and 
DNA quantification were performed as described previously46. Briefly, mineralization of 
the bone matrix was monitored by Alizarin Red staining of the calcium matrix. Cells were 
fixed with 70% ethanol for 60 minutes on ice. After fixation, cells were washed with 1X 
PBS twice and stained with Alizarin Red solution (saturated Alizarin Red in demineralized 
water titrated to pH 4.2 with 0.5% ammonium hydroxide) for 10 minutes. Protein concen-
tration was determined using the BCA kit (Pierce Biotechnology, Rockford, IL, USA) fol-
lowing the manufacturer’s instructions. ALPL activity of the whole cell lysates and EVs 
was determined in a colorimetric assay detecting the release of paranitrophenol from para-
nitrophenyl phosphate upon reaction catalyzed by endogenous ALPL. The activity was 
displayed as enzyme units per milligrams of total protein. DNA was quantified by spectro-
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fluorimetry using ethidium bromide. Samples were analyzed by a microplate reader using 
an excitation filter of 340 nm and an emission filter of 590 nm. 
Immunoblot analysis. Protein samples were prepared by mixing the EVs (in PBS) with 
6X reducing sample buffer immediately after isolation. EV proteins (3µg total protein/ 
sample) were separated by SDS-PAGE at 200 V and transferred onto a nitrocellulose 
membrane (Hybond-ECL, Amersham Biosciences, Buckinghamshire, UK). After blocking 
non-specific signal with 5% BSA in TBS/ 0.1% Tween-20, the membrane was incubated 
with primary antibodies against annexin A2 (rabbit polyclonal, 1:500, Abcam, Cambridge, 
UK) and CD63 (rabbit polyclonal, 1:1000, SantaCruz, Dallas, TX, USA). Membranes were 
probed with secondary antibody conjugated with IRDye 800CW (1:5000, goat anti-rabbit, 
LI-COR, Lincoln, NE, USA) using Odyssey Infrared Imaging System according to the 
manufacturer’s instructions (LI-COR).  
Flow cytometry. PC3 cells were incubated with different concentrations (% v/v) of 
PKH67-labeled day 12 osteoblast EVs and EV control. After overnight culture the mean 
fluorescence intensity was detected by flow cytometry (BD Accuri C6, BD Biosciences, 
San Jose, CA, USA) using the FITC channel. Absolute cell counts were determined using 
counting beads (BD Biosciences).  
Transmission electron microscopy. EVs were fixed in 4% formaldehyde (37% solution, 
Merck, New York, NY, USA) in 1% glutaraldehyde (25% solution, Merck) at 4°C 
(Trump’s fixative). Fixative was removed by incubating the sample in Millonig buffer 
(NaH2PO4.H2O) (BDH Chemicals, Radnor, PA, USA) for 6 hours followed by post-
fixation with 1% osmium tetroxide (4% solution, Electron Microscopy Sciences, Hatfield, 
PA, USA). The samples were rinsed with distilled water and a series of acetone concentra-
tions (50%, 70%, 90%, 96%, 100%). The EV pellets were incubated on pure epoxy resin 
for 1 hour at 37°C, and then embedded in fresh epoxy and polymerized for 12 hours at 
60°C. The polymerized resin was cut into thin sections (40-60 nm) using ultramicrotome 
(Leica Ultracut UCT, Wetzlar, Germany) and a diamond knife (Diatome, Hatfield, PA, 
USA) and mounted on a copper grid. The sample was detected by TEM (Morgagni, 
Philips/FEI, Hillsboro, OR, USA). 
4Pi microscopy. EV uptake by PC3 cells was monitored using 4Pi microscope, which is a 
confocal fluorescence microscope with an improved axial resolution by a factor of 5-7 over 
conventional confocal microscopes47. PC3 cells were seeded on poly-lysine coated quartz 
coverslips. After overnight incubation with PKH67-labeled EVs, cells were washed with 
PBS, fixed with 10% formalin, stained with concanavalin A (Alexa Fluor 647 conjugate, 
Life Technologies, Carlsbad, CA, USA). The fixed cells were washed 3 times with 0.01 M 
PBS and then 3 times impregnated with 87% glycerol. The coverslip was mounted on a 
special 4Pi sample holder and covered with another quartz coverslip, using 87% glycerol as 
mounting medium giving the whole beam path a refractive index of 1.45848. The coverslips 
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were sealed with 2-component silicon (Twinsil, Picodent, Germany). Images were taken 
with a Leica 4Pi TCS microscope using two opposing 100X 1.35NA glycerol HCX PL 
APO objectives. A two-photon Ti-Sapphire laser (Mai Tai, Spectra Physics, Santa Clara, 
CA, USA) was used for excitation at 800 nm wavelength49. Avalanche photo diodes were 
used for detection of the signals with a 500-550 nm bandpass filter for PKH67 and a 647-
703 nm bandpass filter for Alexa647. Images were deconvoluted with Imspector (Max-
Planck Innovation, Munich, Germany). Images and the video were generated using ImageJ 
3D Viewer plugin. 
Mass spectrometry. EV proteins (8 µg protein/ sample) were separated by NuPage Novex 
4-12% Bis-Tris gel (Life Technologies), and stained with Coomassie (Bio-Rad, Hercules, 
CA, USA) for 1 hour and de-stained with water overnight. 1D SDS-PAGE gel lanes were 
cut into 2-mm slices using an automatic gel slicer and subjected to in-gel reduction with 
dithiothreitol, alkylation with iodoacetamide (D4, 98%, Cambridge Isotope Laboratories, 
Inc., Tewksbury, MA, USA) and digestion with trypsin (Promega, sequencing grade, Madi-
son, WI, USA)50. Nanoflow LC-MS/MS was performed on a 1100 series capillary LC sys-
tem (Agilent Technologies, Santa Clara, CA, USA) coupled to an LTQ-Orbitrap XL mass 
spectrometer (Thermo Scientific, Waltham, MA, USA) operating in positive mode25.  Pep-
tide mixtures were trapped on a ReproSil C18 reversed phase column (Dr Maisch GmbH; 
1.5 cm × 100 µm, packed in-house) at a flow rate of 8 µl/ minute. Peptide separation was 
performed on ReproSil C18 reversed phase column (Dr. Maisch GmbH, Ammerbuch-
Entringen, GE; 15 cm × 50 µm, packed in-house) using a linear gradient from 0 to 80% B 
(A = 0.1% formic acid; B = 80% (v/v) acetonitrile, 0.1% formic acid) in 170 minutes and at 
aconstant flow rate of 200 nl/ minute using a splitter. The column eluent was directly 
sprayed into the ESI source of the mass spectrometer. Mass spectra were acquired in con-
tinuum mode, and fragmentation of the peptides was performed in data-dependent mode.  
Microarray analysis. PC3 cells were incubated with day 12 osteoblast EVs and their con-
trols for 4, 24 and 48 hours. Total PC3 cell RNA was isolated using TRIzol (Life Technol-
ogies) extraction method according to the manufacturer’s instructions. RNA samples were 
prepared for microarray analysis using the Illumina TotalPrep RNA Amplification Kit 
(Ambion, Life Technologies) according to the manufacturer’s instructions. Biotinylated 
cRNA was hybridized to HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, 
CA, USA) microarray chips according to the manufacturer’s protocol. Data acquisition was 
performed using iScan (Illumina).  
Bioinformatic analysis. The raw MS data were analyzed using the MaxQuant software 
(version 1.3.0.5)51. A false discovery rate of 0.01 for proteins and peptides and a minimum 
peptide length of 6 amino acids were required. The Andromeda search engine52 was used to 
search the MS/MS spectra against the Uniprot database (taxonomy: Homo sapiens, release 
HUMAN_2013_04) concatenated with the reversed versions of all sequences (maximum of 
two missed cleavages; 0.6 Da fragment mass tolerance, enzyme specificity: trypsin). Only 
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proteins identified with at least 2 unique peptides and 2 quantitation events were considered 
for analysis. The data from the replicates were combined as averages of label-free quantifi-
cation intensity values for each EV group defined by the mineralization condition and the 
day of culture. Perseus 1.3.0.4 (Max Planck Institute of Biochemistry 2012) was used to 
generate the heat map and scatter plots based on iBAQ values. DAVID Bionformatics Re-
sources v6.7 was used to categorize the proteins into overrepresented processes using our 
previously described SV-HFO gene expression dataset as a background53,54. ExoCarta data-
base (Release date: 29 May 2012) was used for comparative EV analysis. IPA (Ingenuity® 
Systems, www.ingenuity.com) was used to analyze the interaction between EV proteome 
and PC3 genes using the path explorer tool in My Pathway analysis. 
Statistics. The results were described as mean ± SD based on at least two independent ex-
periments. Significance was calculated using two-way ANOVA test and P values of < 0.05 
were considered significant. 
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Extracellular vesicles (EVs) are membrane-bound intercellular communication vehicles 
that transport proteins, lipids and nucleic acids with regulatory capacity between cells. 
RNA profiling using microarrays and sequencing technologies has revolutionized the dis-
covery of EV-RNA content, which is crucial to understand the molecular mechanism of EV 
function. Recent studies have indicated that EVs are enriched with specific RNAs com-
pared to the originating cells suggestive of an active sorting mechanism. In this study, we 
present the comparative transcriptome analysis of human osteoblasts and their correspond-
ing EVs using next-generation sequencing. We demonstrate that osteoblast-EVs are specif-
ically depleted of cellular mRNAs that encode proteins involved in basic cellular activities, 
such as cytoskeletal functions, cell survival and apoptosis. In contrast, EVs are significantly 
enriched with 254 mRNAs that are associated with protein translation and RNA processing. 
Moreover, mRNAs enriched in EVs encode proteins important for communication with the 
surrounding cells, in particular with osteoclasts, adipocytes and hematopoietic stem cells. 
Strikingly, EVs are particularly enriched with RAB13 mRNA, which is linked to vesicular 
trafficking. The latter suggests that EVs may affect vesicle production in target cells. These 
findings provide the foundation for understanding the molecular mechanism and function 
of EV-mediated interactions between osteoblasts and the surrounding bone microenviron-
ment. 
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3.1. INTRODUCTION 
Extracellular RNAs have long been utilized as non-invasive tools for early diag-
nosis of clinical disorders1,2. More recently, various studies reported RNA transfer between 
cells providing cues to their biological significance3,4. The majority of the extracellular 
RNA is found in tight complexes with proteins or lipids, as a protection against the action 
of RNases present in the circulation5,6. The discovery of RNA with regulatory capacity 
packaged inside extracellular vesicles (EVs) greatly contributed to the understanding of a 
novel mode of communication between cells7-9.  
EVs are actively secreted small membrane-bound structures consisting of a lipid 
bilayer enclosing a lumen that contains a bioactive message in forms of lipids, proteins and 
nucleic acids10-12. Extensive studies of EVs present in cell culture media or biological fluids 
revealed that EVs are very heterogeneous in size (10 nm to 5 µm) and morphology.  Most 
often they are classified in at least three categories, such as exosomes, microvesicles and 
apoptotic bodies, merely based on their biogenesis. Their specific structure is essential for 
the protection of the vesicular cargo in the extracellular environment until they reach the 
target cells, where they regulate a broad range of biological functions13-15. Advanced high 
throughput RNA and protein analysis methods (‘omics’ technologies) have greatly facili-
tated the characterization of EV content and our ability to understand EV function. Since 
the first discovery of EV-associated RNA, many studies have focused on delineating the 
EV-RNA profile16-18. Interestingly, EVs are devoid of cellular ribosomal RNA (rRNA), and 
instead are enriched with small RNA molecules suggestive of active sorting rather than 
random incorporation as a by-product from dying cells8. Moreover, distinct EV-RNA pat-
terns are evident in EVs from different cellular sources emphasizing the specificity of cargo 
loading in EVs. Expression profiling studies focusing on mRNA and microRNA (miRNA) 
analysis by next-generation sequencing or microarray analyses have shown that numerous 
small non-coding RNA molecules (e.g. small nuclear RNAs, vault RNA, Y RNA) are pre-
sent inside EVs19-21. At present, there is a significant body of evidence indicating that EV-
RNAs are important for development, immunology, angiogenesis, stem cell biology, and 
cancer, among many other biological functions22-25.  
Osteoblasts are specialized bone cells that are responsible for the formation of the 
mineralized bone tissue. It has been well established that they also play pivotal roles in 
maintaining cellular homeostasis by regulating the interactions with the surrounding cells26-
28. In Chapter 2, we showed that osteoblasts secrete EVs packaged with functional proteins 
that contribute to the complex network of communication with the cells in the osteoblastic 
microenvironment29. The crosstalk is also highly regulated at the level of gene expression. 
In the present study, we employed next-generation sequencing analysis for in-depth charac-
terization of the mRNA content of EVs that are secreted by human osteoblasts. Using a 
bioinformatics workflow, we described the mRNA species that are selectively incorporated 
into EVs or depleted from EVs during their biogenesis, and explored the molecular func-
tions by which osteoblasts may deliver their specific message. Our comprehensive tran-
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scriptome profiling represents a versatile resource for diverse biomedical applications rang-
ing from biomarker discovery to gene therapy.  
 
3.2. RESULTS 
3.2.1. Osteoblasts secrete RNA containing EVs  
To characterize the transcriptome of EVs, we isolated RNAs present in EVs re-
leased by human osteoblastic cells (SV-HFOs) at day 12-14 of their maturation. EVs were 
isolated from the conditioned medium by a series of ultracentrifugation steps and character-
ized by microscopy before EV-RNA isolation. Transmission electron microscopy (Fig. 1A) 
and nanoparticle tracking analysis (Fig. 1B) show the heterogeneous morphology and size 
distribution of the EV population with an average size of 158 nm.  
 
 
Figure 1. Size and morphology of osteoblast-EVs. A) Representative transmission electron microscope image 
(× 28,000) of EVs isolated from human osteoblasts. Scale bar: 500 nm. B) Nanoparticle tracking analysis shows 
EV size distribution and concentration. (N = 3). 
 
Next, we isolated total EV-RNA using the TRIzol® extraction method. Quality 
control of RNA samples revealed that the yield is consistent between the independent EV 
preparations, with an average of 2.6 µg EV-RNA deriving from 80 ml of culture medium 
(Appendix A, Table A4). In parallel, we also isolated total RNA from the same osteoblasts 
to permit a direct comparison of RNA content. Representative Bioanalyzer electrophero-
grams show expected differences in the RNA size distribution profiles for osteoblasts and 
their corresponding EVs (Fig. 2A & 2B). EVs mainly contain small RNAs with a size 
range between 25 and 1,000 nucleotides, and lack the intact rRNA peaks characteristic of 
cellular 18S and 28S rRNAs. These findings emphasize the robustness of our isolation 
techniques and clearly demonstrate the distinctiveness of EV-RNA content compared to 
their parental cells. 
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Figure 2. RNA profiling of human osteoblasts and osteoblast-EVs. A-B) Representative Agilent Bioanalyzer 
electropherograms show the size distribution of total RNA extracted from (A) osteoblasts and (B) osteoblast-EVs 
(N = 3). Arrows show the characteristic cellular 18S (left) and 28S (right) rRNA peaks. FU, fluorescent units.  
 
 
 
Figure 3. Flowchart of the mRNA-sequencing data analysis. Total cellular and EV-RNA was isolated using 
TRIzol® extraction method, and after poly-A tail selection with oligo(dT) primers the RNA was sequenced via 
high throughput next-generation sequencing (N = 3). Initially, the reads were mapped to human genome and then 
the read counts were normalized and converted to counts per million mapped reads (CPM), which were subse-
quently converted to reads per kilobase per million (RPKM) mapped reads using Edge R. The reads were further 
filtered to remove low quality reads (CPM ≤ 1 and RPKM ≤ 0.1). Only the transcripts that mapped to mRNAs, 
which were detected in all replicates were considered for further analysis. Highly abundant mRNA transcripts that 
were enriched in EVs compared to the donor osteoblasts were studied via volcano plot and MA plot analyses.  
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3.2.2. EV-mRNA profiling using next-generation sequencing 
We investigated the EV-mRNA profile at high resolution by next-generation se-
quencing. We constructed sequencing libraries from three independent osteoblast cultures 
and their derived EVs, and analyzed the data using an established bioinformatics workflow 
(Figure 3).  
The detected RNA read counts are robust and reproducible between the sequenc-
ing libraries, indicating a consistent distribution across independent preparations (Appendix 
A, Table A5). Scatter plot in Figure 4A shows a fairly strong positive correlation between 
cellular RNA and EV-RNA (R2: 0.731, P < 0.0001). As expected, the majority of the tran-
scripts are mapped to mRNA sequences for both osteoblasts (11,629 mRNAs) and EVs 
(11,714 mRNAs) (Fig. 4B). Classification of cellular- and EV-mRNAs shows a high diver-
sity of biochemical functions (Fig. 4C).  
 
 
Figure 4. Next-generation sequencing mRNA profiling of osteoblast-EVs. A) Scatter plot shows the correla-
tion (R2: 0.731) of normalized read counts (average CPM) between cellular and EV transcripts (N = 3). B) Pie 
chart shows the fraction of transcripts that were mapped to protein-coding mRNAs in EVs (dark gray). Cellular 
mRNA percentage is shown in brackets. C) Functional classification of the detected cellular and EV-mRNAs. 
 
As it is evident from the scatter plot, the majority of the mRNAs are shared be-
tween osteoblasts and their derived EVs. Yet, a small but significant fraction of mRNAs is 
exclusive to either osteoblasts or EVs [5.9% (693 mRNAs) and 5.2% (608 mRNAs), re-
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spectively] (Fig. 5A). These exclusive mRNAs are expressed at relatively low levels and 
represent a small fraction of total cellular- and EV-mRNA read counts (0.16% and 0.17%, 
respectively). Interestingly, the top 100 highly expressed genes account for 58.25% of all 
mapped EV-mRNA read counts, whereas only 34.04% account for the top 100 mapped 
mRNAs in the cells (Fig. 5B). This result suggests a specific enrichment of biologically 
significant mRNAs in EVs. The majority of these mRNAs (78 mRNAs) appear in both the 
top 100 of either the cellular- or EV-derived transcriptome, and many encode rather ubiqui-
tous ribosomal proteins (Fig. 5C). The remaining top EV-mRNAs (22 mRNAs) are mostly 
associated with oxidative phosphorylation and protein transport (Fig. 5D). In contrast, the 
cellular transcriptome is enriched with mRNAs required for essential cellular functions, 
such as glycolysis, cell motion and regulation of apoptosis (Fig. 5E). Taken together, these 
results indicate that even though EV-mRNA content mirrors the transcriptome of their do-
nor cells, EVs exhibit a distinct pattern in distribution of mRNA abundance. These findings 
clearly indicate that mRNAs are selectively sorted into EVs, rather than randomly incorpo-
rated during vesicular trafficking and extracellular release. 
 
3.2.3. EVs are selectively enriched with a subset of mRNAs  
We assessed the relative abundance of mRNAs in cells and EVs to determine the 
types of mRNAs that are specifically enriched in EVs. Volcano plotting shows that 254 
mRNAs are significantly (P < 0.05) more abundant (≥ two-fold) in EVs compared to the 
cells (Fig. 6A, Appendix A, Table A6). The most highly enriched EV-mRNAs (“Top 10”) 
are RAB13, ARRDC4, NEFM, IGIP, NET1, RASSF3, HMGN5, TRAK2, ESF1 and ZEB1, in 
descending order of fold enrichment. Bioinformatic analysis using the Ingenuity Pathway 
Analysis (IPA) revealed that cellular processes, such as RNA post-transcriptional modifica-
tion, gene expression and cell-to-cell signaling and interaction, are strongly overrepresent-
ed in EV-mRNAs. On the other hand, the transcriptome of EVs is depleted of 2,192 cellu-
lar mRNAs that are selectively linked to essential cellular processes, such as cell death and 
survival and cellular growth and proliferation. Strikingly, EVs preferentially contain 
mRNAs that encode proteins involved in cell-to-cell communication in the bone and bone 
marrow microenvironment. These include the genes involved in the recruitment of osteo-
clasts (NFKBIB, PGF), priming of adipose cells (FGF1), as well as self-renewal and pro-
liferative expansion of hematopoietic stem and progenitor cells (FLT3LG, IL18, HOXB7, 
CCND1, CCND2) (Fig. 6B). 
Among the 254 enriched EV-mRNAs, osteoblast-EVs contain 49 unique mRNAs 
that have not been previously detected in EVs secreted by other cells or present in body 
fluids (Fig. 6C)30. These unique mRNAs are mostly annotated to zinc ion-binding (AGAP2, 
ZNF677, ZNF846), regulation of transcription (BDP1, SOX11, TAF7L) and kinase activity 
(LPAR1, MAP3K13, ZEB2). Furthermore, we compared the enriched EV-mRNA dataset to 
the protein content of the corresponding osteoblast-derived EVs described in Chapter 2. For 
§ Chapter 3 
	  68 
a limited number of mRNAs (18 mRNAs), osteoblast-EVs contain the corresponding pro-
tein (Fig. 6D). Two of these are derived from osteoblast-EV specific mRNAs (HIST1H1E 
and LPAR1), whereas the remaining 16 proteins include ribonucleoproteins (HNRNPA1, 
HNRNPA3, HNRNPH3), translation initiation factors (EIF3A, EIF5B), histones 
(HIST1H2BH, HIST1H2BO) and others (MAP4K4, NAP1L1, NCL, PABPC1, SEPT7, SET, 
ST13, YES1).  
 
 
Figure 5. The most abundant cellular and EV-mRNAs. A) Venn diagram shows the distribution of mRNAs 
between osteoblast and EVs. B) Top 100 most abundant mRNAs make up more than 50% of the total RPKM 
values for EVs. C) Top 100 EV-mRNAs are mostly annotated to genes encoding for proteins involved in protein 
synthesis and RNA processing. D-E) RPKM values of the representative top 100 (D) EV-mRNAs and (E) cellular 
RNAs.  
 
Next, we visualized log ratios of the normalized read counts for mRNAs from EVs 
versus cells relative to their mean abundance. The resulting MA plot compares the expres-
sion levels of the 254 mRNAs enriched by at least two-fold in EVs. Remarkably, RAB13 is 
both the most highly enriched and most abundant EV-mRNA that is selectively incorpo-
0 2,000 4,000 6,000 8,000 10,000
RPS18
RPS3A
RPL41
RPS6
RPL37A
LGALS1
GAPDH
PKM2
ENO1
LDHA
ACTB
TUBB
ANXA5
CCL2
IFI6
RPKM
Cells
Ribosomal
proteins
Cell 
motion
Regulation of
apoptosis
Glycolysis
EVs Cells
0
50
100
%
 T
ot
al
 R
PK
M
Top 100
100 - 1000
Other
Figure 4 Morhayim et al. 
A 
D 
EVs 
Cells 
608 
11,021 
693 
B 
Other 
RNA 
 Processing Protein 
Synthesis 
C Top 100 genes 
E 
OK#
0 10,000 20,000 30,000
RPS18
RPL41
RPL37A
RPS27
RPS12
RPL23
RPL31
RPL34
RPL37
RPS20
COX7C
COX4I1
COX7B
RAB13
NPM1
RPKM
EVs
Ribosomal
proteins
Oxidative 
phosphorylation
Protein transport
mRNA profiling of osteoblast-derived EVs 
	   69 
rated in EVs compared to the EV-producing osteoblasts (Fig. 7A). Furthermore, it is the 
only member of the Rab GTPase family with such a striking selective abundance in EVs, 
strongly suggesting that RAB13 is specifically enriched in EVs (Fig. 7B). We evaluated the 
expression levels of RAB13 along with ATP5E, which show similar cellular and vesicular 
abundances in sequencing analysis (Fig. 7C). Quantitative real-time PCR results confirm 
the significant enrichment of RAB13 in EVs, consistent with the sequencing data (Fig. 7D).  
 
Figure 6. Selectively enriched EV-mRNAs. A) Volcano plot (significance versus fold change) shows the signifi-
cantly (P < 0.05, compared with osteoblasts by Student’s t-test) abundant  (≥ two-fold; 254 mRNAs) and depleted 
(≤ 0.5-fold; 2192 mRNAs) EV-mRNAs based on CPM values. The top 10 most enriched EV-mRNAs are high-
lighted in blue. B) Fold change distribution of selected genes annotated to overrepresented biological processes, 
such as induction of proliferation and expansion of hematopoietic stem and progenitor cells (HSPCs), recruitment 
of osteoclasts, and priming of adipocytes. C) Venn diagram shows the number of unique mRNAs detected in 
osteoblast-EVs in comparison with Vesiclepedia. D) Venn diagram shows the overlap between the EV-protein and 
-mRNA content. 
 
Using IPA, we investigated the molecular functions and canonical pathways asso-
ciated with the RAB13 protein (Fig. 7E). We identified 26 proteins that are directly or indi-
rectly coupled to the activity of RAB13. These proteins have molecular and cellular func-
tions related to DNA replication, recombination and repair, cellular growth and prolifera-
tion, cellular assembly and organization, cell movement, and cell morphology. The main 
canonical pathways in which RAB13 participates are TGF-β signaling, cell cycle control of 
chromosomal replication and nucleotide excision repair pathway. In addition, several of 
these RAB13 associated proteins regulate the proliferation of stromal cells, chondrocytes, 
blood cells and tumor cells, which are precisely the potential target cells that physiological-
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ly interact with osteoblasts in the bone microenvironment. Taken together, our study is 
consistent with the broader concept that osteoblasts communicate with their surrounding 
cells by generating EVs that are actively loaded with specific bioactive molecules. This 
molecular cargo encompasses a selective group of mRNAs capable of providing defined 
regulatory signals to recipient cells.  
 
3.3. DISCUSSION 
The discovery of extracellular RNA (e.g. circulating RNA, EV-RNA) with regula-
tory functions has tremendous ramifications for both medical sciences and clinical applica-
tions. In this study, we reported the extensive profiling of mRNAs incorporated within EVs 
released by human osteoblasts. We showed that EVs to some degree contain the mRNA 
signature of their host cells while being selectively enriched with a unique set of mRNAs 
that may support intercellular communication. Our findings provide a major advancement 
in our understanding of EVs as a newly discovered mode of communication between oste-
oblasts and the surrounding microenvironment. 
We previously showed that osteoblasts secrete EVs containing a specific set of 
proteins important for their communication with their target cells29. Here, we investigated 
the mRNA profile of osteoblast-EVs to further characterize and discover the role of EVs in 
intercellular communication. Currently, the EV field is still challenged by variation in the 
reliability and procedural differences in EV-RNA isolation protocols31,32. In our study, we 
reproducibly obtained satisfactory RNA yields with robust size distributions that were con-
sistent between the different preparations. Bioanalyzer profiles of our total RNA prepara-
tions show that osteoblast-EVs lack the typical cellular rRNAs and are enriched with small 
RNAs that range from 25 to 1,000 nucleotides, in accordance with other EV-RNA 
studies33-35. Diverse cell types secrete small EV-RNAs that mainly consist of miRNAs and 
other small non-coding RNA molecules. Yet, there is increasing evidence showing the 
presence of functional mRNA specifically packaged inside EVs. However, intact mamma-
lian mRNAs typically range between 400 and 12,000 nucleotides in length36. The smaller 
size range of EV-derived RNAs inevitably leads to the question whether EVs are enriched 
with full-length mRNAs of intermediate size or merely with mRNA fragments. A report by 
Batagov and colleagues presented data indicating that EVs contain fragments derived from 
the 3'-untranslated regions (3’-UTR) of certain mRNAs to protect the target mRNA against 
miRNA degradation37. On the other hand, several other studies reported the transfer of full-
length EV-mRNA between cells with subsequent translation into functional proteins by the 
recipient cells38-40. It is conceivable that cells may transmit both full-length mRNAs and 3’-
UTR fragments as a two-pronged strategy that, first, instructs translation of proteins in the 
recipient cell, and second, relieves miRNA-mediated translation inhibition by competition 
with 3’-UTRs containing relevant miRNA binding sequences. 
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Figure 7.  EVs are selectively enriched with RAB13 mRNA. A) MA plot (fold change versus abundance) shows 
the RPKM values of the significantly enriched EV-mRNAs. RAB13, which is both the most enriched and abun-
dant mRNA detected in EVs, is highlighted blue. B) MA plot of the Rab family mRNAs detected in both cells and 
EVs. RAB13 is the only Rab family mRNA that is highly enriched in EVs compared to the donor osteoblasts. C-
D) Relative expressions of RAB13 and ATP5E in EVs and cells by (C) qPCR (N = 6) and (D) mRNA-sequencing 
(N = 3).  The qPCR results are normalized to average GAPDH expression. The mRNA-sequencing results are 
shown as average fold change of RPKM values relative to GAPDH. E) IPA interaction network shows the predict-
ed biological functions (grey) associated with the downstream targets (black) of RAB13 protein. * P < 0.05, com-
pared with cells by Student’s t-test; ns, not significant. 
 
Next-generation sequencing technologies have permitted comprehensive analyses 
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RNA levels. We applied next-generation sequencing to identify RNA reads that correspond 
to 11,714 EV-mRNAs. The content and abundance profile of this mRNA set mirrors the 
mRNAs detected in donor cells. Because EVs may form by budding from the plasma 
membrane or exocytosis of multivesicular bodies, it is possible that cellular components are 
non-specifically incorporated into EVs during their biogenesis. Indeed, many mRNAs pre-
sent in EVs are similarly abundant in the cells that produce them suggesting that they are 
simply stochastically distributed into EVs. For example, mRNAs for ribosomal proteins are 
highly abundant in cells and also found in top 100 in EV-mRNAs. Nevertheless, there are a 
number of mRNAs that are either selectively enriched or depleted in EVs compared to the 
producing cells. The quantitative and qualitative differences in the transcriptome of EVs 
versus cells clearly suggest that at least some mRNAs may be specifically sorted and pack-
aged into EVs to support cell–cell communication.  
Comparative transcriptome analyses reveal selective enrichment and depletion of 
particular mRNAs that are significantly overrepresented (254 mRNAs) or underrepresented 
(2,193 mRNAs) in EVs when compared to the producing cells. EVs appear to be specifical-
ly depleted of mRNAs required for vital cellular functions, yet many enriched EV-mRNAs 
encode proteins that directly or indirectly mediate mRNA translation by supporting the 
biogenesis of ribosomes (e.g., enzymes that mediate rRNA processing or structural riboso-
mal proteins). Because 18S and 28S rRNAs, which are two major constituents of the ribo-
some, are not detected in the total RNA distribution of EVs compared to that of cells and 
the abundance of mRNAs encoding a particular subset of ribosomal proteins may suggest a 
specific role in vesicular function. Consistent with our findings, previous studies reported 
that EVs contain mRNAs encoding ribosomal proteins, as well as elongation and transla-
tion factors8,41. Furthermore, Jenjaroenpun and colleagues suggested that these genes upon 
translation in the recipient cells may provide essential ribosomal components to support the 
translation of other EV-mRNAs42. Regardless of the possibility that EV-mRNAs may be 
involved in very common cellular activities, the most interesting mRNA species are those 
that are less abundant, as well as fairly unique to EVs and not represented in the recipient 
cell.  
Crosstalk between osteoblasts and the surrounding bone microenvironment is crit-
ical to maintain essential biological processes, such as osteoclastogenesis, hematopoiesis 
and adipogenesis. Hence, a major objective of our studies is to identify unique mRNAs in 
EVs that could affect the biological state of the recipient cell. The majority of the mRNAs 
enriched in osteoblast-EVs are also detected in EV preparations from other cells and body 
fluids, suggesting that some of these mRNAs may have common functions related to gener-
ic activities of EVs, rather than specific biological roles linked to the bone microenviron-
ment. However, a substantial subset (~20%) of the enriched mRNAs is uniquely detected in 
osteoblast-EVs and thus can be attributed to a specific osteoblast-related and EV-mediated 
function. Enriched osteoblast-EV-mRNAs include those that encode proteins capable of 
regulating the fate of target neighboring cells in the bone microenvironment. Therefore, it 
is intriguing that such regulatory mRNAs are selectively sorted into osteoblast-EVs. We 
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anticipate that further investigation of EV-specific mRNAs will permit delineation of the 
EV-mediated mechanisms by which osteoblasts communicate and control an intricate cell-
to-cell interaction network in the bone microenvironment. 
The most strikingly overrepresented EV-mRNA is RAB13, because it is excep-
tionally abundant in EVs compared to the cells. RAB13 protein is a member of the Rab 
family of small GTPases, which are primarily involved in vesicle trafficking, including 
vesicle production and fusion at the target cell membrane43. Furthermore, even though our 
studies yielded very few examples in which mRNAs and their encoded proteins are co-
packaged in EVs, osteoblasts-EVs not only contain RAB13 mRNA but also the RAB13 
protein. RAB13 protein may have a role in EV biogenesis and cargo sorting at the donor 
cell membrane29. However, the enrichment of this mRNA in osteoblast-EVs and its puta-
tive transfer into recipient cells could represent a regulatory mechanism by which osteo-
blasts control EV production in their target cells. Beyond the latter possibility, Rab proteins 
also regulate cytoskeleton organization and assembly of tight junctions, and thereby regu-
late cell adhesion necessary for cell growth44,45. Accordingly, our network analysis predict-
ed potential RAB13 targets that play important roles in the proliferation of chondrocytes, 
stromal, blood and tumor cells, indicative of a possible role in communication between 
osteoblasts and the target cells within the bone microenvironment.  
Osteoblasts are known to communicate with osteoclasts to coordinate tissue min-
eralization and resorption during bone remodeling. Intriguingly, Rab family proteins have 
essential roles in osteoclastic membrane trafficking required for bone resorption46,47. 
RAB13, in particular, has been shown to be upregulated during osteoclast differentiation 
where it engages in vesicular trafficking events unrelated to bone resorption48. The possi-
bility arises that osteoblasts could deliver RAB13 to immature osteoclasts via EVs to alter 
the osteoclast phenotype and perhaps provoke secondary extracellular signals emanating 
from osteoclasts.  A number of follow-up studies will be required to identify potential tar-
get cells of osteoblast-EVs, establish how EVs unload their cargo and determine how EVs 
affect the biological properties of recipient cells.  
In conclusion, in this study we present a comprehensive analysis of the EV tran-
scriptome that suggests new mechanistic concepts. Our studies suggests a model in which 
EVs produced by osteoblasts may be part of a paracrine signaling system that coordinates 
the biological functions of both skeletal and hematopoietic cells in the bone microenviron-
ment. Our results provide the molecular basis for understanding the biological significance 
of EV-mRNAs in the context of bone related processes. It remains to be elucidated whether 
EV-mRNAs are translated and consequently are rendered functional upon delivery into the 
target cells. Finally, EV transcriptome-profiling offers a potent avenue for discovery of 
non-invasive diagnostics for various diseases and facilitates the development of cell-free 
strategies for regenerative therapy.  
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3.4. MATERIALS AND METHODS 
Cell cultures and EV isolation. Human osteoblast cells (SV-HFO cells) were cultured as 
described in Chapter 229. Osteoblast-EVs were isolated from 20 ml conditioned medium by 
low speed centrifugation (1,500 rpm, 5 minutes; 4,500 rpm, 10 minutes) followed by ultra-
centrifugation (20,000g, 30 minutes; 100,000g, 1 hour at 4°C) of the supernatant using the 
SW32Ti rotor (Beckman Coulter, Fullerton, CA, USA). Transmission electron microscopy 
images were taken as previously described in Chapter 2. EV size distribution and concen-
tration was measured with NanoSight LM10 (Nanosight Ltd., Amesbury, UK) equipped 
with a 405 nm laser. Each sample was tracked for 60 seconds with 3 repetitions. The data 
was processed by NTA 2.3 software.  
RNA isolation and quantitative real-time PCR. Total cellular and EV-RNA was isolated 
using the TRIzol® reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to 
the manufacturer’s instructions. RNA concentration was determined using Nanodrop 
(Thermo Fisher Scientific) and size distribution was checked on an Agilent Bioanalyzer 
RNA 6000 Nano chip (Thermo Fisher Scientific). Quantitative real-time PCR was per-
formed using the SYBRTM Green kit (Eurogentec, Seraing, Belgium) according to the man-
ufacturer’s instructions. The primer sequences are listed in Appendix C. 
 
Next-generation sequencing and bioinformatics analysis. RNA sequencing and bioin-
formatic analysis was performed as previously described49. In brief, sequencing RNA li-
braries were prepared with the TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA, 
USA) according to the manufacturer’s instructions. The concentration and size distribution 
of the libraries was determined on an Agilent Bioanalyzer DNA 1000 chip (Thermo Fisher 
Scientific), and verified with Qubit fluorometry (Thermo Fisher Scientific). Libraries were 
loaded onto flow cells at concentrations of 8–10 pM to generate cluster densities of 
700,000/ mm2 following the standard protocol for the Illumina cBot and cBot Paired-end 
cluster kit version 3. Flow cells were sequenced as 51 × 2 paired end reads on an Illumina 
HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection 
software. Base-calling was performed using Illumina's RTA version 1.17.21.3. The se-
quencing data was analyzed using CAP-miRSeq v1.1. Normalization (counts per million 
mapped reads, CPM; and reads per kilobasepair per million mapped reads, RPKM) analysis 
was performed using edgeR 2.6.2. The data from the replicates were combined as averages 
of the normalized read values, and only transcripts with CPM ≥ 1 for all replicates were 
included in the analysis. Comparative analyses of the EV data were obtained by querying 
the Vesiclepedia plugin provided by FunRich functional enrichment analysis tool (V2.1.2, 
29 April 2015). IPA (Ingenuity® Systems, www.ingenuity.com) was used to classify the 
mRNA categories and predict target pathways and genes. DAVID Bionformatics Resources 
v6.7 was used to categorize the genes into overrepresented processes using human genome 
as a background50.  
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Statistics. The data provided were based on multiple independent experiments. The results 
were described as mean ± SD. Significance was calculated using paired Student’s t-test, 
and P values of < 0.05 were considered significant.  
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Osteolineage cells represent one of the critical bone marrow niche components that support 
maintenance of hematopoietic stem and progenitor cells (HSPCs). Recent studies demon-
strate that extracellular vesicles (EVs) regulate stem cell development via horizontal trans-
fer of bioactive lipids, proteins and RNA, including non-coding microRNAs (miRNAs). 
We hypothesize that the miRNAs in osteoblast-derived EVs may control the expression of 
key regulatory genes that mediate HSPC development. We performed next-generation se-
quencing to characterize global expression of miRNAs in human osteoblast-EVs, and in-
vestigated the role of EVs in crosstalk with human umbilical cord blood (UCB)-derived 
CD34+ HSPCs. Osteoblast-EVs contain a set of highly abundant miRNAs specifically en-
riched in EVs, including critical regulators of hematopoietic proliferation (e.g., miR-29a). 
EV treatment of UCB derived CD34+ cells down-regulated the expression of candidate 
miRNA targets, such as HBP1, BCL2 and PTEN. Furthermore, EVs stimulate cell cycle 
progression and thereby enhance proliferation of CD34+ cells. These discoveries reveal a 
novel osteoblast-derived EV-mediated mechanism for regulation of HSPC proliferation and 
warrant consideration of EV-miRNAs for the development of therapeutic strategies to treat 
hematological disorders. 
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4.1. INTRODUCTION 
Extracellular vesicles (EVs) are secreted nano-sized cellular compartments that 
carry a specific biochemical cargo encompassing bioactive proteins, lipids and nucleic ac-
ids to regulate the function of recipient cells1-3. Circulating microRNAs (miRNAs), which 
are short non-coding RNAs of 21-25 nucleotides in length, are present in EVs and function 
as potent post-transcriptional regulators of gene expression4-6. EV-mediated miRNA trans-
fer regulates various fundamental biological processes, including cell differentiation, pro-
liferation and apoptosis7-10. Recent studies indicate that EV-miRNAs have biological roles 
in the hematopoietic system indicating the importance of EV-mediated paracrine signalling 
in hematopoiesis11,12.  
Hematopoietic stem cells (HSCs) are multipotent cells responsible for constant 
blood supply by undergoing tightly regulated self-renewal, proliferation and differentiation 
into different mature blood cell types. In adult humans, hematopoiesis mainly occurs in the 
bone marrow niche, which provides a supportive network of cells that orchestrate HSC 
fate13,14. Osteolineage cells, ranging from primitive mesenchymal cells to bone-forming 
mature osteoblasts, are thought to be important to maintain hematopoietic stem and progen-
itor cells (HSPCs)15-19. The molecular mechanisms that control the crosstalk between osteo-
lineage cells and HSPCs in humans remain largely unexplored. Comparative gene expres-
sion profiling identified a number of molecules ranging from adhesion molecules to secret-
ed factors, such as growth factors and cytokines, which may be essential for hematopoietic 
activity20,21.  
Even though there is no direct evidence yet, EVs may participate in the regulation 
of HSPC maintenance. We previously reported the protein content of human osteoblast-
derived EVs at different stages of differentiation and mineralization22. Beyond protein car-
go, it has become increasingly clear that miRNAs play a pivotal role in the regulation of 
HSPC fate23-25. Therefore, characterization of the miRNA content of osteoblast-EVs is nec-
essary for appreciating the complexity of the HSPC-osteolineage-cell crosstalk and may 
open new avenues for clinical applications. In this chapter, we elucidate the miRNA profile 
of EVs secreted from human pre-osteoblasts using next-generation sequencing. Based on in 
silico target prediction analyses and in vitro biochemical analyses we define candidate 
hematopoietic development pathways affected by osteoblast-EVs. Our findings provide a 
foundation for the utilization of EVs as novel tools to modulate hematopoiesis for the de-
velopment of suitable strategies to treat hematological disorders.  
 
4.2. RESULTS 
4.2.1. Human osteoblasts secrete EVs that contain small RNAs 
To characterize osteoblast-derived EVs, SV-HFO cells were cultured for 12-14 
days, and EV-RNA was isolated from the conditioned medium by a series of ultracentrifu-
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gation steps followed by TRIzol total RNA extraction. Agilent Bioanalyzer RNA profiles 
show that osteoblast-EVs lack the typical cellular rRNAs, and instead are enriched with 
small RNAs (Fig. 1A). The EV-RNA peak is retained when the EVs are treated with RNase 
A prior to RNA isolation (Fig. 1B), verifying that the majority of the detected RNA is in-
deed present inside the EVs.  
 
 
Figure 1. RNA analysis of osteoblast-derived EVs. A-B) Representative Agilent Bioanalyzer (Pico) RNA pro-
files of osteoblast-EVs (A) before and (B) after RNase A treatment (100 ng/ ml, 30 minutes at 37°C). FU, fluores-
cent units. (N = 3). C) Quantification of vesicular human miR-24 and miR-1 levels by qPCR in the presence or 
absence of exogenous synthetic miR-1 and RNase A. Data is presented as raw threshold cycle numbers (Ct values) 
(mean ± SD) (N = 3). n.d. denotes Ct values above 35 or not detectable. 
 
To demonstrate that small EV-RNAs comprise miRNAs, we performed quantita-
tive real-time PCR (qPCR) of the widely expressed human miR-1 and miR-24. As shown 
in Figure 1C, osteoblast-EVs are devoid of miR-1 (left panel) while they contain relatively 
high amounts of miR-24 (right panel). Interestingly, RNase A treatment does not signifi-
cantly alter the miR-24 level, confirming the presence of nuclease-resistant miR-24 inside 
the EVs. In contrast, exogenously added synthetic miR-1 was immediately degraded when 
spiked into the sample. Collectively, these data demonstrate that miRNAs are present in the 
heterogeneous population of osteoblast-EVs. 
 
4.2.2. Osteoblast EVs contain the signature miRNA content of the donor cells 
To evaluate the miRNA profile of osteoblast-EVs, we performed next-generation 
sequencing using total RNA from three independent osteoblast cultures and their corre-
sponding EVs. The majority of the miRNAs yielded similar read counts in cells and EVs 
(Fig. 2A). In total, we identified 761 mature miRNAs, of which 496 miRNAs are shared 
between cells and EVs and listed in ExoCarta (Fig. 2B)26,27. Notably, all miRNAs exclu-
sively present in cells (82 miRNAs) or EVs (92 miRNAs) are typically of low abundance. 
Only 185 EV-miRNAs are significantly abundant with levels above 100 normalized reads 
per million. This set encompasses 183 miRNAs that are among the 496 common miRNAs 
in both cells and EVs, as well as 2 miRNAs that are not yet listed in ExoCarta. The top 15 
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of miRNAs present in EVs produce ~75% of all the EV-miRNA reads, and more than half 
of the reads belong to just three major miRNA families related to miR-21-5p, miR-100-5p 
and let-7 (let-7f-5p, let-7i-5p, let-7g-5p, let-7a-5p) (Fig. 2C). Figure 2D shows the qPCR 
validation of selected abundant EV-miRNAs. These findings demonstrate that osteoblast-
EVs contain miRNA profile of their donor cells as well as EV-miRNA markers, suggesting 
a conserved and preferential cargo export into EVs across all tissues. 
 
 
Figure 2. Next-generation sequencing miRNA profiling of osteoblast-EVs. A) Scatter plot shows the strong 
correlation (R2: 0.9187) of normalized read counts (average RPKM) between cellular and vesicular miRNAs (N = 
3). B) Venn diagram shows the number of miRNAs detected in osteoblasts and EVs in comparison with ExoCarta. 
Numbers in brackets denote the number of highly abundant miRNAs with reads greater than 100 RPKM among 
all EV miRNAs. C) Pie chart shows the normalized read count proportions of all EV-miRNAs. Only the top 15 
most abundant EV-miRNAs, including let-7f-5p, let-7i-5p, let-7g-5p and let-7a-5p grouped as let7 family, are 
displayed. D) Validation of highly abundant EV miRNAs by TaqMan qPCR miRNA assay. Data is presented as 
raw Ct values (mean ± SD) (N = 3).  
 
4.2.3. Osteoblast-EVs contain a specific set of abundant miRNAs 
Next, we performed relative quantitation of cellular and vesicular miRNAs to as-
sess whether a unique set of miRNAs is enriched in EVs. The Volcano plot in Figure 3A 
shows all EV-miRNAs with statistical significance (P < 0.05) and differential abundance (≥ 
two-fold enrichment); the low abundance miRNAs unique to EVs and cells were excluded 
from this analysis. The results essentially reveal that EVs are preferentially loaded with 82 
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miRNAs (red dots) and depleted of 38 miRNAs (green dots). Table 1 shows the highly 
abundant and enriched 33 miRNAs with normalized reads above 100. Among these miR-
NAs, miR-146a-5p and miR-29a-3p are the most abundant, while miR-1246 and miR-1290 
are most enriched (> 10-fold) in EVs (Fig. 3B). Interestingly, 21 out of 33 enriched EV-
miRNAs have not been previously reported as EV markers that are most commonly detect-
ed across all tissues and body fluids28. Hence, these 21 miRNAs may reflect selective sort-
ing into osteoblast-EVs. 
 
Table 1. The list of highly abundant (RPKM > 100) EV-miRNAs significantly (P < 0.05) enriched (≥ two-fold) in 
osteoblast-EVs compared to the cells.  
 
Mature  
miRNAs 
 
 
EVs 
(RPKM) 
 
Cells 
(RPKM) 
 
Fold 
Change 
 
P value 
(< 0.05) 
miR-146a-5p 22222.93 8704.45 2.6 0.00007 
miR-29a-3p 13142.2 6705.16 2.0 0.00023 
miR-23a-3p 7703.92 1420.23 5.7 0.00183 
miR-181a-5p 6769.81 3463.81 2.0 0.0115 
miR-1246 4118.99 271.75 16.1 0.02431 
miR-574-5p 1984.81 383.66 5.6 0.01881 
miR-374b-5p 1113.04 322.55 3.6 0.00283 
miR-495-3p 1048.32 537.18 2.0 0.00033 
miR-23b-3p 1018.65 290.86 3.6 0.00047 
miR-197-3p 658.81 310.78 2.2 0.02496 
miR-574-3p 625.27 164.21 4.0 0.00979 
miR-34a-5p 575.65 202.6 3.0 0.0171 
miR-19b-3p 529.06 261.05 2.0 0.00993 
miR-106b-5p 521.13 218.05 2.4 0.00096 
miR-214-3p 479.95 171.42 2.8 0.00111 
miR-193b-3p 472.47 129.99 3.7 0.01471 
miR-1290 432.46 36.65 13 0.0375 
miR-30b-5p 400.98 65.07 6.4 0.00734 
miR-29b-3p 338.76 130.27 2.6 0.0324 
miR-15b-5p 318.36 148.02 2.4 0.04894 
miR-320b 294.83 92.36 3.2 0.01741 
miR-365a-3p 282.92 127.6 2.5 0.03148 
miR-365b-3p 282.92 127.6 2.5 0.03148 
miR-487b 204.27 88.43 2.3 0.00437 
miR-130a-3p 172.66 84.39 2.1 0.00158 
miR-485-5p 170.74 75.44 2.3 0.00023 
miR-193a-3p 168.1 17.09 9.8 0.00266 
miR-331-3p 166.59 32.65 5.2 0.00393 
miR-181d 158.26 57.68 2.8 0.00281 
miR-320c 147.98 22.5 6.7 0.01261 
miR-664a-3p 123.31 14.54 8.7 0.00022 
miR-299-5p 122.54 43.88 2.9 0.00022 
miR-132-3p 
 
112.94 
 
47.1 
 
2.5 
 
0.01702 
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Figure 3. The analysis of the overrepresented EV-miRNAs. A) Volcano plot (significance versus fold change) 
shows the significantly (P < 0.05, compared with osteoblasts by Student’s t-test) abundant  (≥ 2-fold; red) and 
depleted (≤ 0.5-fold; green) miRNAs in EVs. Numbers in brackets denote the number of differentially expressed 
miRNAs. FC, fold change. B) MA plot (fold change versus EV abundance) shows the expression levels of the 
selectively enriched EV-miRNAs. The most highly abundant miRNAs are shown in blue. C) IPA network map 
shows the predicted biological functions significantly targeted by some of the highly abundant (RPKM > 100) 
enriched EV miRNAs. Blue, EV miRNAs; Green, biological functions. 
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Ingenuity Pathway Analysis (IPA) was performed to predict the impact of en-
riched EV-miRNAs on target cell gene expression and phenotype. The most significantly 
annotated molecular functions are cellular development, cellular growth and proliferation, 
cell cycle, cell death and survival and cellular compromise (Fig. 3C). Together, our com-
parative analyses revealed overrepresentation of a selective group of miRNAs in osteo-
blast-EVs, indicating specific packaging of biologically functional regulatory molecules as 
EV cargo.  
 
4.2.4. Osteoblast-EVs are enriched with miRNAs crucial for hematopoiesis 
Each stage of hematopoietic differentiation is characterized by a specific miRNA 
signature29. We analyzed the osteoblast-EV-miRNA content for known regulators of hema-
topoiesis to find cues for EV-mediated HSPC-osteolineage-cell crosstalk. Indeed, a number 
of miRNAs that may control distinct stages of hematopoietic development are detected in 
high abundance in EVs (Fig. 4A). Hence, we investigated whether treatment of HSPCs 
with osteoblast-EVs would alter expression of specific mRNAs that are targeted by miR-
NAs enriched in osteoblast-EVs.  
 
 
Figure 4. Osteoblast-EVs downregulate miR-29a target genes in UCB-derived CD34+ cells. A) RPKM values 
(mean ± SD) of osteoblast-EV miRNAs known to be involved in different phases of hematopoiesis. B) Expression 
levels (mean ± SD) of candidate mRNA targets of miR-29a in human UCB-derived CD34+ cells after 24 hours of 
incubation in the absence (control) or presence of osteoblast-EVs (N = 5). Fold change is determined compared to 
control and normalized to average GAPDH expression. * P < 0.05, *** P < 0.005, compared with control by 
Student’s t-test. 
 
We focused initially on miR-29a, which is significantly enriched in osteoblast-
EVs, because it is known to be involved in early stages of hematopoiesis as a regulator of 
self-renewal, survival and proliferation of HSCs and HSPCs30. In silico target prediction 
analysis by TargetScan combined with supervised literature searches refined the large list 
of potential targets to a defined list of validated miR-29a target genes relevant to HSPCs. G0/ G1 S G2/ M
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By qPCR analysis we evaluated the expression level of miR-29a target genes involved in 
proliferation (TET2, PTEN), apoptosis (BCL2), cell cycle regulation (HBP1, CDC42EP2) 
and extracellular matrix adhesion (COL1A1, ELN) of HSPCs30-32. Osteoblast-EVs reduce 
the expression of all selected target genes, except TET2, in human UCB-derived CD34+ 
HSPCs (Fig. 4B). EVs significantly down-regulate the expression of HBP1, BCL2 and 
PTEN, suggesting that osteoblast-EVs control proliferation of the recipient HSPCs. Prolif-
eration assays that monitor Ki-67 staining (Fig. 5A) and cell cycle analysis based on DNA 
content (Fig. 5B) establish that osteoblast-EVs stimulate proliferation and cell cycle pro-
gression of the CD34+ cells 24 hours after treatment. Thus, the integrated results of both in 
silico and in vitro approaches indicate that osteoblast-EVs are enriched with miRNAs in-
volved in signaling cascades that regulate HSPC proliferation. 
 
 
Figure 5. Osteoblast-EVs stimulate proliferation and cell cycle progression of UCB-derived CD34+ cells. A) 
Proliferation assay, determined by the % of Ki-67+ CD34+ cells (mean ± SD), after 24 hours incubation in the 
absence (control) or presence of osteoblast-EVs (N = 3).  * P < 0.05, compared with control by Student’s t-test. B) 
Cell cycle distribution, using propidium iodide (PI) staining of CD34+ cells (mean ± SD), after 24 hours incuba-
tion in the absence (control) or presence of osteoblast-EVs (N = 3). ** P < 0.01, compared with control by two-
way ANOVA. 
 
4.3. DISCUSSION 
EV-mediated intercellular communication is an exciting new area of research that 
is rapidly evolving thanks to the emergence of powerful tools that enable characterization 
of their bioactive cargo. We used next-generation sequencing to study the miRNA profile 
of human osteoblast-derived EVs. Based on the overrepresented EV-miRNAs we delineat-
ed the targeted biological functions associated with hematopoiesis and verified in silico 
predictions with in vitro results.  We showed that osteoblast-EVs stimulate the cell cycle 
progression and proliferation of UCB-derived CD34+ HSPCs. Our findings provide a fun-
damental description of the biological roles of EVs in mediating crosstalk between osteo-
lineage cells and HSPCs. Equally important, osteoblast-derived EVs may present potential 
value in clinical applications to treat hematopoietic disorders. 
There is considerable interest in understanding circulating miRNAs as potential 
disease markers for early diagnosis33. These regulatory miRNAs mostly circulate entrapped 
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in protein complexes that protect them from degradation by circulating nucleases34,35.  Re-
cent studies show that they also exert their effect in a paracrine manner via EV-mediated 
delivery to the target tissue4. The hematopoietic bone marrow niche consists of a tightly 
regulated network of numerous cell types, including osteoblasts, mesenchymal stromal-, 
endothelial- and neuronal cells and hematopoietic progenitors. Characterization of the EV-
mediated intercellular communication within the bone marrow niche may contribute to the 
understanding of this complex network.  
We performed high throughput analysis of miRNAs to assess whether human os-
teoblast-EVs utilize small RNAs to communicate with HSPCs in the bone marrow niche. 
As expected, the EV-miRNA profile mirrors that of the osteoblastic donor cell, but we also 
detected a large number of miRNAs that appear to be enriched in EVs.  Importantly, we 
identified a number of miRNAs that are abundant in osteoblast-EVs and are known regula-
tors of hematopoiesis. We focused on miR-29a because it controls early steps of hemato-
poiesis and is enriched in EVs compared to the donor cells. Our study shows that osteo-
blast-EVs are capable of down-regulating the expression of cell cycle- and growth-related 
miR-29 target genes in CD34+ cells. We further demonstrate that osteoblast-EVs stimulate 
proliferation and cell cycle progression of CD34+ cells, in accordance with the expression 
profile of down-regulated target genes.  
Stem cells are special cells with remarkable regenerative abilities, which make 
them very attractive for the development of cell-based therapies. A complex network of 
environmental cues tightly regulates stem cell fate determination, including self-renewal 
and differentiation. Ratajczak and colleagues were one of the firsts to report the role of EVs 
in stem cell regulation36. They showed that embryonic stem cells released EVs containing 
regulatory proteins and mRNA capable of reprogramming HSCs. Since then numerous 
studies reported the role of EVs in stem cell biology with a major focus on miRNA trans-
fer, suggesting a critical paracrine role for EVs in stem cell niches37-40. We previously 
showed that osteoblast-EVs induced proliferation of bone-metastasizing prostate cancer 
cells22. Recent studies indicate that prostate cancer cells compete with HSCs for the bone 
marrow niche, emphasizing the importance of EVs in the regulation of HSC growth and 
survival41. Hematopoietic differentiation is characterized by specific miRNA signatures, 
which act in each step of linage decision to ensure proper hematopoiesis25,29. The osteo-
blast-EV-miRNA profile we described here provides further insights into the complexities 
of the HSPC-osteolineage-cell crosstalk. 
In conclusion, our findings provide a new paradigm for the role of EVs in the reg-
ulation of stem cell niches. We propose that EVs contain a signature miRNA profile that 
participates in the HSPC-osteolineage-cell crosstalk. It remains to be determined whether 
EV-miRNAs act in concert with other regulatory EV cargo, such as mRNAs and proteins, 
which may contribute to the proliferative effect of osteoblast-EVs. Identification of such 
critical EV components opens up avenues to be exploited clinically to develop novel ap-
proaches not only for the treatment hematological disorders but in a broader context also 
for use in regenerative medicine. 
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4.4. MATERIALS AND METHODS  
Cell cultures. Human osteoblast cells (SV-HFO cells) were cultured as described in Chap-
ter 222. UCB was collected in several hospitals using Stemcare®/CB collection blood bag 
system (Fresenius Kabi Norge AS, Halden, Norway). Approval for collection was obtained 
from the Medical Ethical Committee of the Erasmus University Medical Centre (MEC-
2009-410) and written informed consent from the mother was obtained prior to UCB dona-
tion. Within 48 hours after collection, mononuclear cells were isolated using ficoll (Lym-
phoprep™, Fresenius Kabi Norge AS). CD34+ cells were isolated as described previous-
ly42. 20,000 CD34+ cells were cultured in serum-free Glycostem Basic Growth Medium 
(GBGM; Glycostem, Oss, the Netherlands) supplemented with stem cell factor (SCF; 50 
ng/ ml, Cellgenix, Freiburg, Germany) and Fms-related tyrosine kinase 3 ligand (Flt3L; 50 
ng/ ml, Cellgenix), with or without osteoblast-EVs at 37°C in a humidified atmosphere of 
5% CO2.  
 
EV isolation and characterization. Osteoblast-EVs were isolated from 20 ml conditioned 
medium by low speed centrifugation (1,500 rpm, 5 minutes; 4,500 rpm, 10 minutes) fol-
lowed by ultracentrifugation (20,000g, 30 minutes; 100,000g, 1 hour at 4°C) of the super-
natant using the SW32Ti rotor (Beckman Coulter, Fullerton, CA, USA). EVs were pre-
pared as 100 µl suspensions, and the amount of experimental EV dose was determined as 
5% (v/v).  
 
RNA isolation and quantitative real-time PCR. The purified EV pellet was incubated 
with or without RNase A (100 mM) and synthetic miR-1 (20 pM) at 37°C for 30 minutes, 
and total RNA was isolated using the TRIzol reagent (Thermo Fisher Scientific, Waltham, 
MA, USA) according to the manufacturer’s instructions. RNA concentration was deter-
mined using Nanodrop (Thermo Fisher Scientific) and size distribution was checked on an 
Agilent Bioanalyzer RNA 6000 Pico chip (Thermo Fisher Scientific). RNA from CD34+ 
cells was isolated using NucleoSpin RNA XS kit (Macherey-Nagel, Duren, Germany) ac-
cording to the manufacturer’s instructions. Quantitative real-time PCR for mRNAs and 
miRNAs were performed using the SYBRTM Green (Eurogentec, Seraing, Belgium) and 
Taqman® kits (Thermo Fisher Scientific), respectively, according to the manufacturer’s 
instructions. The primer sequences are listed in Appendix C. 
 
Next-generation sequencing and bioinformatic analysis of miRNAs. Sequencing of 
miRNAs was performed by Illumina HiSeq with samples prepared with the NEBNext 
Small RNA library preparation kit. We used the CAP-miRSeq bioinformatic pipeline for 
mapping of miRNA reads data analysis43. In brief, adaptor sequences were removed from 
50bp reads using Cutadapt44 and sequences of sufficient size (>17 nucleotides in length) 
were aligned to the hg19 reference genome and miRBase 19 reference sequences using 
Bowtie45. Quantitative analysis of known and predicted miRNAs was performed using 
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miRDeep246. Comparative analyses of the EV data were obtained by querying the ExoCar-
ta (V5, 29 July 2015) database. IPA (Ingenuity® Systems, www.ingenuity.com) and Tar-
getScan (Release 7.0) were used to predict target pathways and genes. 
 
Flow cytometry. Analysis of proliferation and cell cycle progression of CD34+ cells was 
performed using flow cytometry by monitoring the proliferation marker Ki-67 relative to 
DNA content. Cells were incubated with or without EVs for 24 hours, and stained with 
Alexa Fluor® 488-conjugated Ki-67 antibody (BD Biosciences, San Jose, CA, USA) fol-
lowed by the addition of propidium iodide (BD Biosciences) according to the manufactur-
ers instructions. All samples were immediately analyzed using BD AccuriTM C6 flow cy-
tometry (BD Biosciences), and the data was analyzed using C6 software.  
 
Statistics. The results were described as mean ± SD based on at least two independent ex-
periments performed with independent EV isolations and/ or different UCB donors. Signif-
icance was calculated using Student’s t-test and two-way ANOVA test, and P values of < 
0.05 were considered significant. 
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Umbilical cord blood (UCB) is increasingly used as an important source of hematopoietic 
stem cells to treat a number of hematological malignancies. The major obstacle to the 
widespread use of UCB is the insufficient amount of progenitor cells to sustain therapy. 
Culturing UCB cells with osteolineage cells or in the presence of osteolineage-cell-derived 
secreted factors have helped the development of successful expansion protocols for clinical 
use. Extracellular vesicles (EVs) are secreted cellular compartments that carry regulatory 
cargo between cells. In this chapter, we investigated the capacity of human osteoblast-
derived EVs to expand human UCB-derived CD34+ hematopoietic stem and progenitor 
cells (HSPCs). Osteoblast-EVs enhance proliferation of CD34+ HSPCs and their immature 
subsets (Lin-CD34+CD38lowCD45RAlowCD90+ cells) in hematopoietic growth factor-driven 
ex vivo expansion cultures. Importantly, EV-expanded cells retain their differentiation ca-
pacity in vitro and successfully engraft in vivo. In conclusion, our findings demonstrate the 
potency of using osteoblast-EVs in development of novel clinically relevant expansion 
strategies. Further investigation of EV content as well as their role in HSPC proliferation 
described in previous chapters is critical to unravel key factors useful for therapeutic appli-
cations. 
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5.1. INTRODUCTION 
Hematopoietic stem cells (HSCs), multipotent cells that give rise to all blood line-
ages, are widely used in stem cell transplantations that have saved many lives where other 
cures are no longer possible1. Umbilical cord blood (UCB) is a rich source of HSCs and an 
attractive alternative to bone marrow due to its rapid availability and less stringent human 
leucocyte antigen match requirement. However, UCB grafts contain a low number of hem-
atopoietic stem and progenitor cells (HSPCs) that poses as a limiting factor for proper en-
graftment, which leads to delayed hematopoietic recovery and patient morbidity and mor-
tality2,3. 
 
 
 
Figure 1. Osteoblast-EVs enhance ex vivo expansion of UCB-derived CD34+ cells. A-B) Osteoblast-EVs in-
crease the expansion of (A) total nucleated cells (TNCs) and (B) CD34+ cells after 10 days of expansion with SCF 
and Flt3L compared to cells cultured in the absence of EVs (control) (N = 7). Expansion is shown as fold change 
(FC) increase in total cell number compared to input. ** P < 0.01, compared with control by Student’s t-test. C) 
Osteoblast-EVs increase the number (mean ± SD) of phenotypic HSCs (Lin-CD34+CD38lowCD45RAlowCD90+) 
compared to control on day 10 (N = 3). *** P < 0.005, compared with control by Student’s t-test. D-E) Osteo-
blast-EVs increase the numbers of (D) TNCs and (E) CD34+ cells after 10 days of expansion with SCF, Flt3L and 
SR1 compared to control (N = 2). Empty and full shapes show the different donors.  
 
Over the past few decades, studies have been focusing on the establishment of ex 
vivo culture systems to expand UCB-derived HSPCs for improved engraftment and post-
transplantation recovery4. Culture systems supplemented with growth factor cocktails, in-
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cluding stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), thrombopoiet-
in (TPO), granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin 6 
(IL-6), successfully stimulate the expansion of the HSPCs, though at the expense of long-
term repopulating HSCs5. Recent studies reported the success of improved expansion by 
mimicking the bone marrow niche, where HSC fate determination is tightly regulated6,7. 
Osteolineage cells represent one of the critical niche components that support self-renewal 
and proliferation of HSCs in vivo8-13. Osteolineage-cell-derived secreted factors and adhe-
sion molecules yield robust in vitro proliferation of HSPCs with long-term repopulation 
ability stressing the importance of discovering other osteolineage cell components that can 
support the growth factor-based expansion culture systems12-17.  
Extracellular vesicles (EVs) are small cellular compartments that alter the function 
of their targets by transferring bioactive lipids, proteins and RNA between cells18-21. In-
creasing studies report the role of EV-mediated intercellular communication within the 
hematopoietic system22-25. A pivotal study by Ratajczak and colleagues highlighted the 
importance of EV cargo on the regulation of HSC fate26. In Chapter 4, we showed that hu-
man osteoblast-derived EVs stimulate the proliferation of UCB-derived CD34+ HSPCs in 
vitro. In this chapter, we take this further and evaluate in greater detail the proliferative 
capacity of human osteoblast-EVs and the opportunity to exploit them to expand human 
UCB-derived CD34+ HSPCs in SCF- and Flt3L-driven serum-free ex vivo expansion cul-
tures. We further verify the functionality of the expanded cells in vivo by performing xeno-
geneic transplantation in sub-lethally irradiated immunodeficient NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice. Taken together our findings demonstrate that EVs prove to be 
powerful tools to expand HSPCs ex vivo suitable for clinical use. 
 
5.2. RESULTS 
5.2.1. Human osteoblasts secrete EVs that promote ex vivo expansion of CD34+ HSPCs 
In this study, we used EVs derived from human pre-osteoblasts (SV-HFO cell 
line) cultured for 12-14 days. We evaluated the capacity of osteoblast-EVs to promote the 
ex vivo expansion of human UCB-derived CD34+ cells in growth factor (SCF and Flt3L)-
driven serum-free expansion cultures. Osteoblast-EVs induce a two-fold expansion of both 
total number of viable nucleated cells (TNCs) (P < 0.01) and CD34+ cells (P < 0.01) in 10 
days as compared to the control cultures (Fig. 1A & 1B). The expansion potential of EVs is 
not masked even in the presence of additional expansion growth factors, such as TPO  
(Appendix A, Fig. A1). We also assessed the presence of the most immature CD34+ cell 
subset in the expanded cells by multicolor flow cytometry using markers for primitive 
HSPCs (Lin-CD34+CD38lowCD45RAlowCD90+), referred to as phenotypic HSCs (Appendix 
A, Fig. A2). EV treatment also increases the number of phenotypic HSCs more than two-
fold (P < 0.005) compared to the control on day 10 (Fig. 1C). Interestingly, the expansion 
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potential of EVs remains clearly evident even in the presence of highly effective expansion 
factors, such as StemRegenin 1 (SR1) (Fig. 1D & 1E)27. These findings demonstrate the 
potency of osteoblast-EVs to promote growth factor-driven HSPC expansion. 
 
5.2.2. EV-expanded cells retain their differentiation capacity in vitro 
We evaluated the functional characteristics of the ex vivo expanded CD34+ cells in 
vitro and in vivo. Initially, we investigated whether the CD34+ cells that were expanded ex 
vivo using EVs retain their differentiation capacity in vitro by performing colony-forming 
unit (CFU) assay. EV-expanded cells exhibit a higher clonogenicity, most likely due to the 
increased number of viable and functional CD34+ cells after expansion (Fig. 2A). However, 
frequencies between control and EV treatment remain comparable suggesting similar ca-
pacities for the preservation of primitive HSCs and their progenitors.  
 
 
 
Figure 2. EV-expanded CD34+ cells retain their differentiation capacity in vitro. A) Total CFUs (mean ± SD) 
in EV-expanded cells  (N = 3). B) The frequencies of the myeloid and erythroid lineages. Control denotes cells 
expanded in the absence of EVs. 
 
Next, we investigated whether EV-treatment alters the ability of the HSPCs to dif-
ferentiate and give rise to colonies of different mature blood cells by enumerating the clas-
ses of myeloid and erythroid progenitor cells (Fig. 2B). Interestingly, frequencies of multi-
lineage progenitors (CFU-GEMM), erythroid progenitors (CFU-E/ BFU-E) and granulo-
cyte/macrophage progenitors (CFU-G/ M/ GM) remain comparable to the control, indicat-
ing that EVs promote expansion but do not favor specific hematopoietic lineages. These 
findings demonstrate that EV-expanded HSPCs retain the pool of progenitor cells that give 
rise to erythrocytes and myeloid cells in vitro. 
 
5.2.3. Osteoblast-EV-expanded cells retain in vivo engraftment potential 
To assess the impact on engraftment and hematopoietic repopulating ability of the 
ex vivo expanded cells, sublethally irradiated immunodeficient NSG mice were transplant-
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ed with CD34+ progeny cells derived from 105 seeded cells after expansion with or without 
EVs for 10 days (Appendix A, Fig. A3). Engraftment was defined as at least 0.1% human 
chimerism in the peripheral blood. All mice show similar levels of human chimerism 
(~20%) in both control and EV treatment groups at 19 weeks after transplantation (Fig. 
3A).  
 
 
Figure 3. EV-expanded CD34+ cells successfully engraft and re-populate NSG mice. A) Human chimerism 
level (% human CD45+ cells) (mean ± SD) in peripheral blood at several time-points after transplantation of 
CD34+ cells expanded in the absence (control) and presence of EVs (N = 5 mice/ group). B) The frequencies of 
human lymphoid and myeloid lineages in peripheral blood after 19 weeks. C) Human chimerism level in the bone 
marrow after 21 weeks. CV (coefficient of variation) is 54.13% and 11.74% for control and EVs, respectively. D) 
The frequencies of human lymphoid and myeloid lineages in bone marrow after 21 weeks. E) The frequencies of 
human CD34+ progenitors within the human CD45+ fraction in the bone marrow after 21 weeks. CV is 100.75% 
and 35.79% for control and EVs, respectively. 
 
EV treatment does not alter the speed and quality of recovery of different human 
lymphoid and myeloid lineages in NSG mice. The predominant human cell population after 
engraftment consists of CD19+ B-cells, as well as very low levels of other lymphoid (NK 
and T-cells) and myeloid cells (Fig. 3B). Moreover, both control and the EV treatment 
groups exhibit similar levels of CD45+ human chimerism in recipient bone marrow at 21 
weeks after transplantation (Fig. 3C). Similar to the peripheral blood, the majority of hu-
man cells in the bone marrow expressed the B-cell marker CD19 (Fig. 3D). As expected, 
only a small (2%) fraction of human cells is positive for CD34 (Fig. 3E). We note that the 
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mice in the control group show a high degree of variability (CV: 54.13%, Fig. 3C; CV: 
100.75%, Fig. 3E) of chimerism in the bone marrow, possibly explained by the lower num-
ber of total transplanted cells after expansion. Taken together, these findings clearly 
demonstrate that ex vivo EV treatment retains the engraftment potential of human cells in 
NSG mice. 
 
 
Figure 4. Osteoblast-EVs enhance ex vivo expansion of sorted phenotypic HSCs. A-B) Osteoblast-EVs im-
prove the expansion capacity of (A) TNCs and (B) CD34+ progenitors after 10 days of expansion with SCF and 
Flt3L compared to cells cultured in the absence of EVs (control) (N = 4). Expansion is shown as fold change 
increase in total cell number compared to input. * P < 0.05, compared with control by Student’s t-test. C) Osteo-
blast-EVs increase the number (mean ± SD) of phenotypic HSCs compared to control on day 10 (N = 4). ** P < 
0.01, compared with control by Student’s t-test. D) EV-expanded immature UCB cells retain their differentiation 
capacity in CFU assay (mean ± SD) (N = 3). The frequencies of the myeloid and erythroid lineages are shown in 
the table. * P < 0.05, compared with control by Student’s t-test. 
 
5.2.4. Osteoblast-EVs stimulate the proliferation of immature cells 
Most conventional expansion protocols, which provide short-term robust prolif-
eration of the CD34+ progenitor cells, are accompanied by concomitant differentiation and 
result in loss of primitive HSC sub-populations4,28,29. To study the effect of EVs on imma-
ture stem cells, we sorted phenotypic HSCs as a starting population. Osteoblast-EV treat-
Control EVs
0.0
5.0×104
1.0×105
1.5×105
2.0×105
CF
U-
To
ta
l
CFU- E/ BFU- E
CFU- G/ M/ GM
CFU- GEMM
% 32.69
% 46.49
% 20.82
% 42.43
% 44.81
% 12.76
Control EVs
0
1
2
3
4
Ph
en
ot
yp
ic
 H
SC
s
FC
 (R
el
. D
10
 C
on
tr
ol
)
Control EVs
0
50
100
150
TN
Cs
FC
 (R
el
.  
t:0
)
Control EVs
0
10
20
30
CD
34
+ 
Ce
lls
 
FC
 (R
el
.  
t:0
)
Figure 5 
A B 
D C 
Chapter 5_Morhayim et al. 
* * 
** OK#* 
§ Chapter 5 
	  102 
ment of phenotypic HSCs significantly induces the expansion of TNCs (Fig. 4A), CD34+ 
cells (Fig. 4B) and phenotypic HSCs (Fig. 4C) after 10 days. Corroborating these results, 
CFU assays reveal an increase in the number of the immature cells while retaining the fre-
quency of the different lineages (Fig. 4D).  
To determine the effect of osteoblast-EVs on the maintenance of CD34 and CD90 
expression after successive cell divisions of phenotypic HSCs, we used CellTraceTM Violet 
staining. Cells that were grown in the presence of osteoblast-EVs undergo a higher number 
of cell divisions while keeping their stem cell phenotype after 5 days compared to control 
(Fig. 5A & 5B). Figures 5C & 5D show the fraction of cells that have divided up to 4 times 
within the CD34+ cell population in the absence or presence of EVs. Our data show that 
EVs stimulate the cell division kinetics of the immature cells, resulting in an increased 
number of CD34+ cells. 
 
 
Figure 5. Osteoblast-EVs stimulate the proliferation of the immature cells. A-B) Sorted phenotypic HSCs 
were loaded with CellTraceTM Violet and incubated in the absence (control) or presence of osteoblast-EVs for 5 
days. Flow cytometry plots show the distribution of the progeny of (A) CD34+ progenitors and (B) CD90+ pheno-
typic HSCs. C-D) The percentages (mean ± SD) of cells that have divided 1 – 4 times within (C) CD34+ progeni-
tors and (D) CD90+ phenotypic HSCs (N = 2).  
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5.3. DISCUSSION 
The ability of EVs to transfer functional cargo between cells brings exciting pos-
sibilities for therapeutic applications. In this chapter, we demonstrated that human osteo-
blast-derived EVs enhance HSPC proliferation leading to the ex vivo expansion of UCB-
derived CD34+ cells, including the most immature subsets in growth factor-driven serum-
free expansion cultures. Importantly, the EV-expanded cells retain their differentiation ca-
pacity in vitro and successfully engraft and re-populate NSG mice in vivo.  
The current expansion protocols primarily focus on the use of a cocktail of hema-
topoietic growth factors, which are successful to stimulate rapid self-renewal of human 
HSPCs30. Combination of SCF and Flt3L with other growth factors, such as TPO, IL-6 and 
GM-CSF, successfully stimulate the expansion of CD34+ progenitors in matter of a few 
weeks31,32. Here, we limited the use of growth factors to SCF and Flt3L, which are neces-
sary for the minimum required potency, to better study the EV effect33. SCF and Flt3L 
alone lead to an average 2.5-fold expansion of UCB-derived CD34+ HSPCs in 10 days. 
Remarkably, the addition of osteoblast-EVs significantly increases the number of CD34+ 
HSPCs by at least two-fold in every UCB donor despite substantial variability among indi-
vidual donors typical to UCB ex vivo expansion. However, EV-treatment does not affect 
the CD34+ cell frequency demonstrating that the expansion of progenitor cells is accompa-
nied by concomitant differentiation (determined by TNC counts) in both conditions. 
Growth factor-based expansion culture protocols are often challenged by the difficulty of 
maintaining human HSPCs in vitro due to the fact that the cues to maintain self-renewal 
and differentiation can only be partially controlled34,35. Nonetheless, flow cytometry-based 
phenotypic HSC and CFU counts demonstrated that EVs also enhance the expansion of the 
most primitive subset of the progenitor cells compared to the control. Interestingly, we ob-
served similar effects when we started with the sorted immature population. In accordance 
with cell cycle analyses presented in Chapter 4, we showed that the EVs enhance the divi-
sion rate of both phenotypic HSCs and CD34+ cells leading to increased proliferation com-
pared to control. These findings clearly demonstrate that despite the accompanied differen-
tiation, EVs stimulate the proliferation and maintenance of HSPCs in short-term cultures.  
It is therefore critical to test the effect of osteoblast-EVs in the long-term maintenance of 
the stem cells in vitro. 
Increasing knowledge on key players of the bone marrow niche, where HSC self-
renewal is supported, greatly contributed to the establishment of optimized expansion con-
ditions to promote the proliferation of the stem cells with true self-renewal and full repopu-
lating capacity36. Co-cultures with primary or immortalized stromal cells as well as secret-
ed or membrane associated factors support the survival and self-renewal of HSPCs in 
vitro37-40. Engineered ligands of Notch pathway, chromatin modifying agents and metals 
are also used to prevent differentiation and thereby promote large expansion of the repopu-
lating cells41-43. Combinatorial screens identified small molecules with promising expan-
sion potential. SR1, a purine derivative that acts as an aryl hydrocarbon receptor antagonist, 
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has been reported to promote immense expansion of CD34+ cells while maintaining the 
primitive stem cell pool27. Interestingly, the addition of SR1 in our cultures promotes more 
effective EV-mediated ex vivo expansion while maintaining the progenitor cell frequency. 
Based on these results we speculate that EVs act as a tool to relieve the initial stress of dif-
ferentiation on HSPCs in vitro, most likely by contributing to prolonged survival. Future 
studies focusing on the discovery of molecules that work cooperatively with osteoblast-
EVs are of great importance to develop improved expansion strategies. 
Successful HSC transplantation relies on the proper homing of HSPCs with full 
repopulation capacity to their niches in the bone marrow. Therefore, it is critical that the ex 
vivo expansion cultures do not produce lineage-biased cells. CFU experiments showed that 
the EV-expanded cells are not skewed into a specific lineage as they have a similar capaci-
ty to generate myeloid and erythroid lineages as the control. We then assessed the in vivo 
hematopoietic function of the expanded cell populations by performing transplantations in 
immunodeficient NSG mice. We demonstrated that important measures, such as engraft-
ment and B-lymphoid lineage reconstituting ability, are not altered as a result of ex vivo 
culture, showing that EV-expanded cells hold the capacity for clonogenicity in vivo. Cur-
rently, the combination of flow cytometric analysis and the repopulating ability in NSG 
mice provide the best pre-clinical estimate for the utilization potential of expanded HSPCs. 
Secondary transplantation experiments are then necessary to provide critical information to 
determine the long-term multi-lineage repopulation potential of HSPCs for clinical applica-
tions in humans.  
In conclusion, we propose osteoblast-EVs as novel powerful tools to expand 
HSPCs for use in regenerative therapy. Based on our findings presented in this chapter, we 
suggest a role for EVs in HSPC cell proliferation; however, the molecular mechanisms 
behind EV-mediated expansion still remain to be explored. Proteomic and genomic anal-
yses presented in previous chapters offer a rich osteoblast-EV cargo repository of great 
value to unravel candidate components that can be modulated to increase expansion capaci-
ty that will meet the clinical need.  
 
5.4. MATERIALS AND METHODS 
Mice. In vivo studies were performed using young NSG mice (8 to 10 weeks old, female). 
All mice were handled under sterile conditions and housed in ventilated micro-isolation 
cages with filter tops. Mice were fed ad libitum.  
Cell cultures. Human osteoblast cells (SV-HFO cells) were cultured for 12-14 days, as 
described in Chapter 2. UCB-derived CD34+ cells were isolated as described in Chapter 4. 
Viable DAPI-Lin-CD34+CD38lowCD45RAlowCD90+ cells were isolated as described previ-
ously44. 20,000 CD34+ cells and 10,000 CD34+CD90+ cells were cultured in serum-free 
Glycostem Basic Growth Medium (GBGM; Glycostem, Oss, the Netherlands) supplement-
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ed with SCF (50 ng/ ml, Cellgenix, Freiburg, Germany) and Flt3L (50 ng/ ml, Cellgenix), 
with or without osteoblast-EVs at 37°C in a humidified atmosphere of 5% CO2. Cells were 
refreshed every 2-3 days with fresh culture medium supplemented with newly isolated 
EVs. In some experiments, TPO (50 ng/ ml; Cellgenix) and SR1 (1µM; Cellagen Technol-
ogy, San Diego, CA, USA) were added. In some experiments, cells were labeled with 
CellTraceTM Violet (Thermo Fisher Scientific, Waltham, MA, USA) according to the man-
ufacturer’s instructions.  
EV isolation. Osteoblast-EVs were isolated from 20 ml conditioned medium as described 
in Chapter 3. EVs were prepared as 100 µl suspensions, and the amount of experimental 
EV dose was determined as 5% (v/v).  
Flow cytometry. Flow cytometry was used to examine subpopulations of CD34+ cells. 
Absolute numbers of viable human CD34+ cells were determined by a single platform flow 
cytometric assay using anti-FITC-CD45, anti-CD34-PE, fluorescence reference counting 
beads (Beckman Coulter, Fullerton, CA, USA) and DAPI (Sigma Aldrich, St. Louis, MO, 
USA). The frequencies of human phenotypic HSCs were determined using anti-Lin-FITC, 
anti-CD38-APC, anti-CD90-PE (eBiosciences, Vienna, Austria), anti-CD34-PE-Cy7, anti-
CD45RA-APC-H7 (BD Biosciences, San Jose, CA, USA); and DAPI. Human chimerism 
in mice blood and bone marrow was determined using anti-mouse CD45-eFluor450, (eBio-
science) and anti-human CD45-APC-Cy7 (BioLegend, London, UK). The human lymphoid 
and myeloid lineages were analyzed by staining with anti-CD19-PE, anti-CD3-APC, anti-
CD33-PerCP-eFluor710, anti-CD56-PE-Cy7, and anti-CD15-BV510. All samples were 
analyzed using BD FACSCantoII (BD Biosciences), and the data was analyzed using 
FlowJo software (Tree Star, Inc., Ashland, OR, USA).  
 
CFU assays. Suspensions of 300 expanded CD34+ cells in MethoCult™ medium  
(MethoCult™ GF H4434, Stemcell Technologies, Vancouver, BC, Canada), were incubat-
ed in standard culture dishes for 11 days at 37°C in a humidified atmosphere of 5% CO2. 
The colonies were counted using an inverted light microscope, and the different lineages 
were evaluated by morphology.  
Transplantation. Transplantation experiments were approved by the Committee on the 
Ethics of Animal Experiments of the Erasmus University Medical Center, Rotterdam, the 
Netherlands. NSG mice were sub-lethally irradiated (3 Gy), and intravenously transplanted 
with the progeny generated from CD34+ cells cultured with or without EVs for 10 days. 
Peripheral blood was collected at 2 weeks intervals starting at 3 weeks post-transplantation 
through a small incision in the tail vein. At 21 weeks post-transplantation, the mice were 
sacrificed by cervical dislocation, and the bone marrow was harvested from the femurs as 
previously described45. 
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Statistics. The results were described as mean ± SD based on at least two independent ex-
periments performed with independent EV isolations and/ or different UCB donors. Signif-
icance was calculated using Student’s t-test and two-way ANOVA test, and P values < 0.05 
were considered significant. 
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Cells communicate with each other by secreting extracellular vesicles (EVs) as carriers of 
regulatory information in forms of proteins, RNA and lipids. Osteoblasts secrete EVs that 
play a role in hematopoiesis by stimulating the proliferation of hematopoietic stem and 
progenitor cells (HSPCs). Here, we performed next-generation sequencing to study the 
effects of osteoblast-EVs on the transcriptome of human umbilical cord-derived CD34+ 
HSPCs. We identified 33 significantly regulated HSPC genes, including genes with known 
roles in HSPC cell proliferation. Using an integrative bioinformatics approach, we connect-
ed the gene expression data with our previously identified protein, messenger RNA 
(mRNA) and microRNA (miRNA) content of osteoblast-EVs to delineate the potentially 
targeted biological functions/ pathways during HSPC proliferation. Our analyses reveal a 
set of candidate EV components, such as signaling proteins, cell cycle related mRNAs and 
miRNAs involved in HSPC self-renewal. In conclusion, our findings demonstrate that os-
teoblast-EVs affect the gene expression of HSPCs, and the transcriptome data in combina-
tion with bioinformatics analyses serve as a useful resource to unveil the fundamental roles 
of EVs in HSPC-osteolineage-cell crosstalk.  
 
 
. 
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6.1. INTRODUCTION 
The secretion of extracellular vesicles (EVs) is an evolutionarily conserved form 
of communication among cells. All living cells secrete EVs selectively packaged with regu-
latory cargo necessary to alter the function of their target cells1-4.  Proteomic, transcriptom-
ic and lipidomic analyses allowed the elucidation of biologically relevant EV cargo from 
diverse types of cells and biological fluids5-11. Advancement of systematic and comprehen-
sive studies further helped us understand the role of EV cargo in various biological func-
tions.  
Hematopoietic stem cells (HSCs) have the capacity to self-renew and replenish the 
entire blood system in a tightly regulated manner. Properly controlled gene expression en-
sures to maintain a fine balance between the number of stem cells and their differentiated 
progeny12,13. Hematopoiesis is mainly restricted to the unique favorable microenvironment 
provided by the bone tissue in adult humans14. Among many others, osteolineage cells are 
one of the main bone residents that provide essential regulatory and stimulatory signals 
critical to support survival and differentiation of hematopoietic stem and progenitor cells 
(HSPCs)15-21. In Chapter 5, we showed that human osteoblasts secrete EVs that stimulate 
the growth and expansion of human umbilical cord blood (UCB)- derived CD34+ HSPCs in 
vitro. We speculate that the selective EV cargo is responsible for the interaction between 
osteoblasts and HSPCs. If osteoblast-derived EVs are indeed important regulators of 
HSPC-osteolineage-cell crosstalk, then exploring the biological pathways that are stimulat-
ed by EVs is critical to understand the complexity of the molecular programs underlying 
HSPC cell proliferation.  
In this chapter, we used bioinformatics analytical tools to gain a comprehensive 
insight into the molecular mechanism of EV action in HSPC fate regulation. Initially, we 
studied the effect of osteoblast-EVs on the gene expression of UCB-derived CD34+ HSPCs 
by next-generation sequencing. Next, we used our previously characterized EV cargo da-
tasets and employed comprehensive integrative bioinformatics analyses to define/ propose 
biological pathways that are dynamically regulated by EV cargo11. The proteogenomics 
approach used in this study is a valuable tool to identify powerful EV cargo candidates, 
which can be used as potential therapeutic agents. 
 
6.2. RESULTS  
6.2.1. Osteoblast-EVs alter the gene expression of CD34+ HSPCs 
In this study, we investigated the effect of EVs isolated from human osteoblasts 
(SV-HFOs) on the gene expression of human UCB-derived CD34+ HSPCs. We performed 
next-generation sequencing to define the alterations on the transcriptome profiling of 
CD34+ cells after 24 hours treatment with osteoblast-EVs. To ensure that the genetic differ-
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ences are less likely due to different cellular composition at the time of RNA isolation, we 
verified that cells did not lose their CD34+ phenotype after 24 hours of culture with or 
without EVs (Fig. 1). Osteoblast-EV treatment does not alter the expression of the majority 
of the CD34+ HSPC genes (Fig. 2A). We identified a small percentage (2.3%) of expressed 
genes that are exclusively detected or absent in EV-treated cells (Fig. 2B). Interestingly, 
these are mostly genes encoding for glycoproteins (108 out of 294 genes) suggesting a link 
to cell adhesion and signalling. We identified 33 known CD34+ HSPC genes, of which 17 
genes are up-regulated and 16 genes down-regulated more than 1.5-fold (P < 0.05) by oste-
oblast-EVs compared to the control (Fig. 2C, Table 1). 
 
 
 
 
Figure 2. Osteoblast-EVs alter the expression of CD34+ HSPC genes. A) Scatter plot shows the strong correla-
tion (R2: 0.9882) of normalized read counts (average counts per million, CPM) between the expressions of CD34+ 
HSPC genes after 24 hours culture in the absence (control) and presence of osteoblast-EVs (N = 2). B) Venn 
diagram indicates the distribution of CD34+ HSPC transcripts between control and EV treatment groups. C) Vol-
cano plot (significance versus fold change) shows the CD34+ HSPC genes that are significantly (P < 0.05, com-
pared with control by Student’s t-test) regulated in response to osteoblast-EVs by at least 1.5-fold. Numbers in 
brackets denote the number of up-regulated (red, 17 genes) and down-regulated (green, 16 genes). FC, fold 
change.  
 
Next, we analyzed the patterns of change in the expression levels of the 33 regu-
lated CD34+ HSPC genes between control and EV-treated cells compared to the expression 
levels at the starting time-point (t: 0). We identified four different expression profiles: en-
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Figure 1. Phenotypic analysis of osteoblast-
EV-treated CD34+ HSPCs.  
Flow cytometry plots show the expression of 
CD45 and CD34 after 24 hours culture in the 
absence (control, left panel) and presence (right 
panel) of osteoblast-EVs. 
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hanced up-regulation (Fig. 3A), lowered up-regulation (Fig. 3B), enhanced down-
regulation (Fig. 3C), and lowered down-regulation (Fig. 3D) of endogenous (control) gene 
expression as a response to EV-treatment in 24 hours. For the majority of the genes, EV-
treatment enhances the endogenous up- or down-regulation (Fig. 3A & 3C). For a small 
number of genes, however, osteoblast-EVs alter gene expression by lowering the extent of 
endogenous up-regulation of MAOA and NFIB and TGFB1I1 (Fig. 3B), and down-
regulation of BCL3, PHLDB2, PIM1 and S100A9 (Fig. 3D). 
 
Table 1. The list of CD34+ HSPC genes significantly (P < 0.05) up- or down-regulated (≥ 1.5-fold) in response to 
osteoblast-EV treatment for 24 hours.  
 
 
Up-regulated 
 
 
 
Down-regulated 
 
Gene Symbols 
 
 
Fold Change 
 
Gene Symbols 
 
Fold Change 
 
 
ABI3 2.47 ITGAX -1.92 
GLYATL2 2.42 NFIB -1.78 
PAQR5 2.15 SLC15A1 -1.68 
S100A9 2.01 HIST1H2AL -1.67 
PIM1 1.78 TGFB1I1 -1.64 
FAM64A 1.73 NSUN7 -1.60 
PTRH1 1.65 CYSLTR2 -1.59 
MAP3K6 1.62 DYNC2H1 -1.58 
DUSP3 1.60 FAT4 -1.57 
SPR 1.60 EGR1 -1.56 
C7orf10 1.59 OVGP1 -1.55 
BCL3 1.56 ZNF286B -1.55 
MRPL27 1.53 ABCA10 -1.52 
PRTFDC1 1.52 DUSP8 -1.51 
PHLDB2 1.52 MAOA -1.51 
ANKRD35 1.50 CYP2W1 -1.50 
CACNA1H 
 
1.50   
 
According to Gene Ontology analysis the 33 regulated genes are mostly (P < 0.05) 
annotated to MAPK signalling pathway (CACNA1H, DUSP3, DUSP8, MAP3K6). Further 
investigation using Ingenuity Pathway Analysis (IPA) indicates that EVs modulate the ex-
pression of CD34+ HSPC genes mostly annotated (P < 0.05) to cellular development, cellu-
lar growth and proliferation, cell-to-cell signaling and interaction, small molecule biochem-
istry and cell cycle. Molecular and cellular functions annotated to these genes are listed in 
Table 2. A set of genes, including BCL3, EGR1, ITGAX, CYSLTR2, PIM1 and S100A9, are 
of particular interest as they are mainly related to the expansion of blood cells, in accord-
ance with our results presented in Chapter 5. We confirmed the differential expression of 
selected genes by qPCR as shown in Figure 4. Despite the donor-related variation, on aver-
age gene expression is in the same direction as determined by sequencing for all the tested 
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genes. These findings showed that osteoblast-EVs are capable of altering the expression 
pattern of cellular growth-related CD34+ HSPC genes, supporting our previous studies re-
porting the proliferative effect of EV cargo.  
 
 
Figure 3. Expression profiles of differentially expressed CD34+ HSPC genes. A-C) Expression profiles show 
the temporal pattern of gene expression defined by normalized read counts (CPM). Osteoblast-EVs enhance the 
(A) up-regulation and (C) down-regulation of CD34+ HSPC genes by control alone in 24 hours. EVs lower the 
control-induced (B) up-regulation and (D) down-regulation of CD34+ HSPC genes by control alone in 24 hours. 
 
 
Table 2. The list of the osteoblast-EV-regulated CD34+ HSPC genes significantly (P < 0.05) annotated to repre-
sentative molecular and cellular functions.  
 
 
Molecular and Cellular Functions 
 
# Genes 
 
Gene Symbols 
 
 
 
Cellular development 
 
 
11 
 
 
BCL3, CACNA1H, CYSLTR2, DUSP8, EGR1, 
ITGAX, MAOA, NFIB, PIM1, S100A9, TGFB1I1 
 
Cellular growth and proliferation 10 BCL3, CYSLTR2, DUSP8, EGR1, ITGAX, MAOA, 
NFIB, PIM1, S100A9, TGFB1I1 
 
Cell-to-cell signaling and interaction 10 BCL3, CYSLTR2, DUSP3, EGR1, ITGAX, MAOA, 
PIM1, S100A9, SPR, TGFB1I1 
 
Small molecule biochemistry 7 BCL3, CACNA1H, CYSLTR2, EGR1, MAOA, SPR, 
TGFB1I1 
 
Cell cycle 3 BCL3, EGR1, PIM1 
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6.2.2. Candidate key molecular players of EV function 
To investigate the molecular basis of EV-mediated gene regulation in CD34+ 
HSPCs we correlated the cargo of osteoblast-EVs to the EV-regulated CD34+ HSPC genes 
using an integrative bioinformatics approach. We used IPA to build a network showing the 
tentative direct molecular relationships between the EV cargo, such as protein, messenger 
RNA (mRNA) and microRNA (miRNA), and the regulated CD34+ HSPC genes (Fig. 5). It 
is important to note that, here we only considered the highly abundant EV-miRNAs and 
EV-mRNAs with normalized read counts above 100, and correlated the EV-miRNAs only 
to the down-regulated CD34+ HSPC genes. More than half (19 out of the 33) of the EV-
regulated CD34+ HSPC genes are mapped with a small number (68 out of 980) of EV-
proteins. 11 genes are mapped with 16 (out of 809) EV-mRNAs, and 14 down-regulated 
genes are mapped with 65 (out of 185) EV-miRNAs. Overall, NFIB and EGR1 are the 
CD34+ HSPC genes targeted by the highest number of EV cargo. While, NFIB is targeted 
mostly by EV-miRNAs (36 miRNAs and 1 mRNA), EGR1 shows interaction with at least 
one biomolecule of each cargo type (12 proteins, 8 miRNAs and 4 mRNAs). 
The mapped EV-proteins are mostly annotated to EV markers (ANXA2, 
HSP90AA1, ITGB1, YWHAZ, BSG), as well as proteins involved in cell cycle (HDAC2, 
SFN, MAPK1) and protein transport (AP2A1, CLTA, IPO7). The EV-proteins interact pre-
dominantly with EGR1 and S100A9. The small group of mapped EV-mRNAs consists of 
genes mostly encoding proteins annotated to cell cycle (CDC20, CDKN1A/2A, UBC), and 
interacts predominantly with PIM1. NFIB, on the other hand, is the most common putative 
target of the EV-miRNAs. Remarkably, a significant number (16 out of 65) of the mapped 
EV-miRNAs are among the highly enriched EV-miRNAs speculated to exert most of EV-
miRNA-mediated functional effect, as described in Chapter 4. These also include the 
known regulators of hematopoiesis, such as miR23a-3p, miR-29a-3p and miR-181a-5p.  
Combined analysis of the mapped EV cargo indicates that cell cycle, as well as re-
lated processes, such as proliferation, are strongly overrepresented in EVs. Particularly, a 
sizeable set of EV cargo is annotated to the proliferation of blood cells and showed interac-
Figure 4  Morhayim et al. Chapter 6_
-4 -3 -2 -1 0 1 2
CYSTLTR2
EGR1
ITGAX
MAOA
NFIB
S100A9
Log2 Fold Change
(Relative to Control)
Figure 4. Verification of differentially expressed 
CD34+ HSPC genes by qPCR. Expression levels 
(mean ± SD) of selected CD34+ HSPC genes after 24 
hours of incubation in the presence of osteoblast-EVs 
(N = 3). Fold change is determined compared to con-
trol and normalized to average GAPDH expression. 
The donors used for qPCR analysis are different than 
the ones used for mRNA sequencing.  
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tion with the above-mentioned six HSPC genes (BCL3, EGR1, ITGAX, CYSLTR2, PIM1, 
S100A9) with known roles in proliferation during hematopoietic development. These EV 
components consist of interesting EV-proteins, including signaling proteins (CAV1, 
CDC42, CTNBB1, PRKCB, STAT1, SFN), DNA-binding proteins (HMGA1, HNRN-
PA2B1), transporters (SLC3A2) and inflammatory cytokines (MIF), which predominantly 
interact with EGR1 and S100A9.  
We also evaluated the horizontal transfer of EV-mRNAs between osteoblasts and 
CD34+ HSPCs. First, we questioned whether the increased expression levels of the HSPC 
genes are due to the accumulation of EV-mRNA inside HSPCs after 24 hours of treatment 
with osteoblast-EVs. Interestingly, none of the up-regulated HSPC genes are among the 
significantly (P < 0.05) enriched (≥ two-fold) EV-mRNAs reported in Chapter 3. This 
holds true also for the down-regulated HSPC genes. Then, we checked the expression pro-
files of the top 10 enriched EV-mRNAs in CD34+ HSPCs (Fig. 6A). Remarkably, RAB13 
shows a trend for down-regulation upon EV treatment, which was also confirmed by qPCR 
analysis (Fig. 6B). Comparison with the expression levels at the starting time-point (0 h) 
indicates that EV treatment lowers the endogenous up-regulation of RAB13 in 24 hours. In 
silico analysis, using TargetScan algorithms, revealed that RAB13 is the predicted target of 
EV-miRNAs, such as miR-19a-3p, miR-19b-3p and miR-194-5p, which might have key 
roles in the down-regulation of RAB13. Together these analyses link the EV cargo to the 
regulation of CD34+ HSPC gene expression, enabling valuable insights into the molecular 
complexity of EV-mediated HSPC-osteolineage-cell crosstalk.  
 
6.3. DISCUSSION  
The findings described in this chapter demonstrate that osteoblast-EVs regulate 
expression of CD34+ HSPC genes encoding for proteins particularly important for prolifer-
ation and cell cycle. Using integrative bioinformatics we unified our osteoblast-EV cargo 
repositories with CD34+ HSPC sequencing data for the extraction of critical knowledge 
towards deeper understanding of the underlying key players and molecular mechanisms of 
EV-mediated HSPC-osteolineage-cell crosstalk.  
A tightly regulated transcriptional program plays a major role in defining the dif-
ferent stages of hematopoiesis. In previous chapters, we showed the effect of osteoblast-
EVs on HSPC proliferation and expansion in vitro. Here, we investigated the molecular 
mechanisms by which EVs may affect the gene expression of CD34+ HSPCs in the early 
steps of hematopoiesis. In accordance with our previous functional studies, the differential-
ly expressed HSPC genes are mostly annotated to cell growth related processes, Moreover, 
some of the genes are also annotated to MAPK pathway, which has recently been demon-
strated to play a key role in the regulation of HSPC self-renewal and homeostasis22. An 
important study by Oostendorp and colleagues showed that hematopoietic growth factor-
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driven stimulation of UCB-derived cells activates MAPK signaling and rapidly induces 
proliferation23. 
 
 
 
Figure 5. IPA network showing the direct relationship maps between the EV-cargo and 33 EV-regulated CD34+ 
HSPC genes. Green, down-regulated CD34+ HSPC genes; red, up-regulated CD34+ HSPC genes; black circles, 
EV-proteins; grey circles, EV-mRNAs; dark grey trapezoids, EV-miRNAs. CD34+ HSPC genes with known roles 
in proliferation during hematopoietic development are highlighted with blue lines. 
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Figure 6. Expression profiles of CD34+ HSPCs mRNAs specifically enriched in osteoblast-EVs. A) Expres-
sion profiles of top 10 enriched EV-mRNAs in CD34+ HSPCs. Expression levels are shown as average fold 
change of normalized reads (RPKM) relative to GAPDH (N = 3). B) Relative expression of RAB13 in CD34+ 
HSPCs in the absence (control) and presence of EVs using qPCR (N = 2).  Expression levels are relative to the 
starting time-point (0 h) and normalized to average GAPDH expression. The donors used for qPCR analysis are 
different than the ones used for mRNA sequencing.  
 
UCB-based stem cell therapies rely on the development of protocols that support 
robust expansion of immature stem cells in culture. In recent years, studies reported the use 
of various hematopoietic factors that improve ex vivo expansion mainly via regulating the 
expression patterns of key players of HSPC self-renewal24-26. Interestingly, osteoblast-EV 
treatment alters the expression of such genes (BCL3, EGR1, ITGAX, CYSLTR2, PIM1, 
S100A9) with important roles in the regulation of proliferation of HSPCs. Recent reports 
showed that S100A9 expression is up-regulated during HSC maturation. Here, S100A9 lev-
els are down-regulated by osteoblast-EVs, suggestive of an effort for EVs to maintain the 
cells in more immature state27. EGR1, on the other hand, encodes for a transcription factor 
that plays a key role in the regulation of hematopoietic homeostasis. Previous studies 
showed that EGR1 levels are high in quiescent cells and they are dramatically down-
regulated upon cell division28. Accordingly, we demonstrate that EGR1 levels drop after 24 
hours as the HSPCs progress into cell cycle. Interestingly, the down-regulation is further 
enhanced in the presence of EVs most likely due to the ability of EVs to drive the cell divi-
sion kinetics of HSPCs.  
Despite increasing evidence reporting single factors that influence cell fate deci-
sions, it is indisputable that complex transcriptional regulatory networks are the key play-
ers. The remarkable power of active sorting mechanism renders EVs with unique combina-
tions of EV cargo that act in concert to modulate the expression levels of their target genes. 
Understanding the role of EVs in hematopoiesis, therefore, requires unraveling the way EV 
regulators interact with each other to regulate transcriptional networks. Thanks to the rapid 
rise of high-throughput technologies we formed comprehensive osteoblast-EV cargo repos-
itories useful to delineate a specific set of candidate components that give insights into the 
biological functions. Using an integrative bioinformatics approach, we investigated the 
tentative molecular relationships between the EV cargo and the regulated HSPC genes con-
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trolling proliferation and cell cycle. Surprisingly, the above-mentioned genes with known 
roles in the proliferation of blood cells are among the predominantly targeted HSPC genes, 
such as EGR1, S100A9 and PIM1. In particular, the targeting EV-proteins mainly consist of 
an interesting set of signaling proteins, including STAT1, CTNBB1 and CDC42, as poten-
tial candidates for further investigation29-33. Moreover, NFIB is the target of the majority of 
EV-miRNAs. The down-regulation of NFIB has been shown to be critical during the transi-
tion of the immature HSCs to the multipotent progenitors34. In previous chapters, we 
demonstrated that osteoblast-EVs stimulate the expansion of the progenitor cells while 
maintaining the immature stem cell pool. Although it is tempting to speculate a role for 
NFIB targeting in the expansion of the progenitors, further functional studies are needed to 
investigate the detailed molecular mechanisms.  
In Chapter 3, we demonstrated that RAB13 mRNA is exceptionally highly abun-
dant in osteoblast-EVs compared to the parental cells suggestive of an essential role in EV-
mediated communication. Contrary to increasing evidence reporting the detection of a vari-
ety of EV-mRNAs in the target cells35,36; it is striking to discover the down-regulation of 
the most enriched osteoblast-EV-mRNA in HSPCs upon EV treatment. We speculate that 
the alteration of RAB13 in HSPCs is most likely connected to other osteoblast cargo, such 
as miRNAs. However, we cannot rule out the possibility of EV-mRNA in regulating gene 
expression in the target cell via an alternative biological mechanism. There are studies re-
porting that EVs contain the 3'-untranslated regions of certain mRNAs to protect the target 
mRNA from miRNA degradation37. As well, EV-mRNAs may function by stimulating cel-
lular mRNA degradation by protecting the EV-miRNAs until they reach their target 
mRNAs in the recipient cells. Furthermore, the biological function of RAB13 down-
regulation in HSPCs still remains to be explored. Network analysis in Chapter 3 suggested 
a role for RAB13 in proliferation of blood cells, which requires further investigation in the 
context of EV-mediated crosstalk between HSPCs and osteolineage cells.  
In conclusion, in this chapter we present an extensive valuable resource for the 
functional exploration of EV-mediated regulation of HSPC-osteolineage crosstalk. We 
identified critical EV-driven molecular mechanisms that trigger transcriptional programs 
and signaling cascades that define HSPC proliferation. However, it is still challenging to 
assess the extent to which individual or combinations of cargo contribute to these effects. 
Elucidating the precise molecular functions regulated by osteoblast-EV cargo is promising 
to provide the basis for the development of effective stem cells therapies. 
 
6.4. MATERIALS AND METHODS 
Cell cultures and EV isolation. Human osteoblast cells (SV-HFO cells) were cultured for 
12-14 days, and EVs were isolated from the conditioned medium using the SW32Ti rotor 
(Beckman Coulter, Fullerton, CA, USA) as described in Chapter 211. EVs were prepared as 
100 µl suspensions, and the amount of experimental EV dose was determined as 5% (v/v). 
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UCB-derived CD34+ HSPCs were isolated as described in Chapter 438. The purity of the 
CD34+ HSPCs was verified using BD FACSCantoII (BD Biosciences) flow cytometer as 
described in Chapter 4. 20,000 CD34+ cells were cultured in serum-free Glycostem Basic 
Growth Medium (GBGM; Glycostem, Oss, the Netherlands) supplemented with SCF (50 
ng/ ml, Cellgenix, Freiburg, Germany) and Flt3L (50 ng/ ml, Cellgenix), with or without 
osteoblast-EVs at 37°C in a humidified atmosphere of 5% CO2 for 24 hours.  
RNA isolation and quantitative real-time PCR. RNA from CD34+ cells was isolated us-
ing NucleoSpin RNA XS kit (Macherey-Nagel, Duren, Germany) according to the manu-
facturer’s instructions. RNA concentration was determined using Nanodrop (Thermo Fish-
er Scientific, Waltham, MA, USA) and size distribution was checked on an Agilent Bio-
analyzer RNA 6000 Nano chip (Thermo Fisher Scientific). Quantitative real-time PCR 
were performed using the SYBRTM Green kit (Eurogentec, Seraing, Belgium) according to 
the manufacturer’s instructions. The primer sequences are listed in Appendix C. 
Next-generation sequencing and bioinformatic analysis. RNA sequencing and bioinfor-
matic analysis was performed as described in Chapter 339. Normalization of the read counts 
was performed using edgeR 2.6.2. DAVID Bionformatics Resources v6.7 was used to cat-
egorize the proteins into overrepresented GO annotations using the human expression da-
taset as a background40,41. IPA (Ingenuity® Systems. www.ingenuity.com) was used to 
predict target pathways and analyze the interaction between EV cargo and CD34+ HSPC 
genes using the path explorer tool in My Pathway analysis. TargetScan (Release 7.0) was 
used for miRNA target prediction analysis. 
Statistics. The results were described as mean ± SD based on at least two independent ex-
periments performed with independent EV isolations and/ or different UCB donors. Signif-
icance was calculated using Student’s t-test, and P values < 0.05 were considered signifi-
cant. 
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7.1. OVERVIEW 
For decades, scientists across the world have observed extracellular vesicles (EVs) 
in their biological systems without realizing that EV-mediated intercellular communication 
is a universally shared biological process1-11. It was not until 2006 that scientists discovered 
EV-associated RNA, which triggered interest in the field and thereafter studies started in-
creasing exponentially12-15. The establishment of an EV society (International Society of 
Extracellular Vesicles, ISEV) in 2011 brought in so many scientists from various fields 
ranging from prokaryotes to eukaryotes, immunology to stem cell biology, cancer to auto-
immune diseases, highlighting the uniformity of the EV-mediated intercellular communica-
tion. 
Throughout this thesis, we investigated the role of osteoblast-derived EVs in 
communication with the neighboring cells residing in the surrounding bone microenviron-
ment. In Chapters 2, 3 and 4, we presented a comprehensive analysis of EV protein, mes-
senger RNA (mRNA) and microRNA (miRNA) cargo, respectively. In Chapters 2, 4, 5 
and 6, we showed the role of EVs mediating communication between osteoblasts and pros-
tate cancer cells as well as hematopoietic stem and progenitor cells (HSPCs). In Chapter 5, 
we investigated possible therapeutic applications of EVs in the field of hematology. In this 
chapter, we discuss the main findings of this thesis with relevance to the current state of the 
field. Furthermore, we discuss the strengths and limitations of our research, and propose 
suggestions for future studies.  
 
7.2. DOES EV CARGO HAVE A BIOLOGICAL MEANING? 
The existence of EVs in bone has been known for many years. Already back in 
1967, Anderson and colleagues reported the discovery of osteoblast-derived matrix vesicles 
as specialized EVs involved in biomineralization of the bone matrix3,4. They showed that 
bone mineral crystal is formed with the coordinated activity of matrix vesicle proteins, such 
as phosphatases, calcium-binding proteins and transporters. However, over the past years it 
has become clear that beyond forming bone, osteoblasts play a role in various biological 
processes, including immune cell development, regulation of hematopoietic niche, and can-
cer metastasis to bone. With this in mind, we aimed to investigate the role of osteoblasts in 
EV-mediated regulation of essential physiological functions. 
 
7.2.1. Exploring the EV cargo 
EVs are actively loaded with a specific repertoire of proteins and RNA molecules 
that are necessary to convey their intercellular message. We employed various large-scale 
analysis technologies, such as proteomics and next-generation sequencing, and used com-
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munity resources, such as EVpedia, and ExoCarta, to perform comparative studies to un-
ravel the osteoblast-specific regulatory EV cargo16,17.  
EVs commonly contain structural cargo important for essential vesicle functions, 
such as biogenesis, sorting, motility and targeting. In Chapter 2, we demonstrated that EVs 
secreted by osteoblasts contain the classical EV marker proteins, such as adhesion mole-
cules (FN1, ITGB1), annexins (ANXA2, ANXA6), cytoskeletal proteins (ACTB, MSN), 
heat shock proteins (HSPA8, HSP90AA1), metabolic enzymes (GAPDH, LDHA) and tet-
raspanins (CD9, CD81). The parental cell type, mode of biogenesis and environmental 
stimuli are among the factors that influence the nature and abundance of EV cargo18. Ac-
cordingly, we showed that osteoblasts secrete EVs that differ in morphology and proteomic 
composition depending on the stage of differentiation and mineralization condition. EVs 
secreted by mineralizing osteoblasts are enriched with biomineralization-related proteins 
indicating an activity associated with matrix vesicles. However, these EVs are also highly 
abundant in proteins involved in RNA binding and processing, suggestive of the presence 
of an EV subgroup with a role in intercellular communication. EVs secreted by non-
mineralizing osteoblasts, on the other hand, are specifically enriched with cell adhesion-
associated extracellular matrix proteins and chromosomal proteins with regulatory poten-
tial. To study communication and avoid the cross contamination of matrix vesicle activity, 
in the reminder of this thesis we focused on non-mineralizing osteoblast-derived EVs that 
we often referred to as “osteoblast-EVs”.  
Comparative analyses demonstrated that EV content is not just a reflection of the 
parental cell composition, but rather a unique set of molecules packaged within the vesicu-
lar structure via a conserved and preferential sorting mechanism. In fact, when compared to 
the cellular RNA distribution, osteoblast-EVs are enriched with small RNAs (25-1,000 
nucleotides), and lack the characteristic cellular 18S and 28S ribosomal RNAs. In Chapter 
3, we showed that EV-mRNAs mostly consist of genes encoding for proteins with riboso-
mal activities, while they lack the genes important to carry out vital cellular processes. EVs 
are particularly enriched with RAB13 mRNA as it is standing out among the overrepresent-
ed EV-mRNAs. Rab family of small GTPases, have been implicated to play roles in EV 
release and transport19,20. Assuming that the EV-mRNA is translated upon delivery, we 
speculate that RAB13 is likely to regulate EV biogenesis in the recipient cells. In Chapter 
4, we presented a selective group of miRNAs that are overrepresented in osteoblast-EVs. 
These are mostly miRNAs involved in molecular functions related to growth and prolifera-
tion. Among these, we were particularly interested miR-29a, which is a well-characterized 
regulator of early hematopoiesis21.  
Taken together, our combined omics data analysis identified overrepresented 
pathways and biological processes important for cellular development and growth of target 
cells. The enrichment of ribosomal proteins and mRNAs that encode for ribosomal proteins 
brings diverse speculations on their role of stabilizing the miRNA cargo or transferring of 
ribosomal parts to facilitate gene expression in the target cells. At this stage, it is still chal-
lenging to distinguish the role of individual EV cargo. In light of our findings, we can con-
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clude that the EV cargo consists of a combination of functionally diverse structural and 
regulatory biomolecules that must work in concert to convey the final message.  
 
7.2.2. EV-mediated interaction with the microenvironment 
Osteoblasts produce a network of receptors and secreted factors that provide the 
means of communication with the surrounding cells in the immediate microenvironment 22-
25. Based on our EV cargo analyses and functional studies, we demonstrated that osteo-
blast-EVs represented one of the critical components of this favorable microenvironment 
necessary to support vital biological processes. We performed bioinformatics analyses to 
delineate a candidate list of regulatory EV cargo predicted to target neighboring cells, such 
as osteoclasts, adipocytes, chondrocytes and hematopoietic stem cells (HSCs).  
To investigate the biological meaning of EV-mediated communication, we studied 
the role of osteoblast-EVs in HSPC-osteolineage-cell crosstalk. In Chapter 4, we demon-
strated that EV treatment induces the proliferation of HSPCs by stimulating cell cycle pro-
gression in vitro. In Chapter 2, we showed that EVs also stimulate the growth of bone-
metastasizing prostate cancer cells, which have been known to compete with HSPCs for the 
interaction with osteolineage cells. It is critical to note the versatility of the manner in 
which EVs influence the behavior of different target cells. Through transcriptomics studies 
in Chapters 2 & 6 we discovered that EVs alter the expression of different sets of HSPC 
and prostate cancer genes. Furthermore, we showed that the regulated genes are targeted by 
different sets of predicted EV cargo. Remarkably, both the altered genes and the predicted 
cargo are eventually annotated to the same pathway, “cell growth”, in accordance with the 
functional studies. It is important to keep in mind that osteoblast-EVs consist of several 
types of vesicles that most likely differ in content and function. Therefore, we speculate 
that EVs exert extrinsic control of their target cells through different EV subgroups that 
activate different signaling cascades, which eventually converge to the same phenotype.  
 
7.3. THERAPEUTIC POTENTIAL  
Stem cell therapies using umbilical cord blood (UCB)-derived CD34+ HSPCs are 
successful treatment options for patients with disrupted hematopoiesis. Increasing reports 
on the molecular mechanisms of HSC maintenance and self-renewal enabled the develop-
ment of ex vivo culture systems to expand HSPCs for improved engraftment and post-
transplantation recovery26-29. As mentioned, osteoblast-EVs showed the potency to stimu-
late HSPC proliferation in vitro making them suitable therapeutic candidates for expansion 
studies. In Chapter 5, we demonstrated that EVs cooperate with hematopoietic growth 
factors not only to promote proliferation but also to preserve the repopulating activity of 
UCB-derived CD34+ HSPCs. The latter is especially important to ensure a constant turno-
ver of new blood cells necessary for accelerated hematopoietic recovery. We successfully 
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showed the ability of the EV-expanded UCB cells to engraft in vivo and re-populate immu-
nodeficient mice. These in vitro and in vivo evaluations indicate the power of an osteoblast-
EV-based novel strategy for clinically relevant ex vivo expansion of UCB cells. With in-
creasing knowledge on EV biology, we believe that it will not be long before EVs will be 
used as therapeutic tools for the treatment of a broad range of disorders. 
 
7.4. CHALLENGES IN THE EV FIELD 
Currently, there are still major unsolved problems, such as phenotyping, sizing 
and enumerating EVs, which delay our ability to truly understand EV biology. The main 
limitation that we frequently faced was the difficulty of distinguishing the different EV 
subgroups, such as exosomes, microvesicles and apoptotic bodies. Even though the recent 
standardization of EV nomenclature has greatly facilitated the EV research, there is grow-
ing evidence that the subgroups may have distinct functions30. The discovery of widely 
accepted morphological or structural markers might help us distinguish the different EVs, 
and consequently study the content and interpret the function more precisely. The lack of 
optimized tools to accurately quantify EVs pose another challenge, especially for function-
al studies 31. Actually, using nanoparticle tracking analysis we managed to obtain consistent 
counts between independent isolations32. However, this method is still troublesome as it 
misses the small EVs, which may attribute to functionally significant differences between 
isolations.  
It is also worth drawing attention to the challenges of interpreting the EV content 
in relevance to the in vivo function. As mentioned, external factors can affect the EV con-
tent. Therefore it is very important to consider these aspects with the particular research 
question in mind. Furthermore, our limited knowledge on the fate of EV cargo once they 
are delivered to the target cells strictly restricts our ability to study their biochemistry. This 
is especially difficult when analyzing the mRNA data. Whether the mRNAs are translated 
using the target cell’s machinery or have a regulatory role still remain to be answered. Re-
garding sequencing studies, the comparison of expression levels across different samples 
and experiments is often difficult and requires complicated normalization methods. This is 
further challenged by the lack of well-established housekeeping RNAs for the comparison 
of cellular versus vesicular mRNAs and miRNAs. Unfortunately, these limitations are 
faced by most studies conducted on EVs, which fortunately brings together many groups to 
join forces to overcome these obstacles in the near future. 
 
7.5. CONCLUSIONS & OUTLOOK 
The discovery of specialized EVs carrying regulatory molecules between cells has 
been the hallmark of a recently discovered novel form of intercellular communication. Us-
ing comparative proteomics, genomics and bioinformatics analyses we showed that osteo-
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blasts secrete EVs containing the signature content of their parental cells while being selec-
tively enriched with a unique set of bioactive cargo. With carefully designed studies, we 
showed that EVs regulate the expression of cell growth-related HSPC and bone-
metastasizing prostate cancer genes, and stimulate their growth in vitro. However, the mo-
lecular mechanisms behind EV-mediated crosstalk still remain to be explored. Thorough 
integrated biochemical and genetic analyses are necessary to identify the biologically active 
EV components and study their physiological relevance in vivo.  
The increasing knowledge on EV biology has brought along therapeutic opportu-
nities to be exploited clinically. We principally investigated the possibility of using osteo-
blast-EVs in stem cell therapies, and consequently demonstrated their potency for ex vivo 
expansion of UCB-derived HSPCs suitable for transplantations. However, this approach 
comes with a caveat: EVs stimulate the proliferation and maintenance of HSPCs in short-
term cultures. Our current knowledge on EV content coupled with further investigation on 
the key molecular mechanism that stimulate HSPC proliferation may give us clues to ma-
nipulate EVs to stimulate long-term maintenance of the stem cells in vitro. This is especial-
ly important to develop improved expansion strategies that will meet the clinical need. 
Moreover, understanding the key players that regulate HSPC fate holds the promise of us-
ing EVs to manipulate other types of stem cells for various regenerative medicine applica-
tions in the future. 
The comprehensive EV data presented throughout this thesis serves as an exten-
sive osteoblast-EV cargo repository that offers a great source for non-invasive diagnostics 
as well as facilitates the development of cell-free strategies for therapeutic applications. We 
showed that the osteoblast-EV protein content is greatly dependent on the stage of mineral-
ization. Therefore, EVs pose as perfect candidates for biomarker discovery useful for the 
early detection of bone diseases. Furthermore, thanks to their endogenous and biocompati-
ble nature EVs are ideal virus-free vector alternatives for safer gene therapy applications. 
We anticipate that an elaborate understanding of the mechanism of EV cargo loading will 
enable us to develop tailored EVs containing therapeutic cargo to treat a broad variety of 
pathological conditions.  
With increasing number of studies deciphering the complexity of EV biology, this 
newly emerging scientific field rapidly advances beyond basic science. In this thesis, we 
presented our in vitro efforts to uncover the intricate interactions networks that underlie the 
function of EVs secreted by osteoblasts. To move forward, we need to identify new re-
search strategies and invest in developing optimized technologies that enhances our 
knowledge required to bring osteoblast-EVs towards clinical applications. 
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Table A1. LS-MS/MS data. EV proteins are defined by their UniProt accessions. x denotes present in a given 
sample. 
 
Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19
A0AVT1 x x x x x x O43324 x x x x x x O95394 x x x x x x P05455 x x x x x x
O00154 x x x x x x O43504 x x x x x x O95772 x x x x x x P05556 x x x x x x
O00159 x x x x x x O43592 x x x x x x O95782 x x x x x x P05771 x x x x x x
O00186 x x x x x x O43633 x x x x x x O95807 x x P06493 x x x x x x
O00194 x x x x O43657 x x x x x x O95816 x x x x P06576 x x x x x
O00231 x x x x x x O43684 x x x x x x O95819 x x x x x x P06703 x x x x x x
O00232 x x x x x x O43707 x x x x x x O95832 x x x x x x P06733 x x x x x x
O00299 x x x x x x O43731 x O95865 x x x x x P06737 x x x x x x
O00303 x x x x x x O43776 x x x x x x P00338 x x x x x x P06744 x x x x x x
O00338 x x x O43795 x x x x x x P00387 x x x x x x P06748 x x x x x x
O00410 x x x x x x O43854 x x x x x x P00441 x x x x x x P06753 x x x x x x
O00425 x x O60488 x x x x x x P00491 x x x x x x P06756 x x x x x x
O00429 x x x x x x O60506 x x x x x x P00492 x x x x x x P06899 x x x x x x
O00443 x x x x O60565 x x x x x x P00505 x x x x x x P07195 x x x x x x
O00468 x x x x x x O60610 x x x x x x P00533 x x x x x x P07237 x x x x x x
O00487 x x x x x x O60637 x x x x x x P00558 x x x x x x P07305 x x x x x x
O00560 x x x x x x O60701 x x x x x x P00749 x x x x x P07339 x x x x x x
O00567 x x x x x x O60763 x x x x x x P00966 x x x x x x P07355 x x x x x x
O00592 x x x x x O60841 x x x x x x P01031 x x x x x P07384 x x x x x x
O00764 x x x x x x O60884 x x x x x x P01111 x x x x x x P07437 x x x x x x
O14672; x x x x x x O75083 x x x x x x P01112 x x x x x x P07741 x x x x x x
O14744 x x x x x x O75131 x x x x x x P01892 x x x x x x P07814 x x x x x x
O14787 x x O75165 x x x x x x P02452 x x x x x x P07900 x x x x x x
O14817 x x x x x x O75340 x x x x x x P02545 x x x x x x P07910 x x x x x x
O14818 x x x x x x O75347 x x x x P02649 x x x x x x P07942 x x x x x x
O14828 x x x x x x O75351 x x x x x x P02751 x x x x x x P07947 x x x x x x
O14929 x x x x x x O75367 x x x x x x P02786 x x x x x x P08107 x x x x x x
O14936 x x x x x x O75368 x x x x P04075 x x x x x x P08123 x x x x x x
O14964 x x x x x x O75369 x x x x x x P04080 x x x x x x P08133 x x x x x x
O14980 x x x x x x O75390 x x x x x x P04083 x x x x x x P08134 x x x x
O15031 x x x x x x O75396 x x x x x x P04179 x x x x x x P08195 x x x x x x
O15067 x x x x x x O75436 x x x x x x P04216 x x x x x x P08237 x x x x x x
O15118 x x x x x x O75531 x x x x x x P04350 x x x x x x P08238 x x x x x x
O15143 x x x x x x O75643 x x x x x x P04406 x x x x x x P08253 x x x x x
O15144 x x x x x x O75695 x x x x x x P04632 x x x x x P08473 x x x x x x
O15145 x x x x x x O75787 x x x x P04792 x x x x x x P08590 x x x x x x
O15162 x x x x x x O75874 x x x x x x P04843 x x x x x x P08648 x x x x x x
O15230 x x x x x O75923 x x x x x x P04844 x x x x x x P08670 x x x x x x
O15243 x x O75954 x x x x x x P04899 x x x x x x P08708 x x x x x x
O15371 x x x x x x O75955 x x x x x x P05023 x x x x x x P08754 x x x x x x
O15372 x x x x x x O76021 x x x x x x P05026 x x x x x x P08758 x x x x x x
O15427 x x x x x x O76094 x x x x x x P05106 x x x x x x P08865 x x x x x x
O15484 x x x x x O94760 x x x x x x P05121 x x x x x x P08962 x x x x x x
O15511 x x x x x x O94973 x x x x x x P05161 x x x x x x P09104 x x x x x x
O15523 x x x x x x O95084 x x x x x x P05186 x x x x x x P09132 x x x x x x
O19617 x x x x x x O95183 x x x x x x P05198 x x x x x x P09211 x x x x x x
O43143 x x x x x x O95197 x x x x x x P05362 x x x x x x P09382 x x x x x x
O43169 x x x x x O95340 x x x x x x P05386 x x x x x x P09496 x x x x x x
O43242 x x x x x x O95347 x x x x x x P05387 x x x x x x P09525 x x x x x x
O43264 x x x x x x O95373 x x x x x x P05388 x x x x x x P09543 x x x x x x
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Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19 Accession 5 12 19 5 12 19
P09619 x x x x x x P13489 x x x x x x P17987 x x x x x x P24821 x x x x
P09651 x x x x x x P13611 x x x x x x P18077 x x x x x x P25205 x x x x x x
P09874 x x x x x x P13612 x x x x x x P18084 x x x x x x P25391 x x x x x x
P09914 x x x x x x P13639 x x x x x x P18085 x x x x x x P25398 x x x x x x
P09936 x x x x x x P13667 x x x x x x P18124 x x x x x x P25445 x x x x x x
P09960 x x x x x x P13726 x x x P18206 x x x x x x P25786 x x x x x x
P09972 x x x x x x P13797 x x x x x x P18564 x x x x x x P25787 x x x x x x
P0C0S5 x x x x x x P13798 x x x x x x P18621 x x x x x x P25788 x x x x x x
P0C0S8 x x x x x x P13861 x x x x x x P18669 x x x x x x P25789 x x x x x x
P0DJG4 x x x x P13987 x x x x x x P19105 x x x x x x P26006 x x x x x x
P10114 x x P14174 x x x x x x P19338 x x x x x x P26022 x x x x x x
P10124 x x x x x x P14209 x x x P19623 x x x x x P26038 x x x x x x
P10301 x x x x x x P14324 x x x x x x P19784 x x P26373 x x x x x x
P10319 x x x x x x P14384 x x x x x x P20020 x x x x x x P26639 x x x x x x
P10321 x x x x x x P14543 x x x x x P20042 x x x P26640 x x x x x x
P10412 x x x x x x P14550 x x x x x x P20073 x x x x x x P26641 x x x x x x
P10599 x x x x x x P14618 x x x x x x P20339 x x x x x x P27105 x x x x x x
P10644 x x x x x x P14625 x x x x x x P20340 x x x x x x P27348 x x x x x x
P10768 x x x x x x P14735 x x x x x x P20591 x x x x x x P27449 x x x x x x
P10809 x x x x x P14866 x x x x x x P20594 x x x x x P27487 x x x x x x
P10915 x x x x x x P14868 x x x x x x P20618 x x x x x x P27635 x x x x x x
P11021 x x x x x x P15121 x x x x x x P20645 x x x x x x P27694 x x x x x
P11047 x x x x x x P15144 x x x x x x P20936 x x P27695 x x x x x x
P11142 x x x x x x P15151 x x x x x x P21281 x x x x x x P27701 x x x x x x
P11166 x x x x x x P15170 x x x x x x P21333 x x x x x x P27708 x x x x x x
P11169 x x x x x x P15311 x x x x x x P21399 x x x x x x P27797 x x x x x x
P11172 x P15529 x x x x x x P21589 x x x x x x P27824 x x x x x x
P11216 x x x x x x P15531 x x x x x x P21741 x x x P28062 x x x x x x
P11217 x x x x P15880 x x x x x x P21926 x x x x x x P28065 x x x x x x
P11233 x x x x x x P15924 x x x x P21980 x x x x x x P28066 x x x x x x
P11279 x x x x x x P16070 x x x x x x P22087 x x x x x x P28070 x x x x x x
P11387 x x x x x x P16152 x x x x x x P22234 x x x x x x P28072 x x x x x x
P11388 x x x x x x P16189 x x x x x x P22314 x x x x x x P28074 x x x x x x
P11413 x x x x x x P16190 x x x x x x P22626 x x x x x x P28482 x x x x x x
P11586 x x x x x x P16401 x x x x x x P22694 x x x x P28838 x x x x x x
P11717 x x x x x x P16403 x x x x x x P23229 x x x x x x P29144 x x x x x x
P11766 x x x x x x P16442 x x x x x P23246 x x x x x x P29317 x x x x x x
P11908 x x x x x x P17066 x x x x x x P23258 x x x x x x P29323 x x x x x x
P11940 x x x x x x P17096 x x x x x x P23284 x x x x x x P29401 x x x x x x
P12004 x x x x x x P17174 x x x x x x P23381 x x x x x x P29692 x x x x x x
P12109 x x x x x x P17301 x x x x x x P23396 x x x x x x P29728 x x x x x
P12110 x x x x x x P17302 x x x x x x P23526 x x x x x x P29966 x x x x x x
P12111 x x x x x x P17612 x x x x x x P23528 x x x x x x P29992 x x x x x x
P12268 x x x x x x P17655 x x x x x x P23634 x x x x x x P30041 x x x x x x
P12429 x x x x x x P17693 x x x x x x P23743 x P30043 x x x x x
P12814 x x x x x x P17812 x x x x x x P23921 x x x x x x P30044 x x x x x x
P12955 x x x x x x P17813 x x x x x x P23942 x x x x x x P30046 x x x x x x
P12956 x x x x x x P17844 x x x x x x P24390 x x x x x P30048 x x x x x x
P13010 x x x x x x P17858 x x x x x x P24534 x x x x x x P30050 x x x x x x
P13473 x x x x x x P17980 x x x x x x P24666 x x x x x x P30086 x x x x x x
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P30101 x x x x x x P37837 x x x x x x P48637 x x x x x x P53396 x x x x x x
P30153 x x x x x x P38606 x x x x x x P48643 x x x x x x P53618 x x x x x x
P30408 x x x x P38646 x x x x x x P48739 x x x x x x P53621 x x x x x x
P30453 x x x x x x P38919 x x x x x x P48960 x x x x x x P53675 x x x x x x
P30499 x x x x x x P39019 x x x P49006 x x x x x x P53680 x x x x x x
P30566 x x x x x x P39023 x x x x x x P49189 x x x x x x P53985 x x x x x x
P30626 x x x x x x P40121 x x x x x x P49207 x x x x x x P53990 x x x x x x
P30740 x x x x x x P40227 x x x x x x P49327 x x x x x x P54136 x x x x x x
P30825 x x x x x x P40261 x x x x x x P49368 x x x x x x P54289 x x x x x x
P31150 x x x x x x P40306 x x x x x x P49419 x x x x x x P54578 x x x x x x
P31153 x x x P40429 x x x x x x P49588 x x x x x x P54652 x x x x x
P31350 x x x x x x P40925 x x x x x x P49589 x x x x x P54687 x x x x x x
P31689 x x x x x x P40926 x x x x x x P49591 x x x x x x P54709 x x x x x x
P31939 x x x x x x P41091 x x x x x x P49720 x x x x x x P54852 x x x x x x
P31942 x x x x x x P41250 x x x x x x P49721 x x x x x x P54920 x x x x x x
P31943 x x x x x x P41252 x x x x x x P49736 x x x x x P55010 x x x x x x
P31946 x x x x x x P42224 x x x x x x P49755 x x x x x P55060 x x x x x x
P31947 x x x x x x P42345 x x x x x P49770 x x x x x x P55072 x x x x x x
P31948 x x x x x x P42677 x x x x x x P49773 x x x x x x P55209 x x x x x x
P31949 x x x x x x P42766 x x x x x x P49915 x x x x x x P55263 x x x x x x
P32119 x x x x x x P42892 x x x x x x P50148 x x x x x x P55268 x x x
P32455 x x x x x x P43007 x x x x x x P50281 x x x x x x P55290 x x x x x x
P32969 x x x x x x P43034 x x x x x x P50395 x x x x x x P55735 x x x x x x
P33176 x x x x x x P43121 x x x x x x P50454 x x x x x x P55769 x x x x x
P33991 x x x x x x P43487 x x x x x x P50502 x x x x x x P55786 x x x x x x
P33992 x x x x x x P43490 x x x x x x P50570 x x x x x P55854 x x x x x x
P33993 x x x x x x P43686 x x x x x x P50748 x x x x x P55884 x x x
P34897 x x x x x x P45973 x P50914 x x x x x x P56192 x x x x x x
P34932 x x x x x x P45974 x x x x x x P50990 x x x x x x P56199 x x x x x x
P35030 x x x x x x P46063 x x x x x x P50991 x x x x x x P56537 x x x x x x
P35080 x x x x x x P46459 x x x x x P50995 x x x x x x P58546 x x x x x x
P35221 x x x x x x P46776 x x x x x x P51148 x x x x x x P59998 x x x x x x
P35222 x x x x x x P46777 x x x x x x P51149 x x x x x x P60033 x x x x x x
P35237 x x x x x x P46778 x x x x x x P51153 x x x x x x P60174 x x x x x x
P35241 x x x x x x P46779 x x x x x x P51178 x x x x x x P60228 x x x x x x
P35268 x x x x x x P46781 x x x x x x P51571 x x x x x P60520 x x x x x x
P35442 x x x x x P46782 x x x x x x P51572 x x x x P60660 x x x x x x
P35579 x x x x x x P46783 x x x x x x P51665 x x x x x x P60842 x x x x x x
P35606 x x x x x x P46926 x x x x x x P51991 x x x x x x P60866 x x x x x x
P35613 x x x x x x P46934 x x x x x x P52209 x x x x x x P60900 x x x x x x
P35659 x x x x x x P46940 x x x x x x P52272 x x x x x x P60953 x x x x x x
P35998 x x x x x x P46976 x x x P52292 x x x x x x P60981 x x x x x x
P36383 x x x x x x P47755 x x x x x x P52306 x x x x x x P60983 x x x x x x
P36406 x x x x x x P47756 x x x x x x P52565 x x x x x x P61006 x x x x x x
P36543 x x x x x x P47813 x x x x x x P52597 x x x x P61011 x
P36578 x x x x x x P47914 x x x x x x P52788 x x x x x x P61019 x x x x x x
P36871 x P48059 x x x x x x P52888 x x x x x x P61020 x x x x x x
P36873 x x x x x x P48147 x x x x x x P52907 x x x x x x P61026 x x x x x x
P37108 x x x x x x P48444 x x x x x x P52926 x x x x x P61077 x x x x x x
P37802 x x x x x x P48509 x x x x x x P53004 x x x x x x P61081 x x x x x x
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P61088 x x x x x x P62714 x x x x x x P83731 x x x x x x Q12765 x x x x x x
P61106 x x x x x x P62745 x P84085 x x x x x x Q12768 x x x x x x
P61158 x x x x x x P62750 x x x x x x P84095 x x x x x x Q12846 x x x x x x
P61160 x x x x x x P62753 x x x x x x P84098 x x x x x x Q12884 x x x x x x
P61163 x x x x x x P62805 x x x x x x P84103 x x x x x x Q12905 x x x x x x
P61201 x x x x x x P62820 x x x x x x P98095 x x x x x Q12906 x x x x x x
P61204 x x x x x x P62826 x x x x x x P98160 x x x x x x Q12907 x x x x x x
P61221 x x x x x x P62829 x x x x x x P99999 x x x x x x Q12959 x x x x x
P61224 x x x x x x P62841 x x x x x x Q00526 x x x x x Q12965 x x x x x
P61225 x x x x x x P62847 x x x x x x Q00610 x x x x x x Q13045 x x x x
P61247 x x x x x x P62851 x x x x x x Q00688 x x x x x Q13085 x x x x x
P61254 x x x x x x P62854 x x x x x x Q00765 x x x x x x Q13126 x x x x x x
P61313 x x x x x x P62857 x x x x x Q00839 x x x x x x Q13144 x x x x x x
P61353 x x x x x x P62861 x x x x Q01081 x x x x x x Q13151 x
P61421 x x x x x x P62873 x x x x x x Q01082 x x x x x x Q13200 x x x x x x
P61513 x x x x x x P62879 x x x x x x Q01105 x x x x x x Q13242 x
P61586 x x x x x x P62888 x x x x x x Q01469 x x x x x x Q13263 x x x x
P61604 x x x x P62899 x x x x x x Q01518 x x x x x x Q13308 x x x x x x
P61764 x x x x x x P62906 x x x x x x Q01628 x x x x x x Q13347 x x x x x x
P61769 x x x x x x P62910 x x x x x x Q01650 x x x x x x Q13409 x x x x x x
P61803 x x x x x x P62913 x x x x x x Q01813 x x x x x x Q13418 x x x x x x
P61923 x x x x x x P62917 x x x x x x Q01995 x x x x x x Q13425 x x x x x x
P61978 x x x x x x P62937 x x x x x x Q02413 x x x x x x Q13443 x x x x x x
P61981 x x x x x x P62942 x x x x x x Q02539 x Q13451 x x x x
P62070 x x x x x x P62979 x x x x x x Q02543 x x x x x x Q13492 x x x x x
P62079 x x x x x x P62995 x x x x x x Q02790 x x x x x x Q13509 x x x x x x
P62081 x x x x x x P63000 x x x x x x Q02878 x x x x x x Q13557 x x x x x
P62136 x x x x x x P63010 x x x x x x Q03135 x x x x x x Q13576 x x
P62140 x x x x x x P63096 x x x x x x Q03405 x x x x x x Q13617 x x x x x
P62158 x x x x x x P63104 x x x x x x Q04446 x x x x x x Q13620 x x x x x x
P62191 x x x x x x P63167 x x x x x Q04760 x x x x x x Q13642 x x x x x x
P62195 x x x x x x P63173 x x x x x Q04837 x x x x x x Q13683 x x x x x x
P62241 x x x x x x P63208 x x x x x x Q04917 x x x x x x Q13740 x x x x x x
P62244 x x x x x x P63220 x x x x x Q04941 x x x x x x Q13765 x x x x x x
P62249 x x x x x x P63241 x x x x x x Q06210 x x x x x x Q13813 x x x x x x
P62258 x x x x x x P63244 x x x x x x Q06323 x x x x x x Q13838 x x x x x x
P62263 x x x x x x P63261 x x x x x x Q06830 x x x x x x Q13867 x x x x x x
P62266 x x x x x x P67809 x x x x x x Q07020 x x x x x x Q13885 x x x x x
P62269 x x x x x x P67812 x x Q07021 x x x x x x Q13907 x x x x x x
P62277 x x x x x x P67936 x x x x x x Q07866 x x x x x x Q14019 x x x x x x
P62280 x x x x x x P68032 x x x x x x Q07954 x x x x x x Q14103 x x x x x x
P62304 x x x x x x P68104 x x x x x x Q07955 x x x x x x Q14108 x x x x x x
P62314 x x x x x x P68371 x x x x x x Q07960 x x x x x Q14152 x x x x x x
P62316 x x x x x x P68400 x x x x x Q08211 x x x x x x Q14192 x x x x x x
P62318 x x x x x x P68402 x x x x x x Q08380 x x x x x x Q14203 x x x x x
P62330 x x x x x x P68431 x x Q08431 x x x x x x Q14204 x x x x x x
P62333 x x x x x x P78371 x x x x x x Q08722 x x x x x x Q14254 x x x x x x
P62424 x x x x x x P78417 x x x x x x Q08945 x Q14258 x x x x x
P62491 x x x x x x P78527 x x x x x x Q09666 x x x x x x Q14315 x x x x x x
P62701 x x x x x x P80723 x x x x x x Q10471 x x x x x x Q14344 x x x x x x
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Q14517 x x x x x x Q53TN4 x x x x x x Q8IWA5 x x x x x x Q96CW1 x x x x x x
Q14566 x x x x Q562R1 x x x x x x Q8IWB7 x x x x x x Q96EK6 x x x x x
Q14699 x x x x x x Q58FF8 x x x x x x Q8IXQ6 x x x x x Q96EY5 x x x x x x
Q14764 x x x x x x Q5JWF2 x x x x x x Q8IY67 x x x x x x Q96F07 x x x x
Q14847 x x x x x x Q5QNW6 x x x x x x Q8IYT4 x x x x x x Q96F85 x x x x x x
Q14974 x x x x x x Q5SSJ5 x x x x x x Q8IZ83 x x x x x x Q96FN4 x x x x x x
Q15008 x x x x x x Q5SZU1 x x x x x x Q8N357 x x x x x Q96FZ7 x x x x x x
Q15012 x x x x x x Q5T091 x Q8N8Y2 x x x x x x Q96G03 x x x x x x
Q15019 x x x x x x Q5T1M3 x x x x x x Q8NBI5 x x x x x x Q96KP4 x x x x x x
Q15029 x x x x x x Q5T4S7 x x x x x x Q8NC51 x Q96P70 x x x x x x
Q15043 x x x x x x Q5T749 x x x x x x Q8ND76 x x x x x Q96QD8 x x x x x x
Q15058 x x x x x x Q5T750 x x x x x x Q8NG11 x x x x x x Q96QK1 x x x x x x
Q15084 x x x x x x Q5T7F0 x x x x x x Q8TAD7 x Q96S44 x x x x x
Q15149 x x x x x x Q5T8U7 x x x x x Q8TB61 x x Q96S86 x x x x x
Q15181 x x x x x x Q5T9B7 x x x x x Q8TDN6 x Q96S97 x x x x x x
Q15185 x x x x x x Q5TZA2 x x x x x x Q8TF09 x x x x Q96T76 x x x
Q15233 x x x x x x Q5VW32 x x x x x x Q8WUM4 x x x x x x Q96TA1 x x x x x x
Q15286 x x x x x x Q5VYK3 x x x x x x Q8WUN7 x x x x x Q99426 x x x x
Q15363 x x x x x Q5W0H4 x x x x x x Q8WV92 x x x x x x Q99436 x x x x x x
Q15365 x x x x x x Q6DD88 x x x x x Q8WWI5 x x x x x x Q99460 x x x x x x
Q15369 x x x x Q6NZI2 x x x x x x Q8WXH0 x x x x x x Q99497 x x x x x x
Q15370 x x x x x x Q6P1R4 x x x x x x Q92499 x x x x x x Q99523 x x x x x
Q15382 x x x x x x Q6P2Q9 x x x x x x Q92520 x x x x x Q99536 x x x x x x
Q15393 x x x x x x Q6TDU7 x x x x x x Q92522 x x x x x x Q99584 x x
Q15404 x x x x x x Q6UVK1 x x x x x x Q92542 x x x x x x Q99613 x x x x x x
Q15436 x x x x x x Q6UXN9 x x x Q92598 x x x x x x Q99685 x x x x x x
Q15582 x x x x Q6VAB6 x Q92608 x x x Q99729 x x x x x x
Q15631 x x x x x x Q6YHK3 x x x x x x Q92616 x x x x x Q99733 x x x x x x
Q15758 x x x x x x Q6ZS74 x x x x x x Q92626 x x x x x x Q99805 x x x x x x
Q15819 x x x x x x Q6ZUX7 x x x x x x Q92633 x x x x x x Q99808 x x x x x x
Q15836 x x x x x x Q71DI3 x x x x x x Q92734 x x x x x x Q99816 x x x x x x
Q16181 x x x x x x Q71U36 x x x x x x Q92743 x x x x x x Q99829 x x x x x x
Q16401 x x x x x x Q71UM5 x x x x x x Q92769 x x x x x x Q99832 x x x x x x
Q16531 x x x x x x Q75T13 x x x x x x Q92783 x x x x x Q99873 x x x x x x
Q16543 x x x x x x Q7KYR7 x x x x x x Q92841 x x x x x x Q99973 x x x
Q16555 x x x x x x Q7KZF4 x x x x x x Q92896 x x x x x x Q9BPX3 x x x x x x
Q16576 x x x x x x Q7L1Q6 x x x x x Q92900 x x x x Q9BQE3 x x x x x x
Q16629 x x x x x x Q7L2H7 x x x x x x Q92930 x x x x x x Q9BRF8 x x x x x x
Q16643 x x Q7L576 x x x x x x Q92973 x x x x x x Q9BSJ2 x x x x x x
Q16658 x x x x x x Q7L5D6 x x x x x Q92982 x x x x x x Q9BSJ8 x x x x x x
Q16666 x x x x Q7L9L4 x x x x Q93008 x x x x x x Q9BTW9 x x x x
Q16851 x x x x x x Q7LBR1 x x x x Q969E2 x x x x x x Q9BUB4 x
Q1KMD3 x x x x x Q7Z304 x x x x Q969P0 x x x x x x Q9BUF5 x x x x x x
Q29963 x x x x x x Q7Z406 x x x x x x Q969Q0 x x x x x x Q9BVK6 x x x x x x
Q2L7G6 x x x x x x Q7Z5G4 x x x x x x Q969X1 x x x x x x Q9BWD1 x x x x x x
Q2M389 x x x x x x Q7Z7A1 x Q96A72 x x x x x x Q9BX67 x x x x x
Q32Q12 x x x x x x Q7Z7G0 x x x x x x Q96AC1 x x x x x x Q9BYE4 x x x x x
Q3ZCM7 x x x x x x Q86VP6 x x x x x x Q96AK3 x x x x x Q9BYT8 x x x x x
Q53EZ4 x x x x x x Q8IUE6 x x x x x x Q96AM1 x x x x x x Q9BZG1 x x x x x x
Q53FA7 x x x x x x Q8IVF7 x x x x x x Q96BY6 x x x x x x Q9BZQ8 x x x x x x
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Q9C0H2 x x x x x x Q9P273 x x x x x x Q9Y315 x x x x x
Q9GZN7 x Q9P2B2 x x x x x x Q9Y376 x x x x x x
Q9H0H5 x x x Q9P2J5 x x x x x x Q9Y3E7 x x x x x x
Q9H0P0 x Q9P2R3 x x x x x x Q9Y3F4 x x x x x x
Q9H0U4 x x x x x x Q9UBG0 x x x x x x Q9Y3I0 x x x x x x
Q9H1C7 x x x x x x Q9UBG3 x x x x x x Q9Y3L5 x x x x x x
Q9H223 x x x x x x Q9UBI1 x x x x x Q9Y3U8 x x x x x x
Q9H444 x x x x x x Q9UBI6 x x x x x x Q9Y3Z3 x x x x x x
Q9H4A4 x x x x x x Q9UBL6 x x x Q9Y490 x x x x x x
Q9H4G4 x x x x x x Q9UBQ0 x x x x x x Q9Y4F1 x x x x x x
Q9H4M9 x x x x x x Q9UBQ5 x x x x x x Q9Y5B9 x x x x x x
Q9H5V8 x x x x x x Q9UBQ7 x x x x x x Q9Y5K8 x x x x x x
Q9H8M9 x x x x x x Q9UBV8 x x x x x x Q9Y5P6 x x x x x x
Q9H9H4 x x x x Q9UDY4 x x x x x Q9Y5S9 x x x x x x
Q9HA64 x x x x x x Q9UGI0 x x Q9Y5X1 x x x x
Q9HAV0 x x x x x x Q9UHB9 x x x x x x Q9Y624 x x x x x x
Q9HAV4 x x x x x Q9UHD8 x x x x x x Q9Y639 x x x x x x
Q9HB71 x x x x x x Q9UIA9 x x x x x x Q9Y696 x x x x x x
Q9HC07 x x x x x x Q9UIQ6 x x x x x x Q9Y6C2 x x x x x x
Q9HC38 x x x x x x Q9UIW2 x x x x x x Q9Y6K5 x x x x x x
Q9HCE0 x Q9UJ70 x x x x x x
Q9HD42 x x Q9UK41 x x x x x x
Q9HD45 x x x x Q9UKD2 x x x x x
Q9NP72 x x x x x x Q9UKK3 x x x x x x
Q9NP79 x x x x x x Q9UKK9 x x x x x x
Q9NPA8 x x x Q9UKS6 x x x x x x
Q9NPD3 x x x x x Q9UL25 x x x x x x
Q9NQC3 x x x x x x Q9UL26 x x x x x
Q9NQW7 x x x x x x Q9UL46 x x x x x x
Q9NR30 x x x x x x Q9ULC3 x x x x x x
Q9NR31 x x x x x x Q9ULV4 x x x x x x
Q9NR45 x x x x x x Q9UMS4 x x x x x x
Q9NRN7 x x x Q9UN37 x x x x x x
Q9NRV9 x x x x x x Q9UN86 x x x x
Q9NRY6 x x x x x x Q9UNF0 x x x x x x
Q9NSD9 x x x x x x Q9UNM6 x x x x x x
Q9NTJ3 x x x x x x Q9UPR3 x x x x
Q9NTK5 x x x x x x Q9UQ80 x x x x x x
Q9NUQ9 x x x x x x Q9UQE7 x x x x x x
Q9NVA2 x x x x x x Q9UQN3 x x x x x x
Q9NVJ2 x x x x x x Q9Y230 x x x x x x
Q9NVP1 x Q9Y262 x x x x x x
Q9NX76 x x x x x x Q9Y265 x x x x x x
Q9NY33 x x x x Q9Y281 x x x x x x
Q9NZM1 x x x x x x Q9Y285 x x x x x x
Q9NZN4 x x x x x x Q9Y287 x x x x x
Q9P003 x x x x x Q9Y2A7 x x x x x x
Q9P1F3 x x x x x x Q9Y2E4 x x
Q9P225 x x x x x x Q9Y2L1 x x x x
Q9P265 x x x x x x Q9Y2X3 x x x x x x
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Table A2. The list of osteoblast-related GO annotations based on the EV proteins shared by all EV groups. 
GO Term Counta) Gene Symbolb)  
Calcium ion binding (GO:0005509)  64 
ANXA2 
S100A6 
CANX 
Extracellular matrix (GO:0031012)  23 
COL1A1 
FN1 
LAMB1 
Skeletal system development (GO:0001501)  16 
ALPL 
COL1A 
EGFR 
Phosphatase activity (GO:0016791)  11 
CYCS 
PPP1CC 
ALPL 
Steroid hormone receptor signaling pathway (GO:0030518)  7 
DNAJA1 
FHL2 
CALR 
Vitamin binding (GO:0019842)  7 
PDXK 
GOT1/2 
FASN 
Mesenchymal cell differentiation (GO:0048762)  3 
CDL1 
CTNNB1 
HNRNPAB 
Collagen metabolic process (GO:0032963)  3 
PEPD 
COL1A1 
BASP1 
a) The total number of proteins annotated to the given GO term. b) Official gene symbols of exemplary proteins for 
each GO term. 
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Table A3. The list of up- and/or down-regulated (≥ 1.5-fold) PC3 genes in response to day 12 NMOB-EVs or 
MOB-EVs.  
N
M
O
B
-E
V
 R
eg
ul
at
ed
 P
C
3 
G
en
es
 
Up-regulated PC3 Genes  
ALPP a, b), C14ORF153, C7ORF54, CENPE, DMC1, GUSBL1, HS.276854, HS.553301, HS.555252, 
HS.579631, LOC100128266, LOC23117, LOC728499, LOC728888, LOC729978, LOC92755, 
NBPF20, RPS17, RPS6KA3 
 
Down-regulated PC3 Genes 
ATP1B1, BMS1P5, C14ORF85, C19ORF10, C2ORF69, CATSPER2, CCBE1, CHRNA5, CSF2RA, 
DAPP1, DEM1, DTWD2, FAM119A, FCF1, FLJ36131, FLJ46309, FTHL12, FTHL8, GMNN, 
HS.544637, IL17RD, KCNH6, LMOD3, LOC100008588, LOC100128062, LOC100128098, 
LOC100128505, LOC100129362, LOC100130445, LOC100131718, LOC100132394, 
LOC100132585, LOC100133516, LOC100133649, LOC100133772, LOC100134159, 
LOC100134364, LOC100190938, LOC389517, LOC389765, LOC399900, LOC644745, 
LOC645452, LOC646786, LOC648210, LOC653086, LOC653489, LOC728809, LOC728903, 
LOC729090, LOC730278, LOC90586, MCART1, PAK2, PDE4C, PPA2, RRP1, SDHALP1, SFRS5, 
SLC44A4, SLC4A5, SPTLC1, SULT1A1, TDP1, TMEM17, TNFSF14, TRMT2B, USP49, VPS41, 
XRCC2, YWHAG, ZMAT3, ZNF428, ZNF486, ZNF682 
 
Up-and-down-regulated PC3 Genes  
C15ORF63, IL10, C21ORF58, CDKN2AIPNL 
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Up-regulated PC3 Genes 
AK1, ALDOA, C14ORF4, CCDC85B, CDCP1, CDK5, CXORF64, EEF1D, GAMT, HIST1H2BK, 
HNRNPH1, LOC100134265, LOC645058, LOC652595, LOC728188, LOC728499, LRFN3, 
NCKAP1, OPN3, PARD6A, PMVK, SPOP, THBS1, TPT1, TUBB2C, TUBG1 
 
Down-regulated PC3 Genes 
DBI, FLNA, FTHL8, HMMR, HS.535360, HSPE1, LOC100128410, LOC100129028, 
LOC100129379, LOC100129685, LOC100130070, LOC100131205, LOC391833, LOC392285, 
LOC402644, LOC440595, LOC441481, LOC644799, LOC645979, LOC646688, LOC648210, 
LOC649009, LOC651202, LOC653156, LOC728481, LOC728553, LOC728590, LOC91561, 
MRPL19, MRPL36, MYO1B, NAP1L1, NCBP2, PBK, RAD21, RDX, RGS7, RPL14, RPL23, RRN3, 
SRP72, STAG3L3, TSPAN13, UAP1, VPS24, WTAP, ZC3H15, ZNF146, ZNF281 
 
Up-and-down-regulated PC3 Genes 
SMG1 
 
a) Official gene symbols. b) PC3 genes that show different regulation pattern after 4, 24 and 48 hours of EV treat-
ment. 
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Table A4. EV-RNA yield expressed as relative RNA amount (ng) per mL of conditioned medium (CM) or rela-
tive RNA amount (pg) per 106 cells seeded on day 0 (N = 3). 
 
Sample RNA Yield 
(ng/ mL CM) 
RNA Yield 
(pg/ 106 cells) 
 
EV_A 30.47 2.44 
 
EV_B 37.20 2.98 
 
EV_C 30.68 2.45 
 
 
 
Table A5. Correlation analysis. Coefficients of determination (R2) show the strength of the correlation between 
the replicates. 
 
Sample 
 
R2 
 
Sample 
 
R2 
 
Sample 
 
R2 
 
EV_A - EV_B 0.8058 OB_A - OB_B 0.9732 
 
EV_A - OB_A 0.7113 
EV_A - EV_C 0.8415 OB_A - OB_C 0.9747 EV_B - OB_B 0.7449 
 
EV_B - EV_C 0.8704 OB_B - OB_C 0.9695 EV_C - OB_C 0.8142 
 
 
 
Table A6. The list of EV-mRNAs significantly (P < 0.05) enriched (≥ two-fold) in osteoblast-EVs compared to 
the cells. FC, fold change. 
 
 
 
 
 
GeneID FC P value GeneID FC P value GeneID FC P value GeneID FC P value
RAB13 117.19 0.03989 EPB41L4A 10.27 0.00079 PNN 5.84 0.00549 SAP18 4.44 0.02514
ARRDC4 49.85 0.00366 PTPN11 9.98 0.00363 NBPF16 5.74 0.02479 HIRIP3 4.42 0.01210
NEFM 43.09 0.01461 HNRNPH3 9.56 0.01398 SYNJ2BP 5.62 0.04265 WDR60 4.38 0.01422
IGIP 41.36 0.00070 NSRP1 9.55 0.00137 CWC27 5.61 0.02645 ZNF850 4.38 0.04640
NET1 38.48 0.00044 EFCAB2 9.50 0.00685 MAP4K4 5.60 0.03780 NEXN 4.32 0.00341
RASSF3 37.72 0.00155 TAF15 8.82 0.04099 KIF3B 5.52 0.03980 MYEF2 4.27 0.00243
HMGN5 34.79 0.02288 MYOZ3 8.72 0.04723 CYP1B1 5.37 0.01694 SYNM 4.12 0.04630
TRAK2 33.71 0.01144 EIF5B 8.57 0.00014 PRPF38B 5.28 0.00069 SREK1 4.10 0.02771
ESF1 25.28 0.00798 TCEAL4 8.29 0.02830 HIST1H2BO 5.15 0.04023 RNF20 4.07 0.00946
ZEB1 24.95 0.01027 TCEAL3 7.99 0.02340 UPF3A 5.15 0.00883 CRTAP 4.07 0.04272
PITPNM3 24.81 0.04366 TCEAL2 7.97 0.02409 APOBEC3D 5.14 0.03880 PAIP2B 4.06 0.03262
ANP32B 23.28 0.00039 TTLL11 7.91 0.04326 NFKBIB 5.10 0.01806 HMHA1 4.05 0.01920
ARHGAP11A 20.81 0.00968 NEFL 7.83 0.00507 LPAR1 5.10 0.00340 HES4 4.01 0.00392
GDF11 20.68 0.02750 KCNK6 7.69 0.03190 FAIM 5.08 0.00532 HIST1H4H 3.94 0.04654
CGNL1 19.04 0.04207 SAMD4A 7.62 0.01601 RBM25 5.05 0.00832 CDK11A 3.94 0.01097
CACNG8 18.02 0.04924 GPATCH4 7.61 0.00286 EIF3A 5.03 0.01457 PPP1R3C 3.92 0.02899
BCL2L2 17.93 0.03936 SCG5 7.57 0.03706 CHAF1A 4.94 0.02494 LUC7L3 3.83 0.01093
LACC1 17.29 0.00220 ZBTB47 7.29 0.03058 HTATSF1 4.85 0.00318 WWTR1 3.81 0.00295
C7orf41 16.18 0.00934 TRAF3IP1 7.25 0.00905 HIST1H2BH 4.81 0.01648 PHF14 3.80 0.01003
NUDT16 16.05 0.02621 CHCHD7 7.00 0.01920 ZNF677 4.80 0.03522 METTL8 3.78 0.02957
ERG 14.37 0.00059 CA11 6.82 0.02844 ANP32A 4.79 0.02467 DNASE1 3.72 0.01570
TP53INP2 14.14 0.04779 GXYLT1 6.68 0.00034 CDK11B 4.76 0.04841 SET 3.71 0.01088
ASPHD1 12.85 0.00275 CCDC34 6.51 0.03558 PALLD 4.74 0.00254 HIST1H3D 3.67 0.00793
UACA 12.44 0.00199 FAM18B2 6.50 0.01580 HNRNPA3 4.73 0.00526 SLC9A3R2 3.66 0.01959
DYNC1LI2 12.05 0.00357 ANP32E 6.26 0.00367 TCEANC2 4.68 0.02317 FAM101B 3.64 0.00769
HIST1H1E 11.88 0.02896 SNX22 6.18 0.00242 ZEB2 4.66 0.00583 SLC25A34 3.63 0.04629
PKP4 11.51 0.01196 CCND2 6.17 0.02208 TAF3 4.64 0.03071 ROM1 3.63 0.01222
PSMC3IP 11.51 0.00725 ARRDC2 6.01 0.00013 NAP1L1 4.54 0.01574 RAI14 3.59 0.03388
CCDC148 11.28 0.02561 UPF3B 5.98 0.00188 PARD3B 4.50 0.04720 RNF207 3.56 0.02501
ZNF326 10.62 0.00100 CENPB 5.92 0.02211 MAP1B 4.50 0.01578 NANOS1 3.52 0.00915
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GeneID FC P value GeneID FC P value GeneID FC P value
LRRC34 3.49 0.03804 CDO1 2.79 0.01827 PTPN2 2.25 0.04113
ANKRD18B 3.46 0.01034 POMC 2.78 0.01149 APOL3 2.23 0.03320
APOL2 3.44 0.00894 RHOD 2.77 0.02006 UPF2 2.22 0.00913
ANKDD1A 3.43 0.02275 KTN1 2.77 0.00871 UFM1 2.22 0.01933
HNRNPA1 3.43 0.04890 C2orf63 2.75 0.01346 RASSF7 2.21 0.02186
MESP1 3.41 0.02638 DNAJC21 2.75 0.01956 MIIP 2.20 0.03658
METAP2 3.39 0.01961 AQP3 2.74 0.00559 CCAR1 2.20 0.00531
ZNF585B 3.37 0.02610 KIAA1377 2.74 0.01723 FBXO32 2.19 0.03563
TSR2 3.37 0.01228 LARP7 2.73 0.04883 RINL 2.19 0.03102
TAF7L 3.36 0.02204 ZNF814 2.72 0.01280 KRT10 2.19 0.03254
ACBD3 3.36 0.00909 C18orf56 2.71 0.02864 PPDPF 2.19 0.02935
GADD45A 3.34 0.00927 KATNAL1 2.70 0.00318 FGF1 2.18 0.01238
ZNF707 3.33 0.01155 NUDT14 2.67 0.03389 PPIG 2.18 0.01174
TTC25 3.33 0.01837 AGAP2 2.64 0.00559 XDH 2.18 0.00295
SRSF12 3.28 0.04205 ENAH 2.63 0.04736 ST13 2.15 0.03153
CDKL3 3.27 0.04774 HABP4 2.62 0.00041 BFSP1 2.14 0.01275
TREM2 3.27 0.04236 MFAP1 2.59 0.01479 RAB4A 2.13 0.03136
MSX1 3.25 0.03556 SEPT7 2.59 0.01236 ATXN3 2.12 0.03498
IL18 3.23 0.04630 HOXB7 2.59 0.00004 SIRT4 2.11 0.00965
CEP19 3.22 0.04448 CALD1 2.58 0.00320 MAFF 2.10 0.00128
CCND1 3.20 0.04860 IL17RE 2.57 0.01686 ADSSL1 2.10 0.02055
WDR43 3.20 0.00240 GGPS1 2.57 0.04253 FRAT2 2.09 0.02667
ARMCX3 3.18 0.00140 FRA10AC1 2.55 0.03590 PSIP1 2.09 0.00388
BDP1 3.18 0.00624 SOX11 2.54 0.04741 ZNF880 2.08 0.02382
PGF 3.15 0.00411 FGFBP3 2.54 0.01106 IK 2.06 0.00835
DNAJC2 3.13 0.02260 SBSN 2.53 0.04817 PPID 2.05 0.01439
PINK1 3.12 0.00496 AP4S1 2.52 0.01915 OPTN 2.05 0.00289
NCL 3.10 0.03721 CFDP1 2.51 0.04925 CD3EAP 2.04 0.04628
SLC16A12 3.10 0.03821 LMOD1 2.48 0.00475 MAP3K13 2.02 0.02914
CCDC152 3.08 0.03877 LYRM7 2.46 0.02442 ABCA10 2.02 0.01909
DDX46 3.08 0.00113 HAGHL 2.46 0.02701 TNFAIP8L1 2.02 0.03529
ZNF283 3.07 0.03048 SLC4A5 2.45 0.00351 GTPBP10 2.01 0.03033
SLTM 3.06 0.02966 EPM2A 2.43 0.02194 CNTNAP2 2.01 0.02551
GOLGA4 3.06 0.02651 ZNF487P 2.39 0.03670 CCDC66 2.00 0.02740
ZNHIT6 3.05 0.04097 CEP63 2.38 0.01549
RPGR 3.00 0.00865 FLT3LG 2.37 0.00260
RRP15 3.00 0.03886 ORMDL3 2.37 0.01343
HDGFRP3 2.99 0.01516 ISY1 2.37 0.04690
YTHDC1 2.99 0.03663 ZNF790 2.37 0.00477
ZCWPW1 2.98 0.04469 CHCHD10 2.35 0.03256
ZNF846 2.98 0.00288 DGCR6 2.35 0.00986
FAM82B 2.94 0.02289 SOCS4 2.33 0.01827
IFI44L 2.92 0.01260 ENHO 2.33 0.01452
NPAS1 2.90 0.00757 CEBPZ 2.32 0.03277
YES1 2.87 0.03825 PABPC1 2.32 0.01825
IFT74 2.85 0.00223 CCDC91 2.32 0.01536
CEP70 2.85 0.00125 KIN 2.32 0.03838
TNNT1 2.83 0.02187 GPS2 2.30 0.01134
MALL 2.81 0.01170 CCDC41 2.30 0.04670
RBM17 2.80 0.02804 HSBP1L1 2.28 0.00973
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Figure A1. A-B) Osteoblast-EVs increase the ex vivo expansion of (A) TNCs and (B) CD34+ cells after 10 days 
of expansion with SCF, Flt3L and TPO compared to control (N = 2). Expansion is shown as fold change (FC) 
increase in total cell number compared to input. Empty and full shapes show the different donors. C) The fold 
change (mean ± SD) of phenotypic HSCs compared to control on day 10 (N = 2).  
 
 
 
 
 
Figure A2. Flow cytometric gating strategy for phenotypic HSCs. 
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Figure A3. A-B) Analysis of mice (A) body and (B) spleen weight 21 weeks post-injection. C) Human chimerism 
level in the spleen after 21 weeks (N = 5 mice/ group). 
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ABBREVIATION INDEX  
 
AFM Atomic force microscopy 
ALPL Alkaline phosphatase, liver/bone/kidney 
α-MEM Alpha- Minimum Essential Medium 
ANXA2 Annexin A2 
ATP5E ATP synthase subunit epsilon, mitochondrial 
BCL2 B-cell lymphoma 2 
BCL3 B-cell lymphoma 3-encoded protein 
BCP B-cell progenitor 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CDC42EP2 Cdc42 effector protein 2 
CFU Colony forming unit 
CMP Common myeloid progenitor 
CLP Common lymphoid progenitor 
COL1A1 Collagen type I alpha 1 
CPM Counts per million 
CT Cycle threshold 
CV Coefficient of variance 
CYSLTR2 Cysteinyl leukotriene receptor 2 
DAPI 4’,6-diamidino-2-phenylindole 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DNA Deoxyribonucleic acid 
EGR1 Early growth response protein 1 
ELN Elastin 
EDTA Ethylenediaminetetraacetic acid 
ESCRT Endosomal sorting complex required for receptor transport 
EVs Extracellular vesicles 
FACS Fluorescence-activated cell sorting 
FC Fold change 
FCS Fetal calf serum 
FDR False discovery rate 
FITC Fluorescein isothiocyanate 
Flt3L Fms-related tyrosine kinase 3 ligand 
FU Fluorescence units 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GBGM Glycostem Basic Growth Medium 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GMP Granulocyte–macrophage progenitor 
GO Gene Ontology 
GVHD Graft-versus-host disease 
HBP1 HMG-box transcription factor 1 
HEK 293 Human Embryonic Kidney 293 cells 
HSCs Hematopoietic stem cells 
HSPCs Hematopoietic stem and progenitor cells 
iBAQ Intensity-based absolute quantification 
IL-6 Interleukin 6 
IPA Ingenuity pathway analysis 
ITGAX Integrin, alpha X 
kDa Kilodalton 
LC-MS Liquid chromatography–mass spectrometry 
Abbreviation index 
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LFQ Label-free quantification 
MAOA Monoamine oxidase A 
MEP Megakaryocyte erythroid progenitor 
mRNA Messenger RNA 
miRNA MicroRNA 
MOBs Mineralizing osteoblasts 
MSCs Mesenchymal stem cells 
MVs Matrix vesicles 
MVBs Multivesicular bodies 
NFIB Nuclear factor 1 B-type 
NMOBs Non-mineralizing osteoblasts 
NSG Next-generation sequencing 
NTA Nanoparticle tracking analysis 
OBs Osteoblasts 
PBS Phosphate-buffered saline 
PC3 Human prostate cancer cell lines 
PI Propidium iodide 
PTEN Phosphatase and tensin homolog 
qPCR Quantitative polymerase chain reaction 
RAB13 Ras-related protein Rab-13 
RNA Ribonucleic acid 
RNase Ribonuclease 
RPKM Reads per kilobase of transcript per million mapped reads 
RPM Revolutions per minute 
rRNA Ribosomal RNA 
S100A9 S100 calcium-binding protein A9 
SCF Stem cell factor 
SD Standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
snoRNA Small nucleolar RNAs 
SR1 StemRegenin 1 
SV-HFOs Simian virus 40-immortalized human osteoblast cell line 
TBS Tris-buffered saline 
TEM Transmission electron microscope 
TET2 Tet Methylcytosine Dioxygenase 2 
TMM Trimmed M-Means 
TNK T-cell natural killer cell progenitor 
TPO Thrombopoietin 
U Enzyme unit 
UCB Umbilical cord blood 
 
 
 
Appendix C 
	  150 
PRIMER SEQUENCES  
 
 
 
Gene Symbol 
 
Forward Sequence (5' è  3') 
 
Reverse Sequence (5' è  3') 
 
ATP5E 
 
AGACTTCTGGCAGCAACGTA 
 
TGCCCACACATCTTCACCTT 
BCL2  AGTACCTGAACCGGCACCT ACAGTTCCACAAAGGCATCC 
CDC42EP2 GTCCAGCTCCTGAGACCTTG GCACTTTGGTCTTGTCACCG 
COL1A1 GACATGTTCAGCTTTGTGGACC TGATTGGTGGGATGTCTTCGT 
CYSLTR2 GCAGCTGAAAGACAGAGACCT CCATACCTTGCATGGACCTTCT 
EGR1 AGCCCTACGAGCACCTGAC TGGGTTGGTCATGCTCACTA 
ELN TCCCGGGAGTTGGCATTTC CAAACTGGGCGGCTTTGG 
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCCGTTG 
HBP1 CCTGTGATGAACACATGGAGC TGGTACATGCCAGATTGGGT 
ITGAX CCTACGGAACCACCATCACC ACATGTCAGGTGCAGGGAAC 
MAOA ATGACACCAAGCCAGATGGG AAGTCGATCAGCTTTCCGGG 
NFIB GTCCAGCCACATCATATCACAG TTGGCAGGATCATTGTGGCTT 
PTEN TGGATTCGACTTAGACTTGACCT ACGCCTTCAAGTCTTTCTGC 
RAB13 GAGGCCGGAGATCAGGAAAC AGGGAGCACTTGTTGGTGTT 
S100A9 GGAATTCAAAGAGCTGGTGCG AGCTGCTTGTCTGCATTTGTG 
TET2 AGCAGCAGCCAATAGGACAT TTCCATCAGGCTTGCTTCGG 
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SUMMARY 
Cell-to-cell communication plays an essential role in regulating homeostasis in 
multicellular organisms. Recent evidence indicates that cells effectively communicate via 
extracellular vesicles (EVs), which carry bioactive cargo, such as proteins, lipids and RNA, 
between cells. Bone is a complex organ consisting of a broad variety of cell types living in 
harmony within the favorable microenvironment of the bone marrow. The establishment of 
a proper communication network is key to ensure not only normal bone development but 
also many other vital physiological processes. In this thesis, we present a thorough charac-
terization of the biochemical content of EVs secreted by human osteoblasts, study their 
biological significance in communication with the cells in the surrounding microenviron-
ment, and investigate their potential application in stem cell therapy. 
In Chapters 2, 3 and 4 we delineate the structural and regulatory cargo of osteo-
blast-derived EVs with a focus on identifying the cargo overrepresented in EVs. In Chap-
ter 2, we present the EV protein content by mass spectrometry. We show the diversity of 
EV cargo depending on the stage of osteoblast differentiation and mineralization condition. 
Notably, EVs secreted by non-mineralizing osteoblasts, are depleted of biomineralization-
related proteins suggestive of an activity independent of matrix vesicles. Instead, they are 
enriched with cell adhesion-associated extracellular matrix proteins and chromosomal pro-
teins with regulatory potential. In Chapter 3 and 4, we present next-generation sequencing 
analyses to delineate the mRNA and miRNA content of EVs secreted by non-mineralizing 
osteoblasts. We define the RNA cargo selectively incorporated into EVs or depleted from 
EVs during their biogenesis. In Chapter 3, we show that EV-mRNAs mostly consist of 
genes encoding for proteins with ribosomal activities, while they lack the genes important 
to carry out vital cellular processes. In Chapter 4, we demonstrate that EV-miRNAs most-
ly consist of miRNAs involved in molecular functions related to growth and proliferation, 
including the well-characterized regulators of early hematopoiesis.  
In Chapters 2, 4, 5 and 6 we focus on the role of osteoblast-EVs as a mean of 
communication with the surrounding cells in the bone marrow microenvironment. In 
Chapters 2 and 4 we demonstrate the molecular function of osteoblast-EVs by showing 
their proliferative effect on bone-metastasizing prostate cancer (PC3) cells and human um-
bilical cord blood (UCB)-derived CD34+ hematopoietic stem and progenitor cells (HSPCs). 
Through transcriptomics studies in Chapters 2 & 6 we confirm that EVs alter the expres-
sion of HSPC and PC3 genes important for cellular development and growth. We use inte-
grated bioinformatics approach to explain the biological mechanism of EV function and 
delineate a list of candidate regulatory EV cargo predicted to target cell growth. In Chap-
ter 5, we show the therapeutic potential of osteoblast-EVs by showing their potency to ex-
pand UCB-derived CD34+ HSCPs in combination with hematopoietic growth factors in ex 
vivo culture systems. Notably, we show the success of using EVs as expansion agents to 
preserve the repopulating activity of UCB-CD34+ HSPCs, necessary for hematopoietic 
recovery.  
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In conclusion, the findings described in this thesis provide insights into the com-
plex osteoblast-EV-mediated communication network within the bone microenvironment. 
Biochemical analyses combined with omics studies identified overrepresented pathways 
and biological processes important for the regulation of target cells. Furthermore, in vitro 
and in vivo evaluations indicate the power of an osteoblast-EV-based novel strategy for 
clinically relevant ex vivo expansion of hematopoietic progenitor cells. Thorough biochem-
ical and genetic analyses are of utmost importance to characterize the biologically active 
EV components, which will open up avenues for the use of EV as therapeutic tools for the 
treatment of a broad range of disorders. 
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SAMENVATTING 
 De communicatie tussen cellen speelt een belangrijke  en essentiële rol in de 
regulatie van de homeostase van meercellige organismen. Recente studies hebben laten 
zien dat extracellulaire blaasjes (extra-cellulaire vesicles, EV's) een bioactieve vracht zoals 
eiwitten, lipiden en RNA bevatten en een belangrijke rol kunnen spelen in de communica-
tie tussen verschillende cellen in het lichaam. Botweefsel is een zeer complex orgaan dat 
uit veel verschillende cellen bestaat die alle met elkaar kunnen communiceren in het been-
merg en bot. Een goede intercellulaire communicatie is niet alleen essentieel voor een goe-
de botontwikkeling  maar ook voor vele andere vitale fysiologische processen. In dit proef-
schrift beschrijven we 1) de karakterisatie van de inhoud van EV’s  die afgescheiden wor-
den door humane osteoblasten; 2) bestuderen we de biologische effecten van EV’s in de 
communicatie met cellen die zich in de directe omgeving van osteoblasten bevinden; 3) 
onderzoeken we een mogelijke toepassingen van EV’s in stamceltherapie. 
 In hoofdstuk 2, 3 en 4 beschrijven we welke structurele en regulerende vracht 
oververtegenwoordigd is in EV’s die afgescheiden worden door  humane osteoblasten. In 
hoofdstuk 2 bestuderen we door middel van massaspectrometrie de eiwit samenstelling 
van EV’s. In dit hoofdstuk laten we zien dat de eiwitten die aanwezig zijn in EV’s afhanke-
lijk zijn van de differentiatie fase van de osteoblasten. EV’s afgescheiden door niet-
mineraliserende osteoblasten bevatten minder mineralisatie verwante eiwitten. Dit toont 
aan dat EV’s die geproduceerd worden door osteoblasten nog andere functies kunnen heb-
ben dan alleen de vorming van matrix blaasjes. In plaats daarvan zijn EV’s  van niet-
mineraliserende osteoblasten verrijkt met cel bindende extracellulaire matrix eiwitten en 
chromosomale eiwitten met een regulerende functie. In hoofdstuk 3 en 4 onderzoeken we 
welke RNA moleculen zich bevinden in  EV’s die worden afgescheiden door niet-
mineraliserende osteoblasten. De analyse van next-generation sequencing data laat zien dat 
RNA moleculen selectief opgenomen worden tijdens de vorming van EV's. In hoofdstuk 3 
vinden we dat EV-mRNA voornamelijk bestaat uit mRNA moleculen die coderen voor 
ribosomale eiwitten, terwijl genen die belangrijk zijn vitale cellulaire processen afwezig 
zijn. Verder zien we in hoofdstuk 4  dat EV-miRNAs voornamelijk bestaan uit miRNAs 
die betrokken zijn bij de groei en proliferatie van cellen, zoals goed gekarakteriseerde 
miRNAs die de vroege hematopoiese reguleren. 
 In hoofdstuk 2, 4, 5 en 6 hebben we vervolgens onderzocht wat de effecten van 
EV’s zijn op cellen die zich in de directe omgeving van osteoblasten bevinden. In de 
hoofdstukken 2 en 4 laten we zien dat EV’s afgescheiden door osteoblasten een prolifera-
tief effect hebben op bot gemetastaseerde prostaatkankercellen (PC3) en CD34+ hematopo-
etische stam- en voorlopercellen (HSPCs) uit humaan navelstrengbloed (UCB). Transcrip-
toom studies in de hoofdstukken 2 en 6 bevestigen dat EV's de expressie van HSPC en 
PC3 genen kunnen veranderen die een belangrijke rol spelen bij de ontwikkeling en groei 
van cellen. Door middel van bioinformatica analyses hebben we een lijst van kandidaat 
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genen geïdentificeerd die aanwezig zijn in EV’s en de effecten op de celgroei kunnen ver-
klaren. Vervolgens bestuderen we in hoofdstuk 5 de therapeutisch potentie van osteoblast-
EV’s. In een ex vivo kweeksystemen laten we zien dat EV’s , in combinatie met hematopo-
etische groeifactoren, CD34+ HSCPs voorlopercellen kunnen expanderen. Verder is het 
mogelijk om beenmerg opnieuw te laten bevolken met EV-geëxpandeerde  UCB-CD34+ 
HSPC voorlopercellen, wat noodzakelijk is voor het hematopoïetisch herstel.   
 Kortom, de in dit proefschrift beschreven resultaten geven meer zicht op het 
complexe osteoblast-EV-gemedieerde communicatie netwerk in het bot. Biochemische 
analyses gecombineerd met omics studies hebben nieuwe signaal paden en processen ge-
identificeerd die van belang zijn voor de regulatie van de target cellen door EV’s. Boven-
dien hebben de  in vitro en in vivo experimenten meer inzicht gegeven op een nieuwe os-
teoblast-EV-gebaseerde strategie voor klinisch relevante ex vivo expansie van hematopoëti-
sche voorlopercellen. Grondig uitgevoerde biochemische en genetische analyses zijn van 
groot belang voor de bepaling van de biologisch activiteit van  EV‘s componenten en opent 
nieuwe mogelijkheden voor het gebruik van EV’s als therapeutische middel voor de be-
handeling van een breed scala aan aandoeningen. 
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